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Deregulation of cellular mechanisms responsible for cell growth, reproduction
and differentiation is one of the hallmarks of all cancers. This study aims to elu-
cidate the mechanisms underlying cell growth and differentiation using innova-
tive computational and experimental tools. In the current study, we first review
the basic cell cycle mechanisms in a typical eukaryotic cell (Chapter 1). In chap-
ter 2, we analyze three published cell-cycle models and test our hypothesis that
cell-cycle control architecture follow the “robust yet fragile” or the Highly Op-
timized Tolerance (HOT) paradigm. A very important fragile sub-system in the
cell-cycle, revealed in our analysis of the cell-cycle models is protein translation.
In chapter 3, we study the process of protein translation in detail, especially pro-
tein translation initiation. We formulate a detailed, mechanistic model of trans-
lation initiation from interactions validated in the literature. Novel systems-
biology tools such as coupling analysis are developed and employed to gain
insight into critical components of translation initiation. This study reveals the
importance of the Akt andmTOR proteins in the presence of growth factors and
that of negative regulators such as PTEN and 4E-BP1 in their absence. Differen-
tiation is the process by which a less specialized cell becomes more committed
in its lineage, in response to the external environment. Chapter 4 presents an ex-
perimental study of Arsenic Trioxide on Human Leukemia (HL-60) myeloblas-
tic cells. Our results show that Arsenic Trioxide enhances All Trans Retinoic
Acid (ATRA) induced differentiation of HL-60 cells. This increase in differen-
tiation is associated with an increase in the sustained Mitogen Activate Protein
Kinase (MAPK) response. Chapter 5 presents an ensemble approach to model
the response of HL-60 cells to ATRA and the role of sustainedMAPK in differen-
tiation. The model and its analysis present a systematic method to understand
mechanisms involved in programmed cell differentiation in adult stem cells. In
Chapter 6, we present a model combining hormone growth factor receptor sig-
naling and prostate specific antigen (PSA) in LNCaP prostate adenocarcinoma
cells. Finally, the concluding chapter discusses future directions of the current
study.
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CHAPTER 1
INTRODUCTION
According to statistics from the American Cancer Society ∼1,500,000 new cases
of cancer are estimated to be diagnosed in the U.S. and ∼560,000 patients are ex-
pected to die, i.e. more that 1500 deaths per day in 2009 alone [1]. Worldwide,
an estimated 12 million new cases were seen in 2007, with around 7.6 million
deaths, i.e., approximately 20,000 deaths per day. [2]. Cancer is the second lead-
ing cause of death in developed countries (after heart diseases) whereas globally
it is responsible for more deaths than HIV, tuberculosis and malaria combined
[2].
Cancer is characterized by the uncontrolled growth and division of cells. In
general, the cellular processes controlling the passage of a cell through its vari-
ous life stages are tightly controlled. However, deregulation of these processes,
referred to as cell-cycle, is one of the hallmarks of all cancers. Another cellu-
lar process often found to be dysfunctional in cancer cells is cell differentiation.
Differentiation is the process by which a less committed cell moves ahead in its
lineage, in response to environmental cues, leading to formation of more spe-
cialized cells. An inability of precursor cells from the bonemarrow to terminally
differentiate leads to a deficiency of healthy blood cells and an accumulation of
immature cells in the body, giving rise to leukemia.
Cellular networks controlling proliferation as well as differentiation are
large, immensely complex systems composed of a huge number of specialized
proteins and protein complexes. We use latest tools from systems biology and
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develop new computational analysis tools to find potential novel targets whose
manipulation could be of therapeutic value. The following section gives a brief
overview of computational biology, its tools and its role in understanding cel-
lular processes controlling critical functions. A good predictive mathematical
model requires that the underlying biology must by thoroughly understood.
Although mathematical methods of biological systems are never complete, it is
imperative that an exhaustive search of underlying biological relationships is
performed and incorporated in the model to make its predictions reliable. Our
research started with the study of cell-cycle, and led us to investigate in detail,
some of its critical sub-systems such as protein translation and cell differentia-
tion mechanisms. To acquaint the reader with biological basis of our models, an
overview of biology behind the cell-cycle presented in the subsequent sections
of this chapter. The other systems are explained in their respective chapters.
1.1 Computational Biology approaches to modeling of biologi-
cal systems
Biological systems are often complex, highly interconnected networks of a huge
number of components. Usually, they are also composed of a number of smaller
sub-systems. The use of computational methods to understand biological sys-
tems is borne out of a desire to understand the complex relationships between
interacting components and predict non-obvious, emergent properties as a re-
sult of these interactions. As observed by Kitano, [3] computational biology
has two distinct roles to play, first it can be used to perform a large number
of in-silico experiments faithfully, which would have otherwise been very time
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consuming and expensive to perform in a lab. Secondly, using tools of knowl-
edge discovery and data-mining it can be used to guide experiments better as
well as to gain valuable insight into biological systems. It can therefore be used
to produce experimentally testable hypotheses as well as provides us with a re-
liable way to test many of those hypotheses rapidly.
Since, biological systems come in a range of sizes and variety, a large number
of computational approaches have been developed to deal with the diversity of
such systems. A popular approach to model cellular systems such as cell-cycle
is the boolean approach [4, 5]. Such an approach is based on the fact that some
molecular systems are very robustly designed and that timing of events is not
of critical importance. The main aim of this modeling approach is to predict
the sequence of dynamical states confidently in cases where intricate machin-
ery of the system is not well-known. On the other end of the spectrum is the
stochastic simulation of models to accurately predict time-dependent behavior
of systems in which interactions are well established [6, 7]. In between, there are
a plethora of modeling approaches, prominent amongst them being reverse en-
gineering genetic networks [8, 9] and bayesian approaches [10, 11]. One of the
most well established and popular approach is the use of differential equations
to model such systems [12, 13, 14, 13, 15]. This modeling approach produces
the most faithful replica of the chemical processes in the cell and is perhaps, the
most accurate representation of the cellular events. Modeling cellular systems
in the form of differential equation though requires a very detailed and mech-
anistic knowledge of the underlying biological interactions, and is thus most
demanding in terms of biological input. Although, this approach is also com-
putationally intensive, due to advances in modern computing technology this
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obstacle has largely been overcome, except for some extremely huge systems.
As diverse as the modeling approaches, a large variety of analysis tools have
also been developed to better understand these models. The tools most of-
ten used in differential equation models of biological systems are dynamical
analysis and sensitivity analysis. Dynamical analysis of models reveals the in-
formation about the different dynamical states of the whole system, e.g. hys-
teresis and bistability in the system, reversibility and oscillatory behavior etc.
[13, 16, 14, 12, 17, 18] Although mathematically elegant and insightful, such
an analysis fails to produce an experimentally testable hypothesis and a valid
target for treatment approaches. For this reason, amongst others, we chose sen-
sitivity analysis as our preferred tool for analysis of kinetic models.
Sensitivity analysis is an enabling tool for the investigation of robustness and
fragility in networks relevant to human health and more generally for model-
based knowledge discovery. Sensitivity analysis is an elegantmethod to compu-
tationally discover critical components of a large and complex system. It aims
to answer the question, which part of the system affects it the most and thus is
most important. It provides a clean, experimentally testable output. The valid-
ity of using such approach is evident in its popularity, as seen from a literature
review.
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1.1.1 Sensitivity Analysis in Literature
Leibler computationally predicted and later experimentally verified robust fea-
tures of chemotaxis control networks [19, 20]. Cho et al., used sensitivity anal-
ysis to study TNF-α-mediated NK-κB signalling where parametric uncertainty
was addressed using a monte-carlo parameter sampling protocol; a family of
random parameter sets, generated from the best parameter guess, was used to
calculate the sensitivity profile in a region of parameter space [21]. Bullinger
and coworkers explored the robustness of models of programmed cell death
or apoptosis [22] while Stelling et al., computationally identified points of ro-
bustness and fragility, using monte-carlo sensitivity analysis and Overall State
Sensitivity Coefficients (OSSCs), in models of circadian rhythm [23]. Mahdavi
et al., employed sensitivity analysis, in conjunction with a mechanistic model of
transcription-3 (Stat3) pathway kinetics, to better understand stem cell differen-
tiation [24], while Luan et al., used an uncertain mechanistic model of the coag-
ulation cascade in combination with monte-carlo sensitivity analysis, to show
that computationally derived sensitive mechanisms were consistent with anti-
coagulation therapeutic strategies [25]. Sensitivity analysis has also been used
to integrate model identification and discrimination with optimal experimen-
tal design. Kremling et al., investigated the benchmark problem of growth of
a microorganism in a continuous bioreactor subject to feed shifts using sen-
sitivity based model identification and discrimination strategies; they deter-
mined optimal experimental design and perturbation strategies to identify and
discriminate between rival model formulations [26]. Gadkar et al., identified
signal transduction models from time-course measurements using a nonlinear
scheme to estimate missing protein measurements from measured values, pro-
posed strategies to calculate D-optimal experimental designs that maximized
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the experimental information for model identification and proposed an itera-
tive strategy to explore the space of model structures [27, 28]. Other optimal
experimental design and model identification studies are resident in the litera-
ture [29, 30, 31] along with many techniques to estimate sensitivity coefficients
for models composed of ordinary differential equations, differential algebraic
and stochastic equations [32, 33, 34, 35, 36, 37, 38, 39, 40, 41].
Themain advantage of using kinetic modeling coupledwith sensitivity anal-
ysis is that such a framework gives results which are directly relatable to the
underlying biology of the system.
1.2 An overview of cell cycle
The process by which cells grow and divide is called the cell cycle. The lifetime
of a cell is divided into G1 (Gap 1), S (Synthesis of DNA), G2 (Gap 2) and M
(Mitosis) phases, and an additional G0, or the resting phase. The cell receives
signals from the extra-cellular environment, e.g. growth hormones as well as
from intracellular checkpoints which determine the rate of growth of the cell
and the appropriate time for cellular division. Three main checkpoints have
been identified at which the cell checks to see whether the previous stages have
been completed satisfactorily and whether it is in a good enough physiological
state to continue to the next stage. These checkpoints occur in the late G1 phase
(Restriction point), late G2 phase and in the latter stage of M phase. Once the
cell gets past the Restriction point, it is committed to go through the cell cycle
[42, 43, 44, 45, 46, 16].
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The cell cycle is regulated by a family of proteins called Cdks (Cyclin de-
pendent kinases) and Cyclins, which bind to them. The programmed synthe-
sis and degradation of different cyclins is responsible for the progression of
cell through the various cell cycle stages [43, 42]. Passage through the Re-
striction point and into the S phase is regulated by Cdk4 and Cdk6, which
complex with CycD and Cdk2 which complexes with CycE. D-type Cyclins
(D1, D2, D3) act as growth factor sensors and get induced in their presence.
CycD2/D3 induce the formation of Cdk2 [42, 43]. The Cyclin-Cdk complexes
are inhibited by special polypeptide inhibitors, called the Cyclin Dependent
Kinase Inhibitors (CDKIs or CKIs). The INK4 family of CKIs consisting of
p16INK4a,p15INK4b,p18INK4c,p19INK4d interacts with CycD-Cdk4/6 complex. Thus,
CycD-Cdk4/6 complex titrates away the CKIs, leading to an increase in the con-
centration of CycE-Cdk2 complex. CycE-Cdk2 is formed in an inactive state
with phosphorylated Cdk2 and has to be dephosphorylated at Thr14 and Tyr15
to become active. Dephosphorylation is catalyzed by a phosphatase known as
CDC25A. Active Cdk2-CycE complex can also interact with CKIs p27KIP1 and
p21CIP1,WAF1,SDI1to form an inactive trimer. Aguda et al. [47] have correctly simu-
lated the Restriction Point to lie somewhere in late G1 phase, originally derived
for NIH 3T3 cells to lie about 2 hrs before the S phase. A central feature of
their model is positive feedback loop between CDC25A and active CycE-Cdk2,
CycE-Cdk2 is activated from its inactive state by dephosphorylation catalyzed
by CDC25A and CycE-Cdk2 catalyzes phosphorylation of CDC25A to make it
active. Another feedforward loop involves E2F and CycE, E2F catalyzes forma-
tion of CycE, and CycE interacts with Cdk2 to form an active complex which
catalyzes formation of free E2F by phosphorylating pRb in the pRb-E2F com-
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plex. The primary role of active CycE-Cdk2 complex is to inactivate Rb famliy
of proteins by phosphorylating them. The main component of this family is the
Retinoblastoma protein or pRb. pRb in its active hypophosphorylated state is
bound with the E2F family of transcription factors [42, 43, 48, 49]. Thus, pRb on
getting hyperphosphorylated by the CycE-Cdk2 complex releases E2F bound
to itself. Release of E2F marks the beginning of S phase as it is a transcription
factor for RNA polymerases, essential for duplication of DNA.The model of
G1/S stage by Hatzimanikatis and Lee [50] is able to predict oscillatory nature
of concentration of Cyclins with time. Theywere also able to simulate activation
of cell from quiescence and vice-versa depending on E2F and CycE concentra-
tion by Bifurcation Analysis. Qu et al.[49] have modeled G1/S phase taking
into account multiphosphorylation of sites at CDC25A, pRb and CKIs p27KIP1
and p21CIP1, and studied the dynamics of the system. They showed that mul-
tisite phosphorylation is critical for instability, and positive feedback between
CDC25A and CycE-Cdk2 is responsible for limit cycle and bistability of the sys-
tem. More importantly, they showed that the same system shows a range of
dynamical behaviors, depending upon the values of kinetic parameters chosen.
Thus, underscoring the need for accurate values of kinetic rate parameter for
each reaction.
In the G2 phase, cell checks its readiness to enter M Phase and DNA dam-
age, if any, is corrected. The main molecular entity driving the cell past the
second checkpoint (G2/M) is called Maturation Promoting Factor (MPF). The
components of MPF are CycB and Cdc2(also called Cdk1 or p34)[51]. Accu-
mulation of CycB actually starts during the S phase and it starts to complex
with Cdc2 (Cdk1) to form an inactive dimer called pre-MPF. Activation of MPF
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requires Cdk1 to be dephosphorylated at Thr14 and Tyr15 residues. This reac-
tion is catalyzed by CDC25C, whereas the reverse reaction requires Wee1/Myt
kinase[52, 42]. Also, the activated CycB-Cdk1 complex can interact with the
CKI p21CIP1 to form an inactivating complex. There exist mechanisms in this
phase to check DNA damage and accordingly halt cell cycle till the damage
has been repaired. The central molecular entity for sensing DNA damage and
taking corrective action is p53. Not surprisingly, p53 is the most frequently mu-
tated gene in cancer and has been implicated in more than 50% of all cancers
[43]. Upon sensing DNA damage, it up-regulates the synthesis of CKIs p21
and p27, amongst others. Thus, p53 induced up-regulation of CKIs is respon-
sible for arresting cells at the G1/S transition (in case of stress) as well as at
G2/M (in case of DNA damage). Also, in case of irreparable DNA damage to
the cell, chemotherapeutic agents etc. p53 guides the cell towards apoptosis
(programmed cell death) by either activating death genes like BAX or down-
regulating survival genes like BCL-2. Aguda [52] has presented a detailed
model of G2/M phase and simulated cell cycle arrest in case of DNA damage.
Themain components of the G2/Mphase areMPF, CDC25C and the DNAdam-
age pathway. There exists an antagonistic behavior between Wee1 and MPF
as MPF also catalyzes phosphorylation of Wee into inactive Wee1P. The DNA
damage pathways consist of Rad3/ATM pathways and p53 pathways. Upon
sensing DNA damage, Rad/ATM pathway catalyzes phosphorylation of Chk1
to Chk1P, Chk1P in turn, phosphorylates CDC25C at Ser216 residue making it
susceptible to combination with 14-3-3σ protein and thus, sequestration. p53
on the other hand, affects a number of molecular entities, it down-regulates for-
mation of preMPF and up-regulates formation of CKI p27 and 14-3-3σ protein.
The author showed that p53 pathway is essential to arrest cell cycle in G2 phase,
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reinforcing experimental reports that p53 is a central character in enforcing G2
cell arrest [53].
Important feature of the full cell cycle model by Tyson et al.[48] is antagonis-
tic behavior between CycB/Cdk1 and Cdh1/APC, i.e. APC dependent degra-
dation of CycB is mediated by adapters Cdc20 and Cdh1. Cdc20 is activated by
CycB-Cdk1 complex, whereas Cdh1 is inhibited by the same. This creates two
antagonistic states, G1 having active Cdh1 and low CycB and S-G2-M having
high CycB and inactive Cdh1. Their model accurately predicts oscillatory be-
havior for Cyclins A, E as well as CycE-Cdk2 and CycB-Cdk1 complex. Also,
it shows rapid decrease in the concentration of tumor suppressors p27KIP1 and
pRb as CycE and CycB concentration begin to rise.
The degradation of Cyclins is done by the Ubiquitin-Mediated-Proteolysis
System (UPS). The UPS has two main steps, first the peptide ubiquitin attaches
itself to a protein, marking it for degradation and then poly-ubiquitinated pro-
teins are degraded by the 26S proteosome complex. Ubiquitination of a protein
involves co-ordinated action of three families of proteins. APC/C is one of the
largest class of ligases involved in the proteolysis of core components of cell
cycle [54, 55]. It consists of three core protein subunits and a variable sub-unit
consisting of Cdc20 and Cdh1 which confer substrate specificity [56].
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CHAPTER 2
A TEST OF HIGHLY OPTIMIZED TOLERANCE REVEALS FRAGILE
CELL-CYCLE MECHANISMS AREMOLECULAR TARGETS IN CLINICAL
CANCER TRIALS
2.1 Abstract
Robustness, a long-recognized property of living systems, allows function in the
face of uncertainty while fragility, i.e., extreme sensitivity, can potentially lead to
catastrophic failure following seemingly innocuous perturbations. Carlson and
Doyle hypothesized that highly-evolved networks, e.g., those involved in cell-
cycle regulation, can be resistant to some perturbations while highly sensitive
to others. The “robust yet fragile” duality of networks has been termed Highly
Optimized Tolerance (HOT) and has been the basis of new lines of inquiry in
computational and experimental biology. In this study, we tested the working
hypothesis that cell-cycle control architectures obey the HOT paradigm. Three
cell-cycle models were analyzed using monte-carlo sensitivity analysis. Over-
all state sensitivity coefficients, which quantify the robustness or fragility of a
given mechanism, were calculated using a monte-carlo strategy with three dif-
ferent numerical techniques along with multiple parameter perturbation strate-
gies to control for possible numerical and sampling artifacts. Approximately
65% of the mechanisms in the G1/S restriction point were responsible for 95%
of the sensitivity, conversely, the G2-DNA damage checkpoint showed a much
stronger dependence on a few mechanisms; 32% or 13 of 40 mechanisms ac-
counted for 95% of the sensitivity. Our analysis predicted that CDC25 and cyclin
E mechanisms were strongly implicated in G1/S malfunctions, while fragility
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in the G2/M checkpoint was predicted to be associated with the regulation of
the cyclin B-CDK1 complex. Analysis of a third model containing both G1/S
and G2/M checkpoint logic, predicted in addition to mechanisms already men-
tioned, that translation and programmed proteolysis were also key fragile sub-
systems. Comparison of the predicted fragile mechanisms with literature and
current preclinical and clinical trials suggested a strong correlation between effi-
cacy and fragility. Thus, when taken together, these results support the working
hypothesis that cell-cycle control architectures are HOT networks and establish
the mathematical estimation and subsequent therapeutic exploitation of fragile
mechanisms as a novel strategy for anti-cancer lead generation.
2.2 Introduction
Robustness, a system level property that allows function in the face of uncer-
tainty and perturbation, is a long-recognized characteristic of living systems
[57, 58, 59, 60]. Conversely, fragility, i.e., extreme sensitivity to small perturba-
tions, is very undesirable, potentially leading to catastrophic system failure fol-
lowing seemingly innocuous perturbations [61]. Biological reaction networks
and cellular systems operate in a dynamic context, hence, they must balance
robustness against evolvability, performance and resource limitations. Venkata-
subramaian and coworkers demonstrated the structure of complex networks
can result from a trade-off between efficiency and robustness [62] while You
and Yin explored how the environment has shaped the robust properties of bac-
teriophage T7 [63]. Stelling et al., reviewed several examples of robust biolog-
ical networks [60]; perhaps no better example of robustness can be found than
cell division. Cell division, sometimes referred to as the cell-cycle, is one of the
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most fundamental and highly regulated processes in biology. The decision to di-
vide is tightly regulated integrating extracellular signals, such as growth factors
and hormones, with intracellular cues that coordinate events leading to division
[64]. Despite extensive control and surveillance subsystems guiding the pro-
gression of cells through the division cycle, malfunctions do occur as evidenced
by the uncontrolled proliferation underlyingmany cancers [65]. Indeed, leading
researchers have hypothesized that the networks underlying cancer progression
and the phenotypic variation observed in solid tumorsmake cancer a robust and
challenging disease [66, 67]. Carlson and Doyle have hypothesized that highly-
evolved networks, e.g., those involved in cell-cycle regulation, can be resistant
to some perturbations while extremely sensitive to others. The “robust yet frag-
ile” duality of networks and systems has been termed Highly Optimized Toler-
ance (HOT) and has been the basis of new lines of inquiry in computational and
experimental biology [61].
In this study, we employ tools from systems biology, namely mathematical
modeling and monte-carlo sensitivity analysis, to explore the working hypoth-
esis that cell-cycle control architectures obey the HOT paradigm. If our work-
ing hypothesis is true, then fragile cell-cycle mechanisms should be overrep-
resented among experimentally observed malfunctions underlying solid and
hematological cancers. Moreover, the manipulation of fragile mechanisms in a
therapeutic context, which has been suggested by Kitano [68] to be more likely
to elicit an efficacious response from a network or system, should also be preva-
lent in the treatment literature. We test our working hypothesis by computa-
tionally screening three overlapping qualitative models of cell-cycle control ar-
chitectures; we employ monte-carlo sensitivity analysis and k-means clustering
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to rank-order mechanisms in cell-cycle and then contrast the predicted fragile
and robust mechanisms with literature. If our working hypothesis is true, then
the classification and therapeutic exploitation of fragile mechanisms could be
a novel strategy for anti-cancer lead generation. Moreover, while the current
development is restricted to cell-cycle control, the broader strategy of computa-
tionally probing and exploiting network weakness could be applied to arbitrary
networks relevant to human health.
2.3 Materials and Methods
2.3.1 Model formulation and validation
The whole-cycle model of Novak and Tyson (Fig. 2.1), the G1-S model of Qu
et al., (Fig. 2.2A) and the G2-DNA damage model of Aguda (Fig. 2.2B) were
implemented from literature and screened for fragile mechanisms using monte-
carlo sensitivity analysis [52, 49, 48]. In each case, the model equations were
represented as a system of Differential Algebraic Equations (DAEs) of the form:
f (x,p) −Θdx
dt
= 0 x (to) = xo (2.1)
where x ∈ Rm denotes the concentration vector, f (x,p) ∈ Rm denotes the mass
balance equation vector describing the kinetics and connectivity of the cell cycle
network and p ∈ Rp denotes the parameter vector. The diagonal m × m matrix
Θ contains 1’s for those elements of the concentration vector that are dynamic
(governed by a differential equation), 0 otherwise. We assume the mass bal-
ance vector f (x,p) is at least once differentiable with respect to its arguments.
The Novak and Tyson model, which employed complex kinetics to describe the
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G1/S and G2/M checkpoints, programmed protein expression and degrada-
tion, was composed of 18 dynamic species, 4 species constraints and 74 param-
eters. On the other hand, the G1/S and G2-DNA damage models described
only the specific molecular logic in their respective checkpoints and were mech-
anism based; the G1/S model was composed of 16 dynamic protein balances,
2 species constraints and 44 parameters while the G2-DNA damage model was
composed of composed of 15 dynamic protein balances,1 constraint and 40 pa-
rameters.
2.3.2 Computation of Overall State Sensitivity Coefficients
(OSSC)
The sensitive or fragile elements of the cell-cycle networks were determined by
computing Overall State Sensitivity Coefficients (OSSC) [23]. OSSC values were
calculated by first calculating the first-order sensitivity coefficients:
σi j (tk) =
∂xi
∂p j
∣∣∣∣∣∣
tk
(2.2)
which are solutions of the differential equation:
ds j
dt
= A (t) s j + b j (t) j = 1, 2, . . . , P (2.3)
subject to the initial condition s j(t0) = 0where j denotes the parameter index and
P denotes the number of parameters. The Jacobian matrix (A) and the matrix of
first-derivatives of the mass balances w.r.t the parameter values (B) are given
by:
A =
∂f
∂x
∣∣∣∣∣∣
(x∗,p∗)
B =
∂f
∂p
∣∣∣∣∣∣
(x∗,p∗)
(2.4)
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where (x∗,p∗) denotes a point along the nominal or unperturbed system solution.
We solved the sensitivity equations for each parameter using three different nu-
merical methods to control for possible artifacts; a 3-order fixed step size Back-
ward Difference (BDF3) method was compared with forward Finite Difference
(FD), and the fifth-order variable step-size ODE15s routine ofMatlab (TheMath-
works, Natick MA). The matrices A and B were estimated numerically at each
time step using a generalized gradient algorithm [69]. Overall State Sensitivity
Coefficients (OSSC), first used by Stelling et al., to characterize mechanisms in
circadian rhythm as fragile or robust [23], were calculated for each parameter j:
S o j (t) =
p∗j
Ns
( NT∑
k=1
Ns∑
i=1
[
1
x∗i
∂xi
∂p j
∣∣∣∣∣∣
tk
]2)1/2
(2.5)
The quantity NT denotes the number of time points used in the simulation while
Ns denotes the number of proteins/protein complexes in the model. To account
for parametric uncertainty, the OSSC values (S o j) were calculated over a family
of random parameter sets; we randomly perturbed each nominal parameter by
up to ±1-order of magnitude then solved the sensitivity balances for each fam-
ily member. To control for perturbation effects, two other random parameter
families were also tested (±50% and ±2-orders of magnitude, N=500 each).
2.3.3 Statistical analysis and clustering of overall state sensitiv-
ity coefficients
Three different statistical tests were performed to identify large statistically sig-
nificant shifts in the OSSC values with qualitative significance between different
numerical solution algorithms and random parameter families. A Welch t-test
[70] was used to find all statistically significant shifts resulting from the different
16
treatments and then a secondary test on the z−score of each shift was preformed
to find only the most prominent significant shifts. The OSSC values calculated
over the family of parameter sets were assumed to follow normal distributions
in each treatment case. The statistical significance of shifts in OSSC values for
each treatment case relative to the control were determined by performing a
Welch t-test with the null hypothesis that the means of the OSSC values were
equal at a 1% significance level. The Welch t-test is similar to the student t-test
with the exception that the two distributions being compared are not required to
have equal variances. The list of significant OSSC values was further restricted
to only those shifts with a magnitude larger than a specified z-score (0.1) away
from the squared mean displacement over the significant OSSC values. We de-
fined the displacement of an OSSC value relative to the control as:
d j,q =
(
S¯ qo j − S¯ co j
)2
, j = 1, 2, . . . , P (2.6)
where S¯ co j denotes the mean OSSC value over the family of parameter sets for
parameter j in the control while S¯ qo j denotes the same quantity for treatment
case q. A significant shift in OSSC value was accepted if:
d j,q > zσdq + µdq (2.7)
where z denotes a desired z-score, σd j denotes the standard deviation of the
total displacement over all significant OSSC values for the qth treatment case
and µdq denotes the mean of the significant displacements for treatment case q.
Large statistically significant shifts in OSSC values, while perhaps indicative of
the shifting importance of mechanisms, do not guarantee that mechanisms are
qualitatively different between treatment cases. The Spearman rank correlation
denoted by ρ and defined as:
ρ = 1 − 6
∑P
i=1 d
2
i
N
(
N2 − 1) (2.8)
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measures the difference in qualitative ranking between mechanisms by quan-
tifying the difference in the ordinal ranking of OSSC values. The quantity di
denotes the difference in the ordinal rank of mechanism i between treatment
cases, N denotes the number of pairs of values and P denotes the number of
parameters considered. The Spearman rank is bounded by −1 ≤ ρ ≤ 1; a Spear-
man rank of one indicates that two ranked lists are identical, a Spearman rank
equal to negative one indicates that two ranked lists are perfectly negatively
correlated, while a Spearman rank of zero indicates that two ranked lists are
uncorrelated.
Lastly, the distributions of OSSC values obtained from monte-carlo sampling
were clustered using a standard k-means algorithm [71]. The mean and stan-
dard deviation obtained from the monte-carlo sensitivity analysis was used to
estimate the underlying OSSC distribution (N=500 points) where the OSSC val-
ues were assumed to be normally distributed. One-hundred different clustering
attempts were run for each model to control for clustering artifacts. The most
probable configuration was reported.
2.4 Results
2.4.1 An implementation of cell cycle models shows results
qualitatively consistent with the published literature
The whole-cycle model of Novak and Tyson (Fig. 2.1), the G1-S model of Qu et
al., (Fig. 2.2A) and the G2/M-DNA damage model of Aguda (Fig. 2.2B) were
implemented from literature and screened for fragile mechanisms using monte-
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carlo sensitivity analysis [52, 49, 48]. The Novak and Tyson model, which em-
ployed complex kinetics to describe both the G1/S and G2/M checkpoints and
programmed protein expression and degradation, was composed of 18 dynamic
species, 4 species constraints and 74 parameters. The G1/S and G2/M-DNA
damage models described only the specific molecular logic in their respective
checkpoints and were mechanism based; the G1/S model was composed of 16
dynamic protein balances, 2 species constraints and 44 parameters while the
G2/M-DNA damage model was composed of composed of 15 dynamic protein
balances,1 constraint and 40 parameters. Parameter values for each model were
taken from literature. Unreported initial conditions were adjusted so that sim-
ulated model trajectories were qualitatively consistent with published values
(Fig. 2.3). Unreported initial conditions were adjusted so that simulated model
trajectories were qualitatively consistent with published values (Fig. 2.3).
2.4.2 Monte-carlo sensitivity analysis of cell cycle models re-
veals model agnostic trends in fragility
The published parameter sets, with fixed initial conditions, were used to gener-
ate families of random parameter sets (N=500, unless otherwise noted) where
each nominal parameter was perturbed by up to ±50%, ± 1-order, or ± 2-orders
of magnitude. Overall State Sensitivity Coefficients (OSSCs) were calculated
over the random parameter families for each cell-cycle model using three differ-
ent numerical algorithms. For each model, the mean OSSC values were ranked-
ordered and plotted. The Area Under the Curve (AUC), calculated using the
trapezoid rule, was used to measure the cumulative sensitivity contribution of
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Figure 2.1: Schematic of the molecular logic of the whole-cycle model of
Novak and Tyson used in this study. The Novak and Tyson
model, composed of 18 dynamic species, 4 species constraints
and 74 parameters, describes both the G1/S and G2/M check-
points and programmed protein expression and degradation.
each parameter. A cumulative cutoff of 95% of the overall sensitivity was used
to establish the list of mechanisms (Fig. 2.4) which were clustered into three
groups using a k-means algorithm. The mechanism clusters were then com-
pared with literature to determine the validity of fragility classification. Ap-
proximately 65% of the G1/S mechanisms were responsible for 95% of the sen-
sitivity, conversely, the G2-DNA damage network showed a stronger depen-
dence on a few mechanisms. Of the 44 mechanisms in the G1/S model, 29 were
responsible for 95% of the sensitivity (Fig. 2.4A). The distribution of fragility
was not specific to any single class of mechanism (Table A.1); 10 of the 29 mech-
anisms were associated with activation, phosphorylation/dephosphorylation,
20
G0 Phase
G 1 
S
G 2 
M (Mitosis)
p21
14-3-3σ p53
iCDC25(P-S216) P
aCDC25(P-S216) P
iCDC25
aCDC25
+
iCDC25(P-S216) P
14-3-3σ
P
P
P
MPF
+
pMPF
p53
-
Wee1
Wee1
P
+
P
+
p21
p53
MPF
+
MPF
+
MPF
+
chk1p
+
chk1p
+
A
G0 Phase
G 1 
S
G 2 
M (Mitosis)
E2F
p27
CDC25A
p27
CycE
Cdk2
p27
CycE
Cdk2
CycE
Cdk2
PP
CycE
Cdk2
PP
E2F
+
CycD
Cdk4/6
CycD
Cdk4/6
CycD
Cdk4/6
CycD
Cdk4/6
CycE
Cdk2
CDC25A
E2F
+
P
P
P
P
+pRB
pRB
+
PP
P
P
P
P
+
+
P
P
P
P
P
pRB
E2F
+
B
Figure 2.2: Schematic of the molecular logic of the G1/S (A) and G2/M (B)
checkpoint models used in this study. The G1/S model of Qu
et al., is composed of 16 dynamic protein balances, 2 species
constraints and 44 parameters. The G2-DNA damage model of
Aguda is composed of 15 dynamic protein balances 1constraint
and 40 parameters. Both the G1/S and G2/M models employ
mass action kinetics and the parameters are linear in the mass
balances.
six of the 29 mechanisms were associated with degradation, seven of the 29
mechanisms were associated with expression or constraints on the total concen-
tration of species in the model, while the remaining six of the 29 mechanisms
were associated with binding interactions. The dephosphorylation of CDC25,
the expression of cyclin E, the degradation of the cyclin E-CDK2 complex, and
the concentration of the transcription factor E2F were classified as the most frag-
ile mechanisms in the G1/S checkpoint (Table A.1, cluster I). The synthesis, ac-
tivation and degradation of CKIs, the expression and degradation of CDC25,
pRB concentration, the expression of cyclin D and cyclin E-CDK2 mechanisms
21
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Figure 2.3: Qualitative comparison of simulations results of the model im-
plementations used in this study. whole-cycle model of Novak
and Tyson.
dominated the second-tier of G1/S fragility (Table A.1, cluster II). Tier-three in-
volved several cyclin D mechanisms, cyclin E-CDK2 activity and E2F mediated
cyclin E expression (Table A.1, cluster III). When taken together, the most heav-
ily implicated G1/S protein was cyclin E, with 11 of 29 mechanisms, followed
by CKIs with six, CDC25 and cyclin D were each involved in five fragile mech-
anisms and E2F and pRB were each listed twice. Cyclin E is the main restriction
point cyclin, directly affecting E2F activation by phosphorylating pRb. More-
over, 16 of the 29 fragile parameters were functionally associated with cyclin
E and cyclin E-CDK2 activity. As expected, the expression and degradation of
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Figure 2.4: Cumulative Sensitivity as a function of parameter rank. The
cumulative sensitivity contribution of each parameter was cal-
culated by calculating the Area Under the Curve (AUC) using
the trapazoid rule. Mechanisms responsible for 95% of the to-
tal sensitivity in each model were collected, clustered and an-
alyzed. Panel A shows the result for G1/S model, Panel B -
G2/DNA damage model and Panel C shows the plot for the
whole cell model.
the G1/S-phase cyclins and their the associated CKIs were predicted to be im-
portant. However, the expression and degradation of cyclin E and all cyclin E
interactions were ranked higher than the corresponding cyclin D mechanisms
with the exception of the dissociation of the cyclin E-CDK2-CKI complex.
The G2-DNA damage network showed a stronger dependence on a few
mechanisms when compared with G1/S. For the G2-DNA damage network, ∼
32% or 13 of 40 mechanisms accounted for 95% of the sensitivity (Fig. 2.4B).
Consistent with G1/S, no single class of mechanism dominated the list of
fragility. The most sensitive mechanisms were related to the generation and
degradation of the cyclin B-CDK1 complex otherwise known as the Matura-
tion Promoting Factor (MPF) and DNA repair mechanisms (Table A.2). The top
five mechanisms were either directly or closely associated with the formation
and activity of MPF while DNA repair mechanisms, e.g., the expression, degra-
dation and activity of p21, 14-3-3σ and Wee1 phosphorylation dominated the
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remaining eight mechanisms (Table A.2, cluster III). Activation of inactive MPF
complex, which is negatively regulated by p53, was the most sensitive mecha-
nism (Table A.2, cluster I), followed by pMPF generation, activation and trans-
port of CDC25 into the nucleus (Table A.2, cluster II). Interestingly, while the
generation of p53 itself was not predicted to be sensitive, interactions involving
p53 were prevalent, e.g., the expression of inactive MPF and p21, both of which
are up-regulated by p53, were predicted to be sensitive.
Approximately 77% of the Novak and Tyson parameters (57 of 74) were re-
sponsible for 95% of the sensitivity (Fig. 2.4C). However, because of the complex
nature of the kinetics in the Novak and Tyson model in some cases multiple
parameters which were functionally related with the same mechanism, were
classified differently. Both global and local components of the model were pre-
dicted to be fragile. The most sensitive global mechanism was the translational
efficiency while local mechanisms such as activation of IE (hypothetical protein
which activates the E3-ligase CDC20), expression of cyclin B and CDH1 degra-
dation were predicted to be the most fragile group (Table A.3, cluster I). The
second-tier of fragile mechanisms were all associated with deregulation of pro-
grammed proteolysis (Table A.3, cluster II). Interestingly, while the percentage
of mechanisms responsible for 95% of the sensitivity of the Novak and Tyson
model was the largest of the three models, several mechanisms in cluster III
were small, including most of the G1/S checkpoint logic. Thus, sampling the
complex Novak and Tyson model produced less information than the mecha-
nistic mass-action based G1/S and G2-DNA damage models.
If our fragility results were strictly artifacts of any particular model struc-
ture, then the classification of common mechanisms in each model would be
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different; this was found not to be true (Table 2.1).
Table 2.1: Comparison of OSSC ranks for common mechanisms in the G1/S,
G2-DNA damage and Novak and Tyson models.
Mechanism G1/S (%) G2-DNA (%) Whole-cell model (%)
Generation of preMPF – 93±2 80±18
Total concentrations
Total E2F concentration 93±15 – 77±10
Total pRb concentration 86±15 – 43±16
Reactions of CKIs
Generation of CKIs 86±10 85±2 68±12
CycE-Cdk2 associating with CKI 70±9 – 38±15
Dissociation of CycE-Cdk2-CKI 57±19 – (8±23, 5±19)
CycD-Cdk4/6 associating with CKI 48±8 – 31±19
Dissociation of CycD-Cdk4/6-CKI 39±11 – (47±14, 8±23, 4±19)
Generation and Degradation
Degradation of CycE 66±24 – 38±15
Degradation of CycD 55±15 – 47±14
CycE generation catalyzed by E2F 41±26 – 73±16
There were 11 mechanisms which appeared exactly in each model, 10 mech-
anisms were classified similarly while one mechanisms was ranked inconsis-
tently across models. All 10 correctly classified mechanisms were fragile. Both
mechanisms in the G2-DNA damage network that appeared in the Tyson and
Novak model were correctly classified, while, one of the eight G1/S mecha-
nisms was misclassified. Analysis of the G2-DNA damage and Novak and
Tyson models predicted the formation of pMPF was an important mechanism
and all threemodels predicted the expression of CKIswas fragile. Both the G1/S
and Novak and Tyson models predicted that the total E2F and pRB concentra-
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tions, the degradation of the G1/S phase cyclins, E2F driven cyclin E expression
and the affinity of the cyclin D-CDK4/6-CKI complex were fragile. The mod-
els differed on the ranking of the off-rate of cyclin E-CDK2-CKI, analysis of the
G1/S phase network predicted this to be important while Novak and Tyson did
not. However, this discrepancy is likely an artifact of our insistence that mech-
anisms appear exactly in each model.
Table 2.2: Statistically significant shifts of OSSCs between solution methods us-
ing the Welch t-test. Only shifts recorded with a p-value of 0.01 and z-score of 1
are shown.
Mechanism ODE15s BDF3 FD
(σ ± µ) (σ ± µ) (σ ± µ)
G1/S model
Generation of CycE 0.6063 ± 0.3502 0.4583 ± 0.3364 0.5131 ± 0.3476
G2/M-DNA Damage model
Generation of p21 0.2846 ± 0.1514 – 0.5016 ± 0.1954
Degradation of p21 0.2823 ± 0.1478 – 0.4847 ± 0.1835
Whole cell-cycle model
CycE dependent CycE:Kip1 dissociation 0.1989 ± 0.2545 0.0463 ± 0.0798 0.0463 ± 0.0798
CycE:Kip1 dissociation giving Kip1 0.1988 ± 0.2545 0.0463 ± 0.0798 0.0463 ± 0.0798
CycE dependent Kip1 accumulation 0.1861 ± 0.2386 0.0438 ± 0.0744 0.0078 ± 0.0371
Degradation of DRGs 0.1461 ± 0.1720 0.0463 ± 0.1020 –
Synthesis of p27Kip1 0.1274 ± 0.1232 0.0272 ± 0.0447 –
Total E2F concentration 0.1524 ± 0.1424 – 0.4249 ± 0.2385
Translational efficiency 0.6657 ± 0.3816 – 0.8647 ± 0.2372
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2.4.3 The qualitative conclusions drawn from sampling the
cell-cycle models were robust to the choice of solution
method and the size of the parameter perturbation but
sensitive to the number of parameter sets sampled.
Three different numerical techniques were used to solve the sensitivity equa-
tions to control for possible numerical artifacts. The ODE15s routine of Mat-
lab (The Mathworks, Natick MA), a third-order backward-difference implicit
method (BDF3) and forward finite difference (FD), all methods generated quali-
tatively similar sensitivity results (Fig. 2.5). The lowest Spearman rank between
any two methods (ODE15s versus FD for the G1/S model) was 0.91 indicating a
worse case correlation of approximately 91%. Interestingly, while the Spearman
rank indicated good agreement between the solutionmethods, there were statis-
tically significant shifts (See 2.2) in OSSC values indicating the solutionmethods
systematically shifted mechanisms, i.e., different OSSC values were calculated
but the order or ranking of mechanisms was maintained.
Second, the cumulative Spearman rank correlation between sensitivity re-
sults generated using the ODE15s, BDF3 and FD methods for each model was
calculated as a function of the number of parameter sets sampled. While the
cumulative Spearman rank converged to the population mean as the number
of parameter sets increased, a strong population size dependence was observed
(Fig. 2.7). For each model, the results reported were obtained in the region of
convergence, hence, no additional information would have been gained if addi-
tional random parameter sets were sampled. Two additional sampling controls
were conducted to verify the robustness of the qualitative conclusions drawn
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Figure 2.5: Sensitivity analysis results as a function of model and numeri-
cal method. Scaled Overall State Sensitvity Coefficients (OSSC)
were calculated for each cell-cycle model over a family of ran-
dom parameters sets (N=500 unless otherwise noted) gener-
ated by randomly pertubing the published set by ±1-order of
magnitude. Three different numerical methods were used to
solve the sensitivity equations to control for numerical arti-
facts.
from our analysis. First, the perturbation size used to generate the random pa-
rameter families was varied to test if different conclusions would have been
drawn with different perturbation sizes; OSSC values computed over random
parameter families generated using ±50%, ± 1-order and ± 2-orders of magni-
tude showed no qualitative difference as quantified by the Spearman rank cor-
relation for the G1/S model (Fig. 2.6). The worst case correlation of 0.90 was
observed between the ±50% and ± 2-orders of magnitude cases indicating on
average 90% of the conclusions drawn between the two cases were consistent.
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Figure 2.6: Effect of the parameter perturbation size on conclusions drawn
from sensitivity analysis of the G1/S model. A family of ran-
dom parameter sets was constructed (N=150) from the nominal
set, where each parameter was perturbed by up to ±50%, ±1-
order or ±2-orders of magnitude. The ODE15s routine of Mat-
lab (The Mathworks, Natick MA) was used to solve the sensi-
tivity equations.
2.5 Discussion
Multiple lines of experimental evidence support the assertion that cell-cycle
control architectures are governed by the HOT paradigm. The single largest
block of fragility predicted in the G1/S network was functionally associated
with CDCD25 activity, cyclin E expression and activity of the cyclin E-CDK2
complex. Traditionally, cyclin E expression and cyclin E-CDK2 activity were
thought to be critical for cell-cycle progression [72, 73]. For example, Ohtsubo
et al., have shown that cyclin E-CDK2 activity was maximum during the G1/S
phase and over-expression of cyclin E accelerated cell-cycle progression [74].
Lucas et al., showed that abnormal expression of cyclin E, but not Cyclin D1, was
able to override G1 phase arrest by the INK4a family of CKIs [75]. Moreover,
studies in cancer cell-lines and patients have suggested that cyclin E expression
playes a strong role human breast cancer progression. Keyomarsi et al., found,
in human breast cancer tumors, that the cyclinE-CDK2 complex remains active
29
100 101 102
0.75
0.8
0.85
0.9
0.95
 
 
Spearman Ranks (cumulative)
Spearman Rank (all sets)
100 101 102
0.8
0.85
0.9
0.95
1
 
 
Spearman Ranks (cumulative)
Spearman Rank (all sets)
100 101 102 103
0.96
0.965
0.97
0.975
0.98
0.985
0.99
0.995
1
 
 
Spearman Ranks (cumulative)
Spearman Rank (all sets)
100 101 102 103
0.8
0.85
0.9
0.95
1
 
 
Spearman Ranks (cumulative)
Spearman Rank (all sets)
100 101 102 103
0.96
0.965
0.97
0.975
0.98
0.985
0.99
0.995
1
 
 
Spearman Ranks (cumulative)
Spearman Rank (all sets)
100 101 102 103
0.8
0.85
0.9
0.95
1
 
 
Spearman Ranks (cumulative)
Spearman Rank (all sets)
(D)(C)
(F)(E)
Parameter Set No. (log scale)
 S
pe
ar
m
an
 R
an
k
 S
pe
ar
m
an
 R
an
k
 S
pe
ar
m
an
 R
an
k
 S
pe
ar
m
an
 R
an
k
 S
pe
ar
m
an
 R
an
k
 S
pe
ar
m
an
 R
an
k
Parameter Set No. (log scale)
Parameter Set No. (log scale) Parameter Set No. (log scale)
Parameter Set No. (log scale) Parameter Set No. (log scale)
(A)
(B)
Figure 2.7: Spearman rank correlation as a function of the number of
random parameter sets sampled. The red-dashed line in all
cases denotes the cumulative Spearman Rank obtained by sam-
pling all parameter sets for any two methods. A-B: Cumula-
tive Spearman rank versus the number of parameter sets sam-
pled for the G1-S model using the BDF3 and ODE15s meth-
ods (A) and Finite Difference (FD) and ODE15s methods (B),
respectively. C-D: Cumulative Spearman rank versus the num-
ber of parameter sets sampled for the G2-M model using the
BDF3 and ODE15s methods (C) and Finite Difference (FD) and
ODE15s methods (D), respectively. E-F: Cumulative Spear-
man rank versus the number of parameter sets sampled for the
whole-cycle model using the BDF3 and ODE15s methods (E)
and Finite Difference (FD) and ODE15s methods (F), respec-
tively.
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throughout the cell-cycle suggesting a hypothesis, which was later confirmed
by Porter et al., [76], that truncated cyclin E variants, which were deregulated,
might be responsible for the constitutive function of cyclin E-CDK2 in breast
cancer tumors [77]. Keyomarsi et al., demonstrated, in a retrospective study
exploring the role of cyclin E in breast cancer patients, that cyclin E levels were
strong clinical predictors of survival andmortality [78] while Span et al., showed
that cyclin E concentration was a strong predictor of endocrine therapy failure
in breast cancer patients [79]. Recent studies, however, have challenged the tra-
ditional role of cyclin E. Geng et al., have shown, in a mouse model, that while
deletion of both cyclin E genes was lethal in-utero, deletion of cyclin E1 or cyclin
E2 was tolerated with no obvious abnormalities [80]. Moreover, double cyclin E
knockout mice were born alive if cyclin E was restored in the embroyoinc com-
ponent of the placenta [80]. Ortega et al., further challenged the role of cyclin
E-CDK2 by showing that CDK2 null mice were born viable and healthy [81].
While the cyclin E and CDK2 knockout studies seem to contradict the essential
role of cyclin E, the clinical evidence supporting the role of cyclin E in human
cancer progression indicates that further studies are required.
In addition to cyclin E expression, the activity of the cyclin E-CDK2 com-
plex and the generation, phosphorylation, dephosphorylation and degradation
of CDC25 were predicted to occupy several positions in cluster(s) I and II of
the G1/S checkpoint. Boutros et al., recently reviewed the role of CDC25 phos-
phatases in cancer progression and summarized the progress of using CDC25
inhibitors in the treatment of several human cancers [82]. The overexpression
of CDC25 at the mRNA and protein has been reported in primary tissue sam-
ples in several human cancers including breast [83], ovarian [84], prostate [85]
and colorectal [86]. Hoffmann et al., demonstrated, in human fibroblasts, that
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expression of anti-CDC25 antibodies in the G1-phase prevented S-phase entry
[87] while Hexl et al., showed that CDC25 was a necessary protein for S phase
entry by dephosphorylating the Thr-14 and Tyr-15 residues of CDK2, thereby
activating the Cyclin E-CDK2 complex [88]. The concentration of E2F and pRB,
which were constrained in both the G1/S and Novak and Tyson models, were
also predicted to be critical components of the G1/S transition. The pRB protein
has long been known to play a central role in the G1/S transition [89]. Richard et
al., showed that high expression as well as absence of pRb were associated with
increased tumor progression and higher recurrence rates in bladder cancer [90]
while Lucas et al., showed that ectopic E2F expressionwas sufficient to induce S-
phase entry and was able to override G1 phase arrest mediated by INK4 family
of tumor suppressors [91, 92]. The sensitivity analysis of the cell-cycle models
predicted that the off-rate of the cyclin D-CDK4/6 complex and the affinity and
degradation of the cyclin D-CDK4/6-CKIs trimer were predicted to be robust
or only moderately sensitive in the G1/S checkpoint while cyclin D expression
was were predicted to be fragile. Overexpression of cyclin D variants, particu-
larly cyclin D1, has been observed in several human cancers [93, 94] while cy-
clin D1−/− mice have been shown to display distinct tissue specific phenotypes
including defective proliferation [95]. Tissue-specific defects were observed in
cyclin D2 and cyclin D3 null mice along with proliferative malfunctions [96, 97].
Mice lacking all the cyclin D genes died prior to day E17.5 of gestation, how-
ever, most tissue and organs were formed by day E13.5 indicating that cyclin
D was not required for embryogenies [98]. More generally, cyclin E expression
and activity were ranked higher in our analysis than the respective cyclin D
mechanisms. Keenan et al., demonstrated in IIC9 Chinese hamster embryonic
fibroblasts that cyclin E expression renders cyclin D-CDK4 dispensable for in-
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activation of pRb, activation of E2F and for promoting G1-S progression [99].
When taken together, the cell-line, animal model and patient studies support
the classification of fragile mechanisms obtained from sensitivity analysis of the
cell-cycle models.
The hypothesis that computationally identified fragile mechanisms can be
exploited as possible molecular targets, first explored using a model of the hu-
man extrinsic coagulation cascade by Luan et al., [25], holds for cell-cycle con-
trol architectures. Consider the G1/S checkpoint prediction of the fragility of
CDC25 mechanisms. While the inhibition of CDC25 as a cancer treatment strat-
egy is still in the laboratory stage, several CDC25 inhibitors in development
have shown promising results. The CDC25 inhibitor PM20 inhibited growth in
human hepatoma-derived Hep3B cell-lines at a inhibitory concentration (IC) >
700 nM, PM-20 also inhibited the growth of MCF7 mammary carcinoma cells,
FemX melanoma cells, PCI squamous cell carcinoma from tongue, albeit at a
higher ICs [100]. BN82685, which inhibited CDC25A, B and C in-vitro and in-
vivo and repressed the growth of HeLa and human pancreatic tumor Mia PaCa-
2 xenografts in athymic nude mice, also inhibited the growth of human cell
lines resistant to cytotoxic drugs e.g., the humanmyeloblastic leukemia cell-line
HL-60 [101, 82]. The CDC25 antagonist, CPD-5, inhibited the growth of the rat
hepatoma cell-line JM-1 in-vitro and the mouse cancer cell-line tsFT210 through
selective inhibition of CDC25 [102, 103]. Orally administered IRC-083864, an-
other CDC25 inhibitor, suppressed tumor growth in an LNCaP xenograft mouse
model [104]. Inhibition and degradation of the active cyclin E-CDK2 complex,
the second ranked mechanism in the G1/S network, has also been exploited
as a treatment strategy. Bristol-Myers-Squibb (BMS) developed BMS-387032, a
cyclin E-CDK2 inhibitor, with an IC50 of 95 nM [105]. Preclinical and phase I
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studies exploring the use of BMS-387032 for the treatment of Ovarian cancer
demonstrated that BMS-387032 possessed better efficacy than Flavopiridol, a
promiscuous CDK inhibitor [106, 107]. More generally, the strategy of inhibit-
ing CDKs, for example using molecules like Flavopiridol, has been an active
area of research. Flavopiridol, which was the first cyclin dependent kinase in-
hibitor in clinical trials, alone or in combination with other drugs is currently
being investigated in 52 active phase I or II trials [108, 109]. Flavopiridol has
been proposed for the treatment of patients with recurrent, locally advanced, or
metastatic soft tissue sarcoma [110], for the treatment of lymphoma and mul-
tiple myeloma [111], for the treatment, in combination with Trastumuzumab,
of metastatic breast cancer [112] or in combination with other drugs such as
Cisplatin and Carboplatin for the treatment of advanced solid tumors [113]. An-
other potent CDK2 inhibitor, CYC202, is in phase II trials for non-small cell lung
cancer [114]. The fourth ranked mechanism in the G1/S model was the genera-
tion of cyclin E. E7070, a synthetic sulfonamide which depletes cyclin E, inhibits
CDK2 in addition to modulating CKIs expression, is currently being evaluated
in a phase I dose ranging study for the treatment of pancreatic and lung cancers
[115, 116].
The correlation between fragility and treatment strategy was also found to
hold for the G2/M-DNA damage network. The activation of preMPF (a com-
plex of cyclin B and CDK1), catalyzed by CDC25, was predicted to be the
most sensitive mechanism in the G2/M-DNA damage model while three of
the four tier-two G2/M-DNA mechanisms were associated with CDC25 ac-
tivity. The CDC25 inhibitors presented in the G1/S discussion, e.g., BN82685
could perhaps be used to modulate CDC25 activity in the G2/M phase of cell-
division. Modulation of the formation of cyclin B-CDK1 Bryostatin-1, a pro-
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tein kinase C (PKC) inhibitor and antagonist of the cyclin B-CDK1 complex,
has been explored in phase II studies for the treatment of patients with multiple
myeloma [117] or metastatic colorectal cancer [118] as well as a phase I study for
the treatment of patients with relapsed non-Hodgkin’s lymphoma and chronic
lymphocytic leukemia [119]. In preclinical models, Bryostatin-1 has demon-
strated single-agent activity against B16 melanoma, M5076 reticulum sarcoma
and L10A B-cell lymphoma [120, 121]. Bryostatin-1 has been shown to dis-
rupt cyclin B-CDK1 complex formation and activity by several different mech-
anisms. Hayun et al., demonstrated, using an in-vivo HL-60 mouse leukemia
model, that Bryostatin-1 in combination AS101 upregulated p21 expression, a
cyclin dependent kinase inhibitor of CDK1 [122]. Aseiedu et al., demonstrated
that Bryostatin-1 was correlated with dephosphorylation of CDK2 [123] while
Koutcher et al., showed in both in-vitro and in-vivo models that Bryostatin-1 in-
hibited p34 kinase activator and decreased cyclin B1 expression [123, 124].
Modulation of translational efficiency, predicted to be the most important
factor in theNovak and Tysonmodel, andmanipulation of programmed protein
degradation, which occupied seven of the top eight mechanisms in the Novak
and Tyson model and was prominently featured in both the G1/S and G2/M-
DNA damage networks, are both active areas of therapeutic development. Ini-
tiation of translation in Eukaryotes is thought to be rate limiting [125, 126]
and overexpression of initiation components, for example the elongation fac-
tor elF4E, occurs frequently in human cancers [127, 128]. Eukaryotic translation
occurs via two mechanisms, a CAP-dependent mechanism which accounts for
processing of 95-97% of the total cellular mRNA [129] and an Internal Ribosome
Entry Site (IRES) dependent route which is active during specific events, for
example, apoptosis where many of the CAP-dependent factors have been de-
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stroyed [129, 130]. Small molecule and peptide protein synthesis inhibitors, for
example, cycloheximide, puromycin, emetine or PE38, a truncated Pseudomonas
exotoxin lacking a cell binding domain, have been shown to induce apopto-
sis by downregulating the rate of macromolecular synthesis albeit with very
different molecular mechanisms. Arnqvist and coworkers demonstrated down-
regulation of macromolecular synthesis in MCF-7 breast cancer cells following
cycloheximide, puromycin or emetine exposure in the presence and absence of
Insulin-like Growth Factor 1 (IGF-1) [131]. Addition of puromycin, cyclohex-
imide and emetine to in-vitro cultures of MCF-7 cells, in the absence of IGF-1,
resulted in increased apoptosis at 48 hr relative to the control. Conversely, in
the presence of IGF-1, a concentration dependent reduction in apoptosis was
observed for all three translation inhibitors. Bjornsti and Houghton recently
reviewed another small molecule translation inhibitor under investigation as
an antitumor agent, Rapamycin [132]. Rapamycin inhibits the Target of Ra-
pamycin (TOR) protein, a serine/threonine kinase involved in several cellular
functions, including CAP-mediated translation initiation. While Rapamycin has
FDA approval as an immunosuppressant, development of anticancer therapies
has been slow, despite antitumor activity against several solid-tumor models
in the National Cancer Institute (NCI) screening program [133, 134, 135]. Sev-
eral different Rapamycin analogs have been evaluated in clinical trials for the
treatment of different indications including pediatric patients with relapsed or
refractory acute leukaemia and renal-cell carcinoma where it resulted in a 7%
objective response rate [132, 136]. Peptide inhibitors have also been used to
downregulate translation; BL22, an immunotoxin developed and tested by Pas-
tan, Krietman and coworkers at theNational Cancer Institute (NCI) for the treat-
ment of Chronic Lymphocytic Leukemia (CLL) [137], consists of the variable FV
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fragment of the RFB4 antibody conjugated to the anti-translation peptide war-
head PE38. Because PE38 lacks a cell-binding domain, it can only be incorpo-
rated into cells where the FV domain of BL22 binds. Once internalized, PE38
is liberated through a specific proteolytic cleavage mechanism and translocated
via the KDEL receptor to the endoplasmic reticulum and eventually to the cy-
tosol where it ribosylates components of the translation machinery. Siegall et al.,
showed that ribosylation of translation components inhibited protein synthesis
[138] often leading to apoptotic cell death [139], however other death mecha-
nisms may have played a role in different cell types [140, 141]. When taken to-
gether, the anti-translation results demonstrate that inhibition of macromolecu-
lar synthesis which in turn induces cell-death could be a viable anti-cancer strat-
egy which is unknowingly based upon the exploitation of a fragile mechanism.
The second group of fragile mechanisms predicted in Novak and Tyson and
more generally across the G1/S and G2/M-DNA damage networks involved
deregulation of programmed protein degradation. Programmed proteolysis of
cell-cycle components via the Ubiquitin Proteasome System (UPS), which is
known to be a critical component driving cell-cycle progression [142], has been
the target of several different therapeutic developments [143]. UPS operates
in two discrete steps: first, the 8kDa peptide ubiquitin is attached to the protein
substrate in an ATP dependent manner therebymarking the protein for destruc-
tion; second, the poly-ubiquinated proteins are degraded by the 26S proteasome
complex [144]. The ubiquination of target proteins involves the coordinated ac-
tivity of three families of enzymes; the ubiquitin activating enzyme family (E1),
the ubiquitin-conjugating enzyme family (E2) and the ubiquitin ligase family
(E3) [145]. While E1 malfunctions have not been observed in cancer, deregula-
tion of E3 and to a lesser extent E2 activity has been directly linked to cancer
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progression [145]. The Novak and Tyson model has only a skeleton representa-
tion of the UPS system, however, it does explicitly represent Cell Division Cy-
cle protein 20 (CDC20), CDH1 and Anaphase Promoting Complex/Cyclostome
(APC/C), all which are components of the E3 complex. APC/C is the core sub-
unit to which the adapter proteins CDC20 and CDH1, which confer substrate
specificity, bind [146, 147, 148]. Inhibition of specific E3 ligases remains a tech-
nical challenge [149], however, there have been some attempts to employ this
strategy therapeutically. A class of cis-imidazoline analogs called Nutlins were
synthesized which could displace p53 from the MDM2-p53 complex thereby in-
hibiting the programmed proteolysis of p53. Anti-tumor activity of Nutlins-3
against a human osteosarcoma xenograft model in nude mice showed 90% in-
hibition of tumor growth relative to control [150].
In this study, we tested the working hypothesis that cell-cycle control archi-
tectures are governed by the HOT paradigm by computationally probing mod-
els of protein-protein networks involved in cell-cycle regulation using monte-
carlo sensitivity analysis. Consistent with the previous work of Luan et al., and
the conjecture of Kitano, the anecdotal comparison between the predicted group
of fragile cell-cycle mechanisms and literature suggested that cell-cycle control
architectures are HOT networks [25, 68]. However, while different controls were
conducted to ensure the fidelity of the monte-carlo sampling protocol, the math-
ematical models being explored were coarse-grained and not structurally com-
plete, hence, unknown factors not included in our analysis may influence our
conclusions. Quantifying the impact of structural uncertainty on the qualita-
tive conclusions drawn from our analysis remains a critical challenge. Certainly
the correlation between efficacy and fragility is model independent; Luan et
al., demonstrated that fragile mechanisms correspond to current preclinical and
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clinical treatment strategies for thrombosis using a similar monte-carlo sam-
pling strategy applied to a model of the human extrinsic coagulation cascade
[25]. What is less clear is when and why the classification of a mechanismmight
switch between fragile and robust or vice-versa. Initial results presented in this
study suggest that while the quantitative values of sensitivity coefficients cal-
culated between several different models with overlapping biology will change
between models, the qualitative conclusions drawn are possibly invariant to
the model description. However, this conclusion has not been generally estab-
lished and is likely, as suggested by recent work by Luan et al., to be true only
for a subset of mechanisms [151]. A top-down strategy to explore the struc-
tural uncertainty issue would be to construct detailed subsystems models of
the coarse-grained components which were determined by our analysis to be
fragile, e.g., translation or the Ubiquitin Proteasome System. While a top-down
strategy does not specifically address the theoretical aspects of the influence of
structural uncertainty, it would allow the determination of the molecular inter-
actions which are perhaps mediating fragility in the coarse-grained model. For
example, if translational efficiency is in fact a fragile mechanism, then analysis
of a detailed model of translation should produce a list of fragile mechanisms
that have been observed experimentally. A similar argument could be made
for programmed proteolysis. A second critical issue that was not addressed in
this study was the safety of exploiting fragile mechanisms. The HOT paradigm
suggests that fragile mechanisms are possible efficacious targets, however, noth-
ing can be said regarding safety. There are several examples resident in the lit-
erature where highly efficacious strategies resulted in unwanted and possible
harmful side effects, e.g., the association of rofecoxib with adverse cardiovas-
cular events [152]. While there may be no direct and obvious linkage between
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fragility and safety for single agents, sensitivity analysis could have a role to
play when exploring drug combinations. Initial studies by Luan et al., using
combinations of coagulation inhibitors and a model of the coagulation cascade,
have suggested that shifts in the ranking of mechanisms could be used to pin-
point the molecular nature of drug-drug synergies, however, this analysis is
preliminary and at best would be retrospective [25].
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CHAPTER 3
MODELING AND ANALYSIS OF AN ENSEMBLE OF EUKARYOTIC
TRANSLATION INITIATIONMODELS
3.1 Abstract
The programmed synthesis and degradation of proteins plays a central role in
the regulation of cell cycle. Analogous to growth-factor stimulated gene expres-
sion, translation initiation is also up-regulated in the presence of growth factor
signals. Deregulation of protein machinery involved in translation initiation
has been implicated in many different cancers. In this study, we constructed a
mathematical model describing the integration of growth factor and stress sig-
nals with the activation of translation initiation. Both kinetic parameters and
unspecified initial conditions (a total of 431 parameters) were estimated using
an adaptive step-size random search algorithm that minimized the residual be-
tween model simulations and 28 experimental data sets taken from multiple
laboratories. We studied the effect of interactions and proteins on the entire
network using systems-biology tools like sensitivity analysis and coupling co-
efficients in the presence and absence of growth factors. We found that whereas
proteins Akt and mTor played an important role in the presence of growth fac-
tors, the effect of negative regulators such as PTEN and 4EBP1 assumed impor-
tance in their absence.
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3.2 Introduction
The regulation of translation is a critical step in the control of eukaryotic prolif-
eration and differentiation programs. Translation rates of many cell-cycle and
survival proteins are modulated by growth factor, hormone and mitogenic sig-
nals [153]. These extracellular signals regulate the availability and activation
of intracellular initiation factors required for the recognition of the 5’ cap on
the mRNA. Given its central role in cell biology, evolutionarily optimized cel-
lular infrastructure like translation might be expected to be robust. Robust sys-
tems or networks are able to maintain function despite component failures or
perturbations. A robust translation architecture could provide cells with a sec-
ondary regulatory system in the event of transcriptional malfunctions. How-
ever, even in highly engineered or evolved subsystems, such as translation, mal-
function of key components could result in program failure [61, 58, 60]. In fact,
deregulated translation, especially involving initiation mechanisms, has been
implicated in a spectrum of cancer types including breast and prostate cancer
[154, 125, 155, 156, 157, 158, 127, 159].
The development of tools to estimate the robustness of network components
has been an important outcome of systems biology. The assessment of robust
and fragile features relies upon the computation of different measures of how
networks respond to perturbation. Techniques such as monte-carlo sensitivity
analysis have been applied to many systems to estimate network properties.
Stelling et al. identified robust and fragile interactions in circadian rhythm by
computing Overall State Sensitivity Coefficients (OSSCs) over a family of ran-
domized parameters [23]. OSSCs measure how an infinitesimal change in the
nominal value of a parameter influences all other network components dur-
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ing a specified time-window. Luan et al. characterized the fragile components
of the human coagulation cascade by computing OSSC values using random-
ized parameters [160]. The Luan et al. study demonstrated that sensitive inter-
actions approximately corresponded with anti-coagulation therapeutic targets.
Similarly, Nayak et al. showed that fragile interactions in cell-cycle control ar-
chitectures were similar to anti-cancer targets [161]. Several other noteworthy
studies have also demonstrated the utility of monte-carlo sensitivity analysis
[26, 24]. However, sensitivity analysis does have limitations. First, the compu-
tation of sensitivity coefficients, especially by brute force methods such as finite
difference, can be numerically problematic. Also, sensitivity analysis does not
evaluate the ability of a network to maintain performance despite structural or
operational perturbations. Other techniques, such as Structured Singular Values
(SSVs) or direct simulation have been used to explore this question [162].
In this study, we investigated possible sources of structural fragility in the
translation initiation architecture using computational tools. The motivation
for this study was, in part, provided by an earlier work that suggested trans-
lation was a fragile subsystem in the eukaryotic cell cycle [161]. However, in
the previous study the description of translation was course-grained and in-
sight into which molecular components were critical could not be determined.
To this end, we formulated and analyzed a canonical family of mechanistic eu-
karyotic translation initiation models compiled across multiple cell-lines. By
exploring a consensus network, our analysis was perhaps more applicable to a
wider range of cell-lines or primary tissues. Currently, we have only explored
initiation mechanisms as translation regulation occurs primary at the initiation
level [154]. The strategy and tools developed here are network agnostic and can
be applied to other molecular networks easily. We tested the hypothesis that
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malfunctions in only a few key proteins or interactions was likely responsible
for translation deregulation. To this end, we analyzed a consensus mechanis-
tic model of the eukaryotic translation initiation program, a canonical archi-
tecture compiled across multiple cell-lines [154]. Our initiation model was not
specific to a cell-line or tissue. Rather, we explored a canonical initiation archi-
tecture compiled across multiple cell-lines. By exploring a consensus network,
our analysis was more general and perhaps applicable to a wider range of tis-
sues. Using literature, we formulated the model as a set of coupled non-linear
Ordinary Differential Equations (ODEs). The model was deterministic and ex-
plained population averaged behavior as opposed to translation dynamics in a
single-cell. Additionally, we assumed spatial homogeneity. However, we did
differentiate between cytosolic and membrane localized processes. Translation
model parameters and initial conditions were estimated by comparing simula-
tions and experimental measurements. Twenty-eight data sets were compiled
from in-vitro and in-vivo studies in multiple cell-lines [163, 164, 165]. Because of
the complexity of initiation network, we were unable to estimate unique model
parameters. Instead, we estimated an ensemble of possible model parameter
sets [166, 167]. We identified over two-thousand probable sets based upon a
similar simulation error. Each member of the parameter ensemble represented
a different operational paradigm for the initiation network. By analyzing the
model over these configurations, we identified structurally fragile components
that were likely parameter independent.
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3.2.1 A brief discussion of the initiation netwok
A mathematical model describing the integration of growth factor and stress
signals with translation initiation was constructed . The model consisted of 145
proteins/protein-complexes and 286 reactions and its connectivity was assem-
bled from literature [168, 129, 169, 170, 171, 172, 173, 174, 132, 175, 176, 177, 178].
While the model described both Cap and Internal Ribosome Entry Site (IRES)
initiation mechanisms, we focused on Cap mediated translation as it is the
dominant translation mechanism accounting for 95-97% of all translated mRNA
[129]. Fig. 3.1 shows a schematic of the initiation network, whereas Table B.1)
gives a description of all the reactions in the model. Two regulatory check-
points control eukaryotic translation initiation following growth factor or hor-
mone binding. We did not differentiate between the behavior of different kinds
of receptors, for e.g., while in Platelet-derived growth factor receptor (PDGF)
family the ligand is a dimer that cross-links the two receptors, in epidermal
growth factor receptor family (EGFR) dimerization takes place through con-
formational change in the extracellular domain [44]. Binding of extracellular
ligands to transmembrane surface receptors promotes the formation of multi-
meric adaptor complexes. These complexes composed of proteins such as Shc,
Grb2, Ras and SoS promote the attachment and activation of Phosphoinositide
3-kinases (PI3K). PI3K and the tumor suppressor PTEN (phosphatase and tensin
homolog) form the first of the two regulatory checkpoints controlling initiation.
PI3K has a wide spectrum of effects in the cell and can regulate receptor origi-
nate MAPK signaling [179]. With respect to translation, PI3K catalyzes the con-
version of plasma membrane lipid phosphatidylinositol-4,5-biphosphate (PIP2)
to phosphatidylinositol-3,4,5-triphosphate (PIP3). Conversely, PTEN converts
PIP3 back to PIP2. The ratio of PIP3 to PIP2 is critical because of the down-
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Figure 3.1: Schematic of the Eukaryotic translation initiation network gov-
erning the formation of the 80S initiation complex. A complete
listing of all interactions and parameters used in this study is
given in Table B.1
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stream role of PIP3. PIP3 is responsible for recruiting key proteins such as Pdk1
and Akt to the plasma membrane where they become activated. Upon local-
ization, Pdk1 phosphorylates and activates Akt [173, 172, 170]. Akt is a kinase
involved in many different cellular processes [180]. In the context of translation,
Akt activates another key kinase mTor (mammalian Target of Rapamycin) both
directly by phosphorylation and indirectly by phosphorylating the TSC com-
plex (TSC1-TSC2 dimer). The state of the TSC1/2 dimer is the effector of the sec-
ond regulatory checkpoint. The TSC1/2 complex controls the balance between
two forms of the Rheb protein, namely, Rheb-GTP and Rheb-GDP. Rheb-GTP
directly activates mTor while the Rheb-GDP form is inactive. Once activated,
mTor is responsible for initiating translation in two distinct ways. First, mTor
activates the p70 protein (also called S6K) by phosphorylation at T-389 [181].
Activated p70 in turn activates the 40S ribosome. Second, mTor phosphorylates
and inactivates 4E-BPx (Eukaryotic initiation factor 4E Binding Protein). In the
absence of external signals, 4E-BPx sequesters eIF4E (Eukaryotic Initiation Fac-
tor 4E) and downregulates cap-binding complex assembly. Three 4E-BPx iso-
forms have been identified, all of which share a common eIF4E binding motif
[182, 183, 184]. 4E-BPx is phosphorylated by mTor at multiple sites [185, 186].
Phosphorylated 4E-BPx realeases eIF4E which then promotes the formation of
the eIF4F cap binding complex. The eIF4F-mRNA complex then binds 43S ribo-
somes. 43S ribosomes are composed of 40S ribosomes, initiation factors (eIF1,
eIF3, etc) and the ternary eIF2-GTP-met-tRNA complex. The aggregate eIF4F-
mRNA-43S complex is also called the 48S ribsome complex. Formation of 48S
is followed by the mRNA scanning step and the subsequent hydrolysis and dis-
sociation of eIF2-GTP. Removal of the eIF2-GTP promotes the binding of 60S
ribosome with the 48S complex to form the final 80S initiation complex.
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3.3 Materials and Methods
3.3.1 Formulation and solution of the model equations.
The translation initiation model was formulated as a set of coupled Ordinary
Differential Equations (ODEs):
dx
dt
= S · r (x,p) x (to) = xo (3.1)
The symbol S denotes the stoichiometric matrix (145 × 286). The quantity x de-
notes the concentration vector of proteins or protein complexes (145 × 1). The
term r (x,p) denotes the vector of reaction rates (286 × 1). Each row in S de-
scribed a protein while each column described the stoichiometry of network in-
teractions. Thus, the (i, j) element of S, denoted by σi j, described how protein i
was involved in rate j. If σi j < 0, then protein iwas consumed in r j. Conversely,
if σi j > 0, protein i was produced by r j. Lastly, if σi j = 0, there was no protein i
in rate j. We assumed mass-action kinetics for each interaction in the network.
The rate expression for protein-protein interaction or catalytic reaction q:∑
j∈{Rq}
σ jqx j →
∑
p∈{Pq}
σpqxp (3.2)
was given by:
rq
(
x, kq
)
= kq
∏
j∈{Rq}
x−σ jqj (3.3)
The set
{
Rq
}
denotes reactants for reaction q. The quantity
{
Pq
}
denotes the set
of products for reaction q. The kq term denotes the rate constant governing the
qth interaction. Lastly, σ jq, σpq denote stoichiometric coefficients (elements of
the matrix S). We treated every interaction in the model as non-negative. All re-
versible interactions were split into two irreversible steps. The mass-action for-
mulation, while expanding the dimension of the initiation model, regularized
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the mathematical structure. The regular structure allowed automatic genera-
tion of the model equations. In addition, an analytical Jacobian (A) and matrix
of partial derivatives of the mass balances with respect to the model parameters
(B) were also generated. Mass-action kinetics also regularized themodel param-
eters. Unknown model parameters were one of only three types, association,
dissociation or catalytic rate constants. Thus, although mass-action kinetics in-
creased the number of parameters and species, they reduced the complexity of
model analysis. In this study, we did not consider intracellular concentration
gradients. However, we accounted for membrane and cytosolic proteins by ex-
plicitly incorporating separate membrane and cytosolic protein species.
3.3.2 Formulation of the objective function used to define the
parameter ensemble and simulation error analysis.
Twenty-eight experimental constraints were used to define the parameter en-
semble. These constraints consisted of in-vitro and in-vivo time-dependent and
steady-state data sets. To compensate for different data time-scales, a weighting
strategy was used in the error computation:
E (p) =
∑
k∈A
2k (p) + γβ
∑
j∈B
2j (p)
 (3.4)
The weighting coefficient 0 ≤ γβ ≤ 1 was a linear function of the fitting algo-
rithm restart iteration β. An evolutionary algorithm minimized the error func-
tion E (p) by searching over different parameter vectors p. The parameter vector
p consisted of kinetic constants and unknown initial conditions. In the current
model 431 model parameters were estimated. The sets A, B denote groups of
constraints. In this study, A consisted of the in-vitro time-series data of Lorsch
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et al. [164]. The Garami et al. constraints made up B. The terms 2k and 2j de-
note the squared error between simulations and experimental measurements.
Steady-state values were estimated by allowing the simulation to run to steady-
state. Parameter sets were accepted into the parameter ensemble based upon
the overall error of the simulation. All parameter sets with error less than or
equal to the median error were automatically accepted. Those sets with error
larger than the median were accepted with the probability:
P (p) = exp (−E (p) /δ) (3.5)
where δ = 0.5. The form of the acceptance probability was similar to the pre-
vious work of Battogtokh et al. [167]. The scaled standard error was used to
measure the agreement between the model and experiment:
sE =
1
maxk (Y (tk))

∑NT
k=1
(
Y (tk) − Y¯m (tk)
)2
NT

1/2
(3.6)
Y (tk) denotes the experimental measurement at time k. Y¯m (tk) denotes the mean
simulated value over the parameter ensemble at time k. NT denotes the number
of experimental data points. The scaled standard error was taken from Spiegel
[187].
3.3.3 Sensitivity analysis of the initiation network.
Overall State Sensitivity Coefficients (OSSC) were used to estimate which struc-
tural elements of the initiation network were sensitive [23]. OSSC values were
determined by first calculating the first-order sensitivity coefficients at time tk:
si j (tk) =
∂xi
∂p j
∣∣∣∣∣∣
tk
(3.7)
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First-order sensitivity coefficients were computed by solving the matrix differ-
ential equation:
ds j
dt
= A (t) s j + b j (t) j = 1, 2, . . . , P (3.8)
subject to the initial condition s j(t0) = 0. In Eqn. 6.10, j denotes the parameter
index, P denotes the number of parameters in the model, A denotes the Jaco-
bian matrix, and b j denotes the jth column of the matrix of first-derivatives of
the mass balances with respect to the parameter values (denoted by B). An an-
alytical Jacobian and matrix of first-derivatives of the mass balances w.r.t the
parameters:
A =
∂fx
∂x
∣∣∣∣∣∣
(x∗,p∗)
B =
∂fx
∂p
∣∣∣∣∣∣
(x∗,p∗)
(3.9)
were generated from the model equations. The quantity fx = S · r (x,p) and
(x∗,p∗) denotes a point along the unperturbed model solution. The sensitivity
equations required that we solve the model equations to evaluate the A and B
matrices. Thus, we formulated the sensitivity problem as an extended kinetic-
sensitivity system of equations [188]: x˙s˙ j
 =
 S · r (x,p)A (t) s j + b j (t)
 j = 1, 2, . . . , P (3.10)
where x˙ = dx/dt and s˙ j = ds j/dt. We solved the kinetic-sensitivity system for
multiple parameters in a single calculation using the LSODE routine of OC-
TAVE (www.octave.org). The first-order sensitivity coefficients were then used
to calculate the OSSC value for parameter j:
O j (t) =
p j
Ns
( NT∑
k=1
Ns∑
i=1
[
1
xi
∂xi
∂p j
∣∣∣∣∣∣
tk
]2)1/2
(3.11)
The terms NT , Ns denote the number of time points considered and the state
dimension of the model, respectively. To account for parametric uncertainty,
OSSC values were calculated over a sparse sampling the parameter ensemble (N
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= 77). The scaled parameter ranking was calculated based upon the magnitude
of the OSSC value:
θs j =
NP − Rs j
NP
(3.12)
NP denotes the number of kinetic parameters and Rs j denotes the ranking of
parameter j calculated using parameter set s. We estimated the fragility of each
protein or protein-complex in the network according to the relationship:
Fs = |S|Θs (3.13)
|S| denotes the absolute value of the stoichiometric matrix. Θs denotes the vector
of scaled parameter rankings calculated using parameter set s.
3.3.4 Monte-carlo coupling analysis of the initiation architec-
ture.
Coupling coefficients of the form:
α
(
i, j, to, t f
)
=
(∫ t f
to
xi (t) dt
)−1 (∫ t f
to
x( j)i (t) dt
)
(3.14)
were calculated to understand the regulatory connectedness of the initiation
network. Here t0 and t f denote the initial and final simulation time respectively.
i and j denote the indices for the reference species (here 80S complex) and the
perturbed species respectively. The coupling coefficient α
(
i, j, to, t f
)
is the ratio
of the integrated concentration of a network output in the presence (numer-
ator) and absence (denominator) of structural or operational perturbation. If
α
(
i, j, to, t f
)
> 1, then the perturbation increases the output concentration. Con-
versely, if α
(
i, j, to, t f
)
 1 the perturbation decreases the output concentration.
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Lastly, if α
(
i, j, to, t f
)
∼ 1 the perturbation does not influence the output concen-
tration. In this study, we used two structural perturbations to probe the regula-
tory connectedness of initiation. Protein knock-downs and over-expression was
simulated where the network output was the concentration of 80S ribosomes.
Because 80S concentration was a functions of the model parameters, coupling
coefficients were calculated over the parameter ensemble.
3.4 Results
3.4.1 An ensemble model of the initiation network was able
to capture formation of 80S and predict formation of 48S
complexes
An ensemble of model parameters was constructed by minimizing the differ-
ence between model simulations and 28 experimental data sets. Both in-vitro
and in-vivo dynamic and steady-state measurements were used to estimate
model parameters. An initial best fit parameter set was randomized to form
a family of seed parameters (N = 50). The seed parameters served as start-
ing points for an adaptive step-size evolutionary algorithm [189]. The search
algorithm minimized the residual between model simulations and the 28 ex-
perimental constraints simultaneously. Both kinetic parameters and unspeci-
fied initial conditions were estimated using the search algorithm (a total of 431
parameters). The search algorithm took 100 steps (approximately 4 error func-
tion evaluations per step) from each parameter seed. The error at each step
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was stored along with the current parameter estimate. The error was calculated
by comparing the simulated value or feature with experimental observations.
Quantitative time-series data was directly compared with simulations. In ad-
dition, qualitative estimates of the phosphorylation state of key proteins were
determined from published western blots. Western blot bands were assigned
a value between (0,1) depending upon intensity (one being the maximum in-
tensity band). The difference between these normalized intensity estimates and
the simulated fraction of phosphorylated protein was minimized as part of the
ensemble. While this was not ideal, it allowed us to train the model to repro-
duce published qualitative regulatory features. Parameter estimation generated
a family of 5000 possible parameter sets each with a specified error (Fig. 3.2).
In this study we used an error cutoff to decide whether a parameter set should
be admitted into the ensemble. The median simulation error was used as a cut-
off to include/exclude parameter sets in the ensemble (Fig. 3.2, dark circles).
Parameter sets with error greater than the median were accepted with a proba-
bility (Fig. 3.2, light circles) similar to Battogtokh et al. [167]. All the parameters
below the median error were selected. Parameter sets with error greater than
the median were accepted with a probability < 1 (Fig. 3.2, light circles), with the
exact probability calculated similar to Battogtokh et al. [167]. Approximately,
52% of the possible 5000 parameter sets generated by the fitting algorithm met
the ensemble selection criteria (N = 2552). Analysis of the parameter ensemble
showed that approximately 55% of the unknown parameters and initial condi-
tions (240 of 431) were constrained with a Coefficient of Variation (CV) of less
than or equal to 50% (Fig. 3.2, inset). Of the 240 constrained parameters, 82%
were rate constants while the remaining 18% were initial conditions. The most
highly constrained initial condition belonged to eIF4E. Conversely, parameters
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Figure 3.2: Ensemble error trajectories and Correlation Matrix of Parame-
ters. (A)Model residual versus iteration number of the param-
eter fitting algorithm. Each point represents a possible param-
eter set. The dark circles denote parameter sets that met the en-
semble selection criteria. Inset: The relative distance from the
mean of sets chosen for sensitivity analysis is shown. (B)Corre-
lation coefficients were calculated for each parameter over the
entire ensemble.
governing the assembly of the adaptor complex, 48S assembly and p70 activa-
tion were the most constrained rate constants. Time dependent measurements
with/without growth factors and inhibitors were used to estimate model pa-
rameters governing the rate of 80S assembly and the phosphorylation of Akt
pathway proteins. The in-vitro study of Lorsch et al. was used to estimate model
parameters governing the kinetics of 80S assembly. Conversely, 43S data taken
from the same study was used for model validation [164]. Thus, while 80S initi-
ation complex trajectory was used to constrain the model and used as training
data. The trajectories of 43S-mRNA-GMP-PNP and 43S-mRNA-GTP generated
by the model were compared with literature data for validation. Simulations of
in-vitro 80S formation in the absence of stress had a scaled standard error (sE)
of approximately 8% (Fig. 3.3A). The predicted 43S-mRNA-GMP-PNP and 43S-
mRNA-GTP trajectories had a scaled standard error of 21% and 39%, respec-
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Figure 3.3: Simulation of in-vitro 80S formation. Dashed lines denote the
mean simulation over the parameter ensemble while points de-
note experimental measurements. The shaded region denotes
one ensemble standard deviation. A. in-vitro time-course for
the 80S complex measured by the puromycin assay. B. in-vitro
time-course for the formation of the 43S-mRNA complex (also
called 48S) when the in-vitro translation reaction was quenched
at the specified time-points by substitution of GMP-PNP in
place of GTP. The GMP-PNP and GTP 43S-mRNA simulations
were scaled by the simulated 43S-mRNA-GMP-PNP value at
20 min.
tively. The small standard fitting and prediction errors suggested the ensemble
described the in-vitro kinetics of 80S formation.
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3.4.2 A comparison of model predictions with experimental re-
sults obtained in conditions with and without serum
The study of Garami et al. was used to constrain the in-vivo phosphorylation
of Akt (PKB), p70 (S6K) and 4E-BPx [165]. The Garami et al. study contained
14 steady-state and 12 time-dependent in-vivo constraints (Fig. 3.4 - 3.5). Ap-
proximately 73% (19 of 26) of the Garami et al. constraints were captured by
the ensemble. The fraction of pAkt (S473) in serum-starved A14 NIH 3T3 cells
with/without insulin was consistent with measurements (Fig. 3.4B). Without
insulin no phosphorylated Akt was observed experimentally or in the simula-
tion (Fig. 3.4B, lane 1). Thirty-minutes following insulin addition, the fraction
of pAkt increased (Fig. 3.4B, lane 2). Reduced pAkt following the addition of
the Wortmannin, a selective PI3K inhibitor, confirmed that Akt activation was
dependent upon upstream PI3K signaling (Fig. 3.4B, lane 3). However, addition
of Rapamycin, an inhibitor of mTor in the presence of insulin increased the frac-
tion of pAkt (Fig. 3.4B, lane 4). The difference in uncomplexed pAkt with and
without Rapamycin suggested that pAkt mediated mTor activation was signif-
icant in the simulations. The in-vivo kinetics of mTor phosphorylation were not
directly constrained in the ensemble calculations. Rather, measurements of the
Rheb-GTP/GDP ratio and the fraction of phosphorylated p70 were used to con-
strain mTor activation. p70 (also known as S6K) is a downstream target of mTor
while Rheb-GTP directly activates mTor. The phosphorylation of p70 in serum
starved A14 NIH 3T3 cells with/without insulin, wortmannin and rapamycin
was captured (Fig. 3.4C, lane 2-4). However, the basal fraction of phosphory-
lated p70 (Fig. 3.4C, lane 1) was under-predicted by the model. Upstream of
mTor/p70, the Rheb-GTP/GDP ratio with/without insulin, wortmannin or ra-
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pamycinwas also only partially constrained (Fig. 3.4A). Themean basal fraction
of Rheb-GTP without insulin was consistent with observations (Fig. 3.4A, lane
1). However, the effect of insulin and insulin+wortmannin on the kinetics of the
Rheb-GTP/GDP ratio was not well described (Fig. 3.4A, lane 2-3). Interestingly,
the model was able to predict programming at the 4E-BPx-eIF4E node follow-
ing H2O2 exposure (Fig. 3.4D, A1) and heat-shock (Fig. 3.4D, A2) in Chinese
Hamster Ovary (CHO) cells [182, 163]. When taken together, these conflicting
results suggested missing structural elements governing TSC1/2 heterodimer
function and possible downregulation of phosphorylated p70 activity. The en-
semble did not capture the dynamics of the Rheb-GTP/GDP ratio following
insulin addition. However, the model did capture the steady-state behavior of
several key nodes. Consistent with [32P]-orthophosphate labeling studies with-
out insulin in serum-deprived Mouse Embryo Fibroblasts (MEFs), the loss of
TSC2 function led to increased Rheb-GTP (Fig. 3.5A). The agreement between
simulation and experiment following TSC2 deletion suggested we were captur-
ing the proper steady-state behavior of TSC1/2. The steady-state behavior of
other key proteins upstream and downstream of TSC1/2 was also captured by
the ensemble of models. Simulations of the ectopic expression of Akt, 4E-BPx
or p70 with/without insulin exposure and Rheb overexpression in HeLa and
A14 NIH 3T3 cells were compared with data as part of the ensemble calcula-
tion [165]. Ectopic expression was modeled by adding zero-order source and
first-order degradation terms to the protein balance of interest. The ectopic ex-
pression and degradation rate constants were assumed to be the same for each
protein explored. The steady-state phosphorylation of Akt, 4E-BPx and p70
with/without insulin was correctly captured by the model (Fig. 3.5A-C). Ec-
topic Rheb expression resulted in phosphorylated p70 in the absence of insulin
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Figure 3.4: Comparison of model simulations with experimental data
probing the time-dependent integration of insulin signals. All
experimental data was taken from the study of Garami et al.,
with the exception of D. All simulations were conducted over
the entire parameter ensemble (N = 2552). The bars denote
the mean fraction of activated (phosphorylated) target protein
in the presence and absence of insulin and Wortmannin (PI3K
inhibitor) or Rapamycin (mTor inhibitor). The error-bars de-
note one standard deviation over the ensemble. A: Compari-
son of the fraction of Rheb-GTP to Rheb-GDP following addi-
tion of insulin in the presence and absence of the translation
inhibitors. B: Fraction of activated Akt following insulin addi-
tion in the presence and absence of the translation inhibitors.
C: Fraction of activated p70 following the addition of insulin in
the presence and absence of the translation inhibitors. D:Effect
of physiological stress on 4E-BP1 and eIF4E binding.
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(Fig. 3.5B). Phosphorylation of 4E-BPx with/without ectopic Rheb expression
and insulin was also consistent with observations (Fig. 3.5C). However, the
model only partially captured Akt (PKB) phosphorylation following Rheb ex-
pression with/without insulin (Fig. 3.5D, lane 3-4).
3.4.3 Monte-carlo Sensitivity Analysis of the initiation net-
work shows the fragiltiy of Akt, mTOR and PI3K axis
Protein fragility was estimated based upon the sensitivity of the interactions
a protein participated in and its connectivity (see Methods). If proteins were
involved in several interactions with large sensitivity they had a high fragility
score. Conversely, proteins involved in insensitive or only a few sensitive in-
teractions were ranked lower. Protein fragility was computed over a sparse
sampling of the parameter ensemble (N = 77) 5 min and 30 min after insulin ad-
dition (Fig. 3.6A and 3.6B). The fragility of some proteins was time-dependent.
For example, proteins involved in receptor dimerization and adaptor complex
assembly (Fig. 3.6A, green) and 80S assembly (Fig. 3.6A, black) were more sen-
sitive during the early time-window. However, the fragility of translation regu-
lators was time-invariant, Globally, the most sensitive proteins were regulatory
proteins upstream of p70 activation (Fig. 3.6, red). Activated Akt, mTor, PIP3,
TSC2/TSC2-complexes and Rheb-GTP were sensitive during both time periods
following insulin addition. Activated Akt, mTor, PIP3, TSC2/TSC2-complexes
and Rheb-GTP, all of which play a role in p70 activation of 4E-BPx phosphory-
lation, were sensitive during both time-periods following insulin addition (Fig.
3.6, red). To better understand the role of connectivity, we computed the aver-
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Figure 3.5: Comparison of model simulations with experimental data
probing the steady-state integration of insulin signals. All ex-
perimental data was taken from the study of Garami et al.. All
simulations were conducted over the entire parameter ensem-
ble (N = 2552). The bars denote the mean fraction of activated
(phosphorylated) target protein in the presence and absence of
insulin and ectopic Rheb expression and the error-bars denote
one standard deviation. A: Fraction of Rheb-GTP for TSC2 wt
and knock-out MEFs. TSC2 knockout simulations were con-
ducted by setting the initial TSC2 concentration and all source
terms to zero. B: Fraction of activated p70 (S6K) in the pres-
ence and absence of ectopic Rheb expression and insulin. C:
Fraction of activated 4E-BP1 in the presence and absence of ec-
topic Rheb expression and insulin. D: Fraction of activated Akt
(PKB) in the presence and absence of ectopic Rheb expression
and insulin.
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Figure 3.6: Sensitivity analysis of the initiation architecture. (A). Esti-
mated protein fragility in the initiation model calculated over a
sparse sampling of the parameter ensemble (N = 77) for early (5
min) and late (30 min) time-windows following the addition of
100µM insulin. Overall State Sensitivity Coefficients (OSSCs)
were used to estimate the scaled ranking of each interaction
in the model from which the protein fragility was estimated.
Points denote the mean value computed over the parameter
sets sampled while the error bars denote one standard devia-
tion. (B). Estimated protein fragility normalized by the number
of interactions per protein (indicated on bars) for the 30 min
time-window. The bars denote the mean sensitivity calculated
over a sparse sample of the ensemble (N = 77), error bars de-
note one standard ensemble deviation.
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age protein fragility per connection for the mTor/p70 pathway (Fig. ??B). On
a per-connection basis, Akt was still the most sensitive protein in the initiation
model. Akt was connected with 12 other proteins where each connection had
an average ranking of approximately 0.90. mTor, which was connected with
15 other proteins, was ranked fourth with an average connection rank of 0.70.
Rheb-GTP, with 15 interactions, was ranked last with an average connection
rank of approximately 0.5. Thus, Rheb-GTP was estimated to be fragile largely
because of its connectivity instead of its innate role in the network. Interest-
ingly, pTSC1/2 and TSC1/2 were more sensitive on a per-connection basis than
either mTor or Rheb-GTP. pTSC1/2 was not highly connected, however, its one
connection (with Akt) was highly sensitive (scaled ranking of approximately
0.90).
3.4.4 Monte-carlo Coupling Analysis of the initiation network
shows the difference in network operation with or with-
out growth factors
The fragility of network components was further explored by coupling analysis.
Coupling coefficients were computed over the entire parameter ensemble (see
Methods). Protein knockdown analysis followed by k-means clustering segre-
gated proteins into three groups with/without insulin (Fig. 3.7A and 3.7B, re-
spectively). With insulin, the first group contained proteins whose knockdown
resulted in null or positive changes in 80S formation (cluster I). All members of
the second cluster were required to integrate insulin signals (cluster II). Lastly,
the third cluster contained proteins strictly required for 80S formation (cluster
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Figure 3.7: Knockdown coupling analysis of the translation initiation net-
work. The protein knockdown coupling coefficient relative to
nominal 80S complex formation was calculated for 43 differ-
ent proteins over the parameter ensemble (N = 2552) following
exposure to 200µM insulin for 6 hours. Coupling analysis was
performed for the casewhen therewas growth factor in the sys-
tem (Panel A) and with no growth factor in the model (Panel
B).
III). The knockdown of 14 proteins in cluster I had a limited or even a positive
impact on 80S formation. In these cases, redundant interactions were available
or the proteins were negative regulators of initiation. For example knockdown
of 4E-BPx enhanced 80S formation by freeing eIF4E that would have otherwise
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been bound. Knockdown of other proteins, such as PTEN, Rheb or TSC1/TSC2,
were predicted to have a negligible effect on 80S formation following insulin ad-
dition. The minimal impact of the PTEN knockdown suggested the PIP2/PIP3
ratio was strongly in favor of PIP3 following insulin addition. Knockdown of
Rheb and TSC1/TSC2 highlighted the existence of the redundant Akt-mediated
route of mTor activation. Likewise, knockdown of the Shc and Gab adaptor pro-
teins revealed a redundant dimerized-receptor/adaptor complex still capable of
binding PI3K and catalyzing the formation of PIP3. Knockdown of proteins in
cluster II, e.g., Akt and mTor reduced 80S formation to approximately basal lev-
els and removed the ability to sense and integrate insulin signals. Decreased 80S
initiation formation, following the knockdown of Akt andmTor, agreedwith the
sensitivity results, which predicted these proteins were fragile. In the absence of
insulin, the regulatory connectedness of the initiation architecture was altered.
Without insulin, most proteins were grouped similarly as the insulin positive
case. However, key proteins such as PTEN, TSC2 and Rheb behaved differently
(Fig. 3.7B). For example, a PTEN knockdown resulted in a two-fold increase in
80S formation without insulin. A TSC2 knockdown increased 80S formation by
approximately 1.5 fold. Conversely, Rheb knockdown reduced 80S formation
by approximately 60%.
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3.4.5 in-silico overexpression studies of the initiation network
reveals the roles of key initiation factors in conditions of
with or without serum in the environment
In addition to knockdowns, the effect of overexpression of key proteins upon
80S formation was calculated with (Fig. 3.8A) and without (Fig. 3.8B) insulin.
Again, coupling coefficients were computed over the entire parameter ensem-
ble. Overexpression was modeled by adding a zero-order source and first-order
degradation terms to each protein balance of interest, with the associated ki-
netic constants kept uniform throughout the model. In the presence of insulin,
overexpression of 9 of the 33 proteins explored significantly influenced 80S for-
mation (Fig. 3.8A). Statistical significance was established using a two-tailed
student t-test assuming unequal variances. Overexpression of 4E-BPx, eIF1A
and eIF5 in the presence of insulin reduced 80S formation to approximately 80%
± 11%, 70% ± 20% and 20% ± 10% of nominal levels. Conversely, overexpres-
sion of initiation factors (eIF4E, G, A, B and H) increased 80S formation by up
to 1.5-fold with insulin. Without insulin, overexpression of initiation factors
had almost no effect with the exception of eIF1A and eIF5. Overexpression of
membrane phospholipid PIP3 or inactive regulatory proteins positively (mTor,
TSC1, Rheb, p70, Akt and Pdk1) or negatively (TSC2, 4E-BPx) influenced 80S
formation without insulin (Fig. 3.8B). On average the proteins explored were
overexpressed by > 10-fold. While we are confident in the direction of coupling
between 80S and proteins overexpression, the magnitude of the shifts in 80S
could be dose dependent.
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Figure 3.8: Overexpression coupling analysis of the translation initiation
network with (A) and without (B) insulin. The protein overex-
pression coupling coefficient was computed relative to nom-
inal 80S formation with and without insulin exposure (1hr
200µM). Thirty-three proteins were overexpresed where over-
expression wasmodeled as a zero-order source term in the pro-
tein balance.
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3.5 Discussion
Understanding the regulation of eukaryotic translation initiation could be an
important step toward the development of novel anti-cancer drugs. In this
study, we analyzed a model of translation initiation to better understand the
role of key proteins like eIF4E. We estimated a family of model parameters
by comparing simulations with 28 in-vitro and in-vivo data sets. We then an-
alyzed the ensemble of initiation models to estimate qualitatively important
regulatory and network features. Our analysis suggested that translation ini-
tiation was governed by a balance between two interconnected control pro-
grams. The first control element integrated growth-factor signals with the re-
lease of eIF4E thereby up-regulating translation. The second control element
restrained initiation in the absence of stimulation by down-regulating the first
loop and sequestering eIF4E. Sensitivity analysis, conducted over the parame-
ter ensemble, suggested that Akt and mTor were structurally fragile and likely
the key elements promoting the integration of growth factor signaling with ini-
tiation. The classification of Akt and mTor as sensitive was not a function of
parameter values or time. Rather, it was a consequence of the network archi-
tecture. Interestingly, one of the components at the intersection of the two con-
trol programs, namely PIP3, was also estimated to be structurally fragile. The
increased fragility of PIP3 versus the second element of the negative loop, 4E-
BPx, suggested the balance between the promotion or restraint of initiation was
controlled at the PI3K node, upstream of Akt and mTor. The PI3K/Akt/mTor
pathway has long been known to be important in the oncogenic transforma-
tion of several tissues [172, 190]. Thus, our Akt/mTor results were consistent
with the literature. Not suprisingly, sensitivity analysis also predicted eIF4E
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was moderately sensitive given its role in the recognition of mRNA secondary
structure. Overexpression of eIF4E is known to cause pro-survival pleiotropic
effects and has been observed in several cancers including breast and prostate
cancer [153, 125, 155, 156, 157, 158, 127, 191, 154]. The expression of several
prominent proliferation and survival proteins e.g., cyclin D1, p27kip1, mdm2
and Bcl-2/Bcl-xL 9 (among others) are all translationally regulated, partly by
eIF4E levels and its interactions with other initiation factors and proteins in-
volved in translation initiation [153]. However, more studies to estimate the rel-
ative role of translation deregulation versus other factors such as transcriptional
events or deregulated apoptosis should be conducted. Moreover, we expect that
there are un-modeled effects that could influence our analysis results. For ex-
ample, Akt is integrated into many cellular subsystems, including cell-survival
pathways [172].
A limitation of sensitivity analysis is its inability to estimate the operational
implications of structural or environmental perturbations. For example, eIF4E,
4E-BPx and PTEN were all predicted to be only moderately sensitive in the
presence of insulin despite their key roles in initiation, as suggested by litera-
ture. However, we know from literature that structural perturbations involving
these proteins e.g., overexpression of eIF4E or deletion of PTEN are common
in several human cancers [153, 192]. In this study, we directly estimated the
functional relationship between structural perturbations and initiation network
operation using coupling analysis. Previously, coupling analysis has been used
in several studies to understand the role of components in complex networks
[193, 194]. We considered the coupling between the deletion/overexpression
of network proteins and 80S formation with/without insulin. Our coupling
analysis generated insight into the regulatory connectedness of the initiation
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network as a function of growth factor as a driving force. The relationship be-
tween perturbed proteins and 80S formation was classified as either durable,
perturbation-dependent, or growth factor dependent. For example, knockdown
of Akt and mTor, consistent with the sensitivity analysis, removed the ability to
up-regulate initiation with/without insulin. However, overexpression of inac-
tive Akt and mTor increased 80S formation without insulin but resulted in no
change in 80S with insulin present. Other notable examples include 4E-BPx,
eIF4E and PTEN. For example, 4E-BPx was found to be a durable negative-
regulator of 80S formation independent of perturbation or growth factor sta-
tus. Overexpression of 4E-BPx with/without insulin reduced 80S formation
albeit with different degrees of reduction. Conversely, knockdown of 4E-BPx
increased 80S formation by approximately 1.5-fold with and without insulin.
4E-BPx shRNA studies in hypoxic Rh30 rhabdomyosarcoma cells confirm in-
creased translation of markers such as cyclin-D1 following 4E-BPx knockdown
[195]. The coupling between other proteins and 80S formation was depended
upon the presence/absence of insulin or the type of structural perturbation. For
example, knockdown of eIF4E was predicted to remove the ability of the net-
work to form 80Swith/without insulin. This findingwas consistent with an ear-
lier study showing that anti-sense knockdown of eIF4E disrupted the prolifera-
tion and morphology of HeLa cells [196]. Conversely, overexpression of eIF4E
increased 80S formation by approximately 1.5-fold with insulin. The predicted
increase in translation following eIF4E overexpression was consistent with the
oncogenic role of eIF4E in immortalized cell-lines, primary tissue and patients
[153]. Interestingly, eIF4E overexpression led to only a negligible 80S increase
in the absence of insulin. Ectopic 4E-BP1 expression rescued tumorigenic 3T3
cells that overexpressed eIF4E, suggesting the ratio of free eIF4E to 4E-BPx is
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a critical parameter controlling initiation [197]. Comparison of the simulation
results with the 3T3 studies suggested that 4E-BPx levels in the model were suf-
ficient to sequester free eIF4E. PTEN deletion had little effect in the presence of
insulin but increased 80S exposure by 2-fold when insulin was absent. PTEN
is an established negative regulator of PI3K signaling [198]. Moreover, PTEN
mutations have been observed in a spectrum of cancer types [199]. In the pres-
ence of insulin the activity of PTEN was predicted to be overwhelmed by PI3K.
Thus, a PTEN knockdown, in the presence of growth factors, resulted in little or
no change to 80S because the network was programmed to promote initiation.
However, a PTEN knockdown in the absence of insulin removed the ability of
the network to downregulate Akt and mTor activation. If PIP3 is present in suf-
ficient quantity in a PTENmutant, Pdk1 and Akt could become activated allow-
ing 80S complex formation in the absence of growth factors. Thus, the inability
to modulate the level of PIP3 as a function of condition could be an important
factor for malignant transformation. When taken together, the coupling results
demonstrated the multifaceted nature of initiation regulation. Sensitivity anal-
ysis using a sparse sampling of the ensemble suggested structurally important
proteins in the presence of insulin. Coupling analysis expanded our under-
standing of these proteins and provided a detailed portrait of the relationships
between network nodes and 80S formation.
Sensitivity and coupling analysis using the ensembles of mechanistic mod-
els could be used to robustly rank-order the therapeutic value of molecular tar-
gets. Coupling coefficients describing conditions under which the network will
fail could provide therapeutic insight. For example, knockdown of eIF4E was
predicted to remove the ability of the network to form 80S with/without in-
sulin. This finding was consistent with an earlier study showing that anti-sense
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knockdown of eIF4E disrupted the proliferation and morphology of HeLa cells
[196]. Recently, Soni et al. demonstrated the potential therapeutic effectiveness
of targeting eIF4E in breast cancer, including in triple-negative (estorgen recep-
tor/progesterone receptor/HER2) cancer cells [200]. Coupling analysis could
also be used to generate falsifiable hypotheses regarding the role of network
proteins. For example, 4E-BPx was found to be a durable negative-regulator
of 80S formation independent of perturbation or growth factor status. 4E-BPx
shRNA knockdown studies in hypoxic Rh30 rhabdomyosarcoma cells confirm
increased translation of eIF4E-sensitive markers such as cyclin-D1 [195]. Con-
versely, ectopic 4E-BP1 expression reduced tumorigenic 3T3 cells [197]. For
other proteins coupling dependend upon the presence/absence of growth fac-
tors or the type of structural perturbation. In these cases shifts in coupling gave
insight into the role of a protein under different conditions. For example, the
deletion of PTEN, an established negative regulator of PI3K signaling [198], had
little effect in the presence of stimulation but increased 80S exposure by 2-fold
when growth factors were absent. This suggests that PTEN activity in the pres-
ence of growth gactors may be overwhelmed by PI3K. However, a PTEN mal-
function in the absence of stimulation could be a potentially important route
on oncogenic transformation. Indeed, mutation in PTEN have been observed
a spectrum of cancer types [199]. When taken together, these results support
the use of mechanistic models to better understand the functional components
of molecular networks relevant to human health. Perhaps, they are a first re-
alizing the vision of Kitano who has suggested that insight into the fragility of
networks could lead to new paradigms for drug discovery and the understand-
ing of disease processes [68].
The translation architecture was assembled from an extensive literature anal-
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ysis, however, they are likely missing model features. First, mTor was assumed
to be activated and function in the absence of binding partners such as Raptor
and LST8/GβL. The regulation of these binding partners and their role on mTor
function needs to be explored. Moreover, Akt is integrated into many cellular
subsystems, including cell-survival pathways [172]. Thus, we should reexamine
the role of the Akt including these factors. Second, the activation of p70 bymTor
was described as a single irreversible phosphorylation event at T-389. In-vitro
studies support the phosphorylation of p70 at T-389 by mTor [201]. However,
the in-vivo regulation of p70 may be far more complex with at least 12 distinct
phosphorylation sites [202]. Proteins other thanmTormay also play a role in p70
activation. For example, the PDK1 protein has been shown to phosphorylate
p70 at T-229 both in-vitro and in-vivo [203]. It has also been hypothesized that
perhaps mTor indirectly regulates p70 through secondary phosphatases [204].
Third, we modeled the regulation of 4E-BPx as a single phosphorylation event
where phosphorylated 4E-BPx was unable to bind to eIF4E. In reality, 4E-BPx
family members, such as 4E-BP1, have several phosphorylation sites [205] and
the release of eIF4E is driven only after multiple conserved phosphorylation
events [186]. In addition, eIF4E itself is phosphorylated at S-209 byMMK.While
there is agreement that the phosphorylation of eIF4E does have a regulatory sig-
nificance, the data is contradictory as to whether it is positive or negative [206].
Fourth, a generalized model of surface receptor activation, akin to the Epider-
mal Growth Factor Receptor (EGFR) family, was used in the study. Currently,
the binding of extracellular ligands to transmembrane surface receptors pro-
motes dimerization and the formation of multimeric adaptor complexes. These
complexes composed of proteins such as Shc, Grb2, Ras and SoS promote the at-
tachment and activation of Phosphoinositide 3-Kinase (PI3K). While we consid-
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ered the formation of two independent adapter complexes, we did not include
other types of growth factor sensitive receptors, e.g.. Platelet-derived Growth
Factor (PDGF) receptors which signal by different mechanisms [44].
Lastly, the regulation and activity of phosphatases that down-regulate ini-
tiation after excitation need to be included in the model. This could involve
adding new proteins to the network or updating the functionality to current
proteins. For example, PTEN is known to dephosphorylate activated Platelet-
derived Growth Factor (PDGF) receptors and attenuate their activity, a class of
feature not included currently [207].
74
CHAPTER 4
ARSENIC TRIOXIDE (ATO) COOPERATES WITH ALL TRANS RETINOIC
ACID (ATRA) TO ENHANCEMAPK ACTIVATION AND
DIFFERENTIATION IN HUMANMYELOBLASTIC LEUKEMIA (HL-60)
CELLS
4.1 Abstract
Arsenic trioxide (ATO) synergistically promotes retinoic acid (RA)-induced dif-
ferentiation of HL-60 myeloblastic leukemia cells, a PML-RARα negative cell
line. In PML-RARα positive myeloid leukemia cells, ATO is known to cause
degradation of PML-RARα with subsequent induced myeloid differentiation.
We find now that ATO by itself does not cause differentiation of the PML-
RAR? negative HL-60 cells, but enhances RA’s capability to cause differentia-
tion. RA-induced differentiation of HL-60 cells is known to be propelled by
an induced hyperactive/persistent MAPK signal. ATO augmented RA-induced
RAF/MEK/ERK axis signaling and expression of CD11b, an integrin receptor
that is a myeloid differentiation marker. p47PHOX, a component of the respi-
ratory burst machinery and inducible oxidative metabolism, a functional dif-
ferentiation marker, were also enhanced. However, ATO did not enhance RA-
induced CD38 expression, an early cell surface differentiation marker. ATO en-
hanced RA-induced population growth retardation without evidence of apop-
tosis or an enhanced G1/0 growth arrest. But compared to RA, ATO plus RA
showed reduced pAKT, suggesting that an overall biosynthetic/metabolic retar-
dation was seminal to the apparent enhanced growth retardation due to ATO.
In sum, our results indicate that ATO can augment the action of RA in causing
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differentiation of myeloid leukemia cells through promoting MAPK signaling
and independent of PML-RARα.
4.2 Introduction
Arsenic has historically been used as a medicinal agent for a variety of dis-
eases such as psoriasis, eczema, asthma, malaria, ulcers, syphillis and leukemia.
Arsenic and its derivatives have been used as antiseptics, antispasmodics, an-
tipyretics, sedatives and tonics etc., especially in traditional Chinese medicine
[208]. The most popular compound of Arsenic used in medicine is Arsenic Tri-
oxide. Arsenic Trioxide (As2O3) or ATO is the active ingredient in the Fowler’s
solution developed in 18th century and has been used to treat different malig-
nancies for over a 100 years. In 1930s, before the introduction of chemotherapy
and radiation therapy, arsenic was used as one of the standard treatments for
chronic myeloid leukemia and other leukemias [208, 209]. Modern use of ar-
senic trioxide as a therapy for Acute Promyelocytic Leukemia (APL) started in
China in 1990s [210]. In a study at the Shanghai Institute of Hematology (SIH)
in 1999, patients with relapsed APL were treated with Arsenic Trioxide (ATO).
Complete remission (CR) was achieved in 9/10 of the cases treated with ATO
alone and 5/5 cases treated with ATOwith chemotherapy (CT) or Retinoic Acid
[210, 211, 212]. This suggests that ATO is potent as a single agent in APL. This
was further proved by relatively high 2- and 3-year Disease Free Survival (DFS)
rates seen recently in newly diagnosed leukemias also[213].
All Trans Retinoic Acid (ATRA) has been used as an inducer of differenti-
ation therapy in APL cell lines since early 1980s [214, 215]. A recent clinical
study of APL treatment with ATRA differentiation therapy in Japan resulted in
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a complete remission (CR) rate of 94% and a 6-year Disease Free Survival rate of
68.5% and a 6-year overall survival (OS) rate of 83.9% [216]. Clinical studies per-
formed for combination treatment of ATRA-ATO and ATRA alone in APL have
revealed that the time required to achieve complete remission (CR) was statis-
tically significantly different (25.5 days) than the ATRA treatment alone (40.5
days) or ATO treatment alone (31 days). The median disease free survival (DFS)
rate had also increased to 20 months for the combination treatment as com-
pared to ATRA alone (13 months) and ATO alone (16 months) [217]. Also, the
disease burden, determined by fold change in PML-RARαwas much shorter in
the combination treatment as compared to monotherapy. Clinical studies thus
show a synergistic effect of ATRA and ATO treatments, providing us with the
motivation to probe the cause of this synergy at a biochemical level.
HL-60 is a myeloblastic leukemia cell line which serves as a model for dif-
ferentiation therapy in cancer. HL-60 cells can undergo myeloid or monocytic
differentiation along with G0/G1 growth arrest when treated with different in-
ducers such as All Trans Retinoic Acid (ATRA) or 1-25-dihydroxyvitamin D3
(Vitamin D3) respectively. Previous studies in our lab have showed that ATRA
induced differentiation and accompanying G0/G1 cell arrest is caused by sus-
tained activation of proteins in the MAPK proteins [218, 219]. Various cell sur-
face markers such as CD38, CD11b as well as functional markers such as in-
ducible oxidative metabolism are seen to be enhanced as the cells proceed to
their differentiation states.
HL-60 is negative for t(15:17), a hallmark of APL and lacks the PML-RARα
fusion protein. However, it still undergoes differentiation when induced with
agents such as ATRA, D3 etc. with enhanced MAPK activation being a neces-
sary condition for differentiation. Buoyed by the synergy shown between ATRA
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and ATO in clinical setting, in this study we tested the following hypothesis. If
ATO’s ability to promote differentiation is solely through the degradation of
PML-RARα fusion protein, as seen in typical APL cell lines such as NB4 cells
we should not see any enhanced differentiation in the combination treatment of
ATRA and ATO. However, if in HL-60 the mechanism of ATO action impinges
upon the mechanism of ATRA induced differentiation, e.g., by promoting sus-
tained activation of MAPK, then addition of ATO to ATRA treatment should
lead to augmented differentiation in HL-60 cells.
To test this hypothesis, we looked at well-established markers of differen-
tiation and cell-cycle arrest to elucidate the role of cooperative synergy in the
RAF/MEK/ERK axis of the MAPK pathway. Our investigations using low
doses of ATO revealed that HL-60 cells treated with a combination of ATRA
and ATO show augmented differentiation propelled by an enhanced activation
of sustained MAPK proteins. Although MAPK proteins showed an increased
activation, there was no such additive increase seen in their expression levels.
This suggests that the synergy is at a protein interaction and phosphorylation
level, not at a transcriptional level. Also, there was no similar cooperative in-
crease seen in percentage of cells undergoing cell-cycle arrest. Additionally, it
was seen that ATO alone treatment did not lead to differentiation in HL-60 cells,
as shown before [220]. This study establishes that enhanced differentiation in
case of combination treatment of ATRA-ATO is a result of increased sustained
activation of MAPK proteins in HL-60 cells. Since ATO is already FDA ap-
proved (Trisenox R©), along with ATRA differentiation treatment for APL, we
believe a more thorough understanding of its mechanism of action, especially
on the MAPK proteins and related pathways will help in duplicating success in
various other leukemias, or even non-hematologic cancers.
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4.3 Methods and Materials
4.3.1 Cell Culture
HL-60, Human Leukemia Myeloblastic cells were grown in RPMI 1640 media
supplemented with 5% heat-inactivated fetal bovine serum (Invitrogen, Carls-
bad, CA, USA) in a 5% CO2 humidified environment at 37◦C and were main-
tained in an exponential growth phase. All the experimental cultures were ini-
tiated at a density of 0.2 × 106 cells/mL [221]. Cell viability was monitored by
Trypan Blue Stain (Invitrogen) and it consistently exceeded 95%.
4.3.2 Reagents Used
All Trans Retinoic Acid (ATRA) (Sigma-Aldrich, St. Louis, MO, USA) and dis-
solved in 100% ethanol solution to a stock concentration of 5 nM. The concen-
tration of ATRA used in cultures was 1 µM. Arsenic Trioxide (ATO) (Sigma-
Adlrich) was diluted in water to a stock concentration of 5 nM. ATO was used
at a final concentration of 2 µM, and was added at the same time as ATRA to the
cultures. Anti-bodies for SDS-PAGE analysis against ERK1/2, phosphorylated
ERK-1/2 (Thr-202/Tyr-204), MEK1/2, phosphorylated MEK1/2 (Ser-217/221),
RAF1, phosphorylated Akt (Ser-473), phosphorylated Akt (Thr-308), PARP,
p47PHOX and GAPDH were obtained from Cell Signaling (Beverly, MA, USA).
PD98059 was added 16h before addition of ATRA and ATO to make its concen-
tration in culture to be 1 µM. It was also re-added along with ATRA and ATO (at
0h) and finally at 16h after the addition of ATRA and ATO. The detailed proce-
dure for addition of PD98059 has been explained here [218]. Antibody against
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phosphorylated c-RAF1(Ser-621) was ordered from BIOSOURCE/Invitrogen.
4.3.3 Procedure for preparing Total Cell Lysates, Nuclear Frac-
tion and Western Blots
Total cell lysates were prepared as follows. Cells were harvested at 24h and 48h
time points and washed with PBS and centrifuged three times to wash away
any culture medium. After washing away the media, cells were resuspended in
100 µl M-Per Mammalian Protein Extraction Reagent (Invitrogen) buffer mixed
with a phosphatase and protease inhibitor. Western analysis of Akt phospho-
rylation was done on the nuclear fraction. The nuclear fraction was prepared
by re-suspending the cells after centrifugation for 10 min in 100 µL of hypo-
tonic propidium Iodide, sodium citrate (50 µg/mL propidium iodide (PI), 1 µL
Triton-X100 and 1 mg/ml sodium citrate) solution. The cells were vortexed and
kept on ice for 15 min, and the procedure was repeated 3 times. Nuclei were col-
lected by centrifugation for 10 min, resuspended in 100 µL/sample RIPA buffer
(Thermo Scientific, Rockford, IL USA) and freeze-thawed 3 times. Finally, the
lysate was centrifuged (16060 x g) for 30 min and the supernatant was collected.
Western analysis was done by resolving the lysates on 12% Tris-HCL gels (Bio
Rad) and the membrane was blocked overnight with 5%w/V non-fat milk. The
membrane was then probed using primary and secondary antibodies described
in the Reagents section.
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4.3.4 CD38 and CD11b Expression Studies by Flow Cytometry
At the 24h and 48h time points, 0.5 × 106 were collected, pelleted and resus-
pended in 100 µL PBS containing 5µL allophycocyanin(APC)-conjugated CD11b
and 5µL of phycoerythrin(PE)-conjugated CD38 antibody. The cells were then
incubated for 1 hr in a humidified atmosphere of 5% CO2 at 37 ◦C and expres-
sion levels were measured in a BD LSR II flow cytometer. CD11b expression
was measured by providing excitation by 633 nm red laser and collecting emis-
sion through a 735 long-pass dichroic and a 660/20 band-pass filter. For CD38
expression, excitation was provided by 488 nm laser and the emitted fluores-
cence was collected through a dichroic 550 long-pass and 576/26 band-pass fil-
ter. Gates to determine the shift in fluorescence intensity were set at the highest
5% of the control (untreated) cells.
4.3.5 Measurement of Inducible Oxidative Metabolism
Approximately 0.5 × 106 cells were collected at 48h, 72h time points, pel-
leted and resuspended in 200 µL PBS at 37◦C containing 5µmol/L 5- (and 6)-
chloromethyl-2’,7’-dichlorodihydro-fluorescence diacetate acetyl ester (H2DCF,
Molecular Probes) and 0.2 µg/mL 12-O-tetradecanoylphorbol-13-acetate (TPA,
Sigma). H2-DCF and TPA stock solutions were made in DMSO at concentra-
tions of 0.2 mg/mL and 0.5 mg/mL respectively. Cells were incubated for 20
min in a humidified atmosphere of 5% CO2 at 37◦C. Flow cytometric analysis
was done on a BD LSR II flow cytometer, using a 488 nm excitation laser and
emission from oxidized DCF was collected through 505-nm long pass dichroic
mirror and 530/30 nm band pass filter. The shift in fluorescence intensity in
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response to TPA was used to determine the percentage of parent cells with the
capability to generate inducible oxidative metabolites. Gates to determine per-
centage of positive cells were set at the highest 5% of the cells not treated with
TPA.
4.3.6 Cell cycle analysis
About 0.5 × 106 cells were harvested at 72h by centrifugation and resuspended
in 200 µL hypotonic staining solution (at 20◦C) containing 50 µg/mL propidium
iodide (PI), 1 µl Triton-X100 and 1 mg/ml sodium citrate. Cells were incubated
at room temperature for 1 h and analyzed using flow cytometry (BD LSR II).
Excitation was provided by a 488 nm laser and the emission was collected using
550 long-pass dichroic and a 576/26 band-pass filter.
4.3.7 Statistical Analysis
Statistical Analysis was done using MATLAB’s statistical toolbox. Three inde-
pendent repeats were performed in each case. Means of treatment cases were
compared using paired-samples t test, using the ttest2 function inMATLAB’s
statistical toolbox. The bar graphs show means of three independent repeats
along with standard errors.
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4.4 Discussion
In this report we studied the effect of ATO on ATRA induced differentiation in
HL-60 cells. Earlier studies of biochemical effects of ATO treatment leukemia
cells have concentrated on the PML-RARα protein and the Glutathione (GSH)
redox system. In NB4 cells, ATOwas seen to induce degradation of PML/RARα
fusion protein, but not the mRNA in both retinoic acid sensitive and RA resis-
tant cells lines [222]. ATO was also seen to affect the reorganization of PML and
PML/RARα inside the nucleus in NB4 cells [222, 220]. Glutathione (GSH) redox
system has also been known to be effected by Arsenic Trioxide (ATO) in vari-
ous APL cell lines. The GSH redox system is an important component of cell’s
response to oxidative stress. Its function is to scavenge free radicals and neu-
tralize the toxins in the cells. NB4 cells have the lowest levels of basal GSH and
were found to be most sensitive to arsenic treatment. It was observed that in
NB4 cells, ATO treatment modulated the GSH levels, which sensitized the cells
towards apoptosis [223, 224]. In NB4 cells there is a dose dependent growth in-
hibitory, differentiation enhancing or apoptosis enhancing role of ATO, even
though HL-60 cells were shown to be resistant to a treatment of ATO alone
[225, 220]. Although the effects of ATO treatment has been studied in various
APL cell lines, its mechanism of action is still not fully understood.
Clinically, a synergistic effect has been seen in the ATRA-ATO combina-
tion treatment, when compared with either ATRA or ATO monotherapies. We
have tried to understand this synergy at a biochemical level, particularly in
the MAPK pathway. Other studies for the biochemical effects of ATRA-ATO
combination treatment have revealed additive effects in JNK/p38, TNF and
cAMP/PKA pathways in APL cell lines[226, 227]. For e.g, in the cAMP/PKA
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study, it was found that cAMP, which can induce monocytic differentiation
in HL-60 cells was synergistically induced by ATRA and low doses of ATO
[228, 227]. Our results showed that the combination treatment lead to an
additive increase in molecular markers of differentiation such as CD11b and
p47PHOX. CD11b, a cell surface antigen, is a late stage marker of differentia-
tion in HL-60 cells, which has been shown to be up-regulated with inducers
such as Vitamin D3 and ATRA [229, 230]. p47PHOX, on the other hand, is a part
of the NADPH oxidase which catalyzes the ability to generate superoxides, a
hallmark of neutrophils [231, 232]. Thus, an increased expression of CD11b, as
seen by flow cytometry and p47PHOX, as seen by SDS-PAGE analysis indicates
enhanced differentiation in the combination treatment. Similar pattern of coop-
erative upregulation was observed in the measurement of inducible oxidative
metabolism, as observed by generation of ROS in HL-60 cells. It is interesting
to note that in these results, the ATO treatment behaved similar to the control
(untreated) cells. This suggests that even though ATO is not able to induce dif-
ferentiation on its own, it impinges on pathways responsible for ATRA induced
differentiation, and modulates them to enhance the ATRA effect.
To understand the causes of this synergy we probed cellular pathways
known to be affected by ATRA and looked for cooperative increase in them
upon ATO treatment, starting with the MAPK pathway. Activation of
RAF/MEK/ERK axis in MAPK pathway was seen to be enhanced synergisti-
cally in the combination treatment of ATRA and ATO. Increase in sustained
phosphorylation of ERK1/2(Thr-202/Tyr-204) has been correlated with en-
hanced differentiation in HL 60 cells [219, 218]. We found that even though
the activation of ERK1/2 (by phosphorylation) was enhanced by the combina-
tion treatment, there was no effect on expression of total ERK1/2 levels, either
84
in single treatments (ATRA and ATO), or in the combination treatments. We
observed a similar trend in the activation of MEK1/2 (Ser-217/221), i.e., there
was enhanced phosphorylation in the combination case but total MEK1/2 ex-
pression remained the same at 24h and 48h for all treatment cases. SDS-PAGE
analysis of c-RAF and c-RAF(Ser621) followed the trend of enhanced activation
and nearly constant expression levels. The activation and expression patterns
of MAPK proteins suggest that the synergy between ATRA and ATO is at the
protein-protein interaction level, rather than at the transcriptional level. This
agrees with a recent systems level study which indicated that while the the ef-
fects of ATRA involved transcriptional remodeling ATO effects were seen at a
proteome level, although the study was done for NB4 cells [226]. An intriguing
result in our study was the slowing down of cell growth rate in treatments with
ATO, without an increase in the percentage of cells arrested in G0/G1 phase.
We hypothesized that the probable reason of low growth rate could be slowing
down of proliferative process in the cell, which will elongate the cell cycle and
hence decrease cell growth rate. To this end, we studied the phosphorylation of
a key proliferative kinase Akt. Phosphorylation of Akt at Ser-473 and Thr-308
residues leads to activation of proliferative processes such as protein translation.
SDS-PAGE analysis of phosphorylation of Akt(Ser473 and Thr308) revealed the
combination treatment lead to lower phosphorylation, when comparedwith the
control (intreated) and the ATRA treated case, especially at 48h. However, we
did not see a similar reduction in ATO alone treatment, even though there was
a growth rate reduction in that case. The reduction of pAkt phosphorylation
seems to suggest a slow down on the translation machinery of the cell, since ac-
tivated Akt plays a central role in the formation of the 80S translation initiation
complex. However, this argument needs to be further explored as the effect of
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ATO on other important regulators such as eIF4E, mTOR and p70SK needs to
be clearly understood. Such studies, which aim to elucidate the role of ATRA in
conjunction with ATO on the translation machinery of the cell form the basis of
our future experiments on this topic. To understand this anomalous behavior in
the ATO treated cells constitutes a part of our future work.
In sum, in PML-RARα negative HL-60 human myeloblastic leukemia cells,
ATO causes MAPK signaling and augments ATRA-induced differentiation. The
effects are more prominent as the MAPK signal augmentation increases, en-
hancing expression of later differentiation markers, but not the earliest, de-
tected. A further potential contributor to the enhanced differentiation by ATO
is the retardation of growth, possibly slowing down the self-renewal capacity of
these progenitor cells and favoring differentiation. The results show that ATO
may be of therapeutic use to augment the effects of ATRA.
4.5 Results
4.5.1 Arsenic Trioxide (ATO) leads to enhanced sustained acti-
vation of ATRA induced MAPK proteins
It is well known that transient activation of MAPK leads to proliferation,
whereas a sustained activation of MAPK, especially ERK1/2 has been thought
to drive differentiation in a variety of cell lines including HL-60 cells, [219, 218].
We investigated the effect of ATO in the sustained activation of MAPK, in order
to better understand the biochemical effects of ATO. The most well character-
ized effect of ATO inside the cells is that on the glutathione (GSH) redox system.
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GSH redox system is a critical modulator of cellular response to increase in ox-
idative stress. Action of ATO has been inversely correlated with levels of GSH
or GSH-associated proteins with ATO treated cells showing low levels of re-
duced glutathione [233, 223, 234]. Previous studies have shown that addition
of ATO in acute promyelocytic leukemia cells (NB4) cells leads to activation of
stress-activated protein kinase, c-jun N-terminal kinase (JNK) [235]. This acti-
vation is directly related to apoptosis as inhibition of JNK was seen to reduce
ATO induced apoptosis in NB4 cells. With regards to MAPK, the effect of ATO
on p38MAPK has been widely studied, Verma et al., showed that p38 is phos-
phorylated and activated by ATO in a sustained manner and that this activation
is downstream of redox events activated by arsenic trioxide [236] in NB-4 cells.
Activation of other MAPK proteins, such as Mkk 3 and Mkk 6 was also seen in
NB-4 cells and in CML-derived KT-1 cell line, which was seen to be essential for
p38MAPK activation.
We studied the effect of ATO on the RAF/MEK/ERK axis of MAPK signal-
ing, in particular the potential synergistic effects of ATRA and ATO on these
three central kinases. Treating cells with ATO plus ATRA enhanced the increase
in phosphorylation at Thr-202/Tyr-204 and activation of ERK1/2 elicited by
ATRA alone (Fig 4.1 (C)). This is seen in the comparison of Western blots of
pERK1/2(Thr-202/Tyr-204) after 48 hrs of combination ATRA-ATO) treatment
versus ATRA alone treatment. This enhanced activation was sustained and ob-
served at both 24h and 48h. Interestingly, there was also increased activation
of ERK1/2(Thr-202/Tyr-204) in the ATO alone treatment case compared to the
control (untreated) case. The ATO induced increase could be compromised by
addition of PD98059 (See Figure 4.1 (D)). Western analysis of ERK1/2 expres-
sion showed that there was no increase in the total expression of ERK1/2 in any
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of the treatment cases. The expression levels of ERK1/2 were thus unaffected
by treatment, although their activation increased.
Neither ATRA, not ATO or their combination seems to have an effect on the
expression levels of ERK1/2, even though they increase its activation. Western
blot analysis of other MAPK proteins showed similar results in MEK1/2 and
RAF1. As seen in Fig. 4.1(B)., the combination treatment of ATO and ATRA
lead to increased phosphorylation and activation of MEK (Ser-217/221), when
compared with the ATRA treatment alone. Unlike ERK1/2 phosphorylation
however, ATO treatment alone did not lead to an increase in phosphorylated
MEK1/2 (Ser-217/221). SDS-PAGE analysis of the total MEK1/2 revealed that
there is no effect of either ATRA or ATO treatment on its expression. These
results suggest that the increase in phosphorylation of MEK1/2 in the combina-
tion treatment is solely due to increase in activation, and not due to increased
expression of MEK1/2. Moving up the MAPK axis, we saw an increased phos-
phorylation of RAF1(Ser-621) residue, in both ATRA and ATRA-ATO combina-
tion treatments. As seen from Fig. 4.1(A), there is a synergy in the activation of
RAF1(Ser-621) as the combination treatment of ATRA-ATO leads to more phos-
phorylation than the ATRA alone treatment.
It is interesting to note the ATO alone treatment did lead to an increase in
p-RAF1(Ser621) and pERK1/2(Thr-202/Tyr-204) also, especially at 48h, when
compared with the untreated (control) case, however this difference was not
significant when compared with the ATRA alone treatment case. Having estab-
lished enhanced activation of MAPK cascade in the combination treatment, we
then proceeded to see if this augmentation translated to enhanced differentia-
tion in HL-60 cells. Cells with ATO treatment alone did not show differentiation
but a general decrease in growth rate. To investigate if combination treatment
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Figure 4.1: Western Blot analysis of MAPK proteins showed enhanced ac-
tivation in the combination treatment of All Trans Retinoic
Acid (ATRA) and Arsenic Trioxide (ATO), (ATRA-ATO) com-
pared to ATRA treatment. (A), (B) and (C) show the effect of
the different treatments on expression and activation levels of
RAF1, MEK1/2 and ERK1/2 respectively. The left columns
show the effect on expression levels at 24 h and 48h, whereas
the right columns show the effect on activation of MAPK pro-
teins. The lanes show control (untreated) cells, cells treated
with ATRA, ATRA plus ATO, and ATO only. (D) shows the
effect of adding MEK1 inhibitor (PD98059) on p-MEK and p-
ERK at 48h time-point.
89
lead to enhanced differentiation we started by looking at the various cell surface
markers of differentiation like CD38 and CD11b.
4.5.2 Arsenic Trioxide (ATO) enhances ATRA induced CD11b
expression, but not CD38 expression
Having established enhanced activation of MAPK signaling in the combination
treatment, we then proceeded to see if this augmentation translated into en-
hanced differentiation in HL-60 cells. A visual inspection of different treatments
at 96h suggested that there was a synergy in the combination treatment which
lead to enhanced differentiation. Figure 4.2 shows that there was an increase
in the percentage of potentially differentiated irregularly shaped cells after the
combination treatment compared to treatment with ATRA alone. Cells treated
with ATO alone did not cause any apparent differentiation, but did exhibit a de-
crease in growth rate. To investigate if combination treatment lead to enhanced
differentiation, we started by looking at the cell surface markers of differentia-
tion, CD38 and CD11b.
CD38 is 45 kDa ectoenzyme receptor with a Retinoic Acid Receptor Element
(RARE) in its first intron, which makes it responsive to ATRA [237]. CD38 is
thought to be an activator of MAPK through activation of RAF, although the
mechanism of its action is not fully understood. One possible mechanism is
via the c-Cbl adaptor mechanism [238]. We measured expression of CD38 at an
early time point (6 h) and at 24 h after various treatments using a PE-conjugated
CD38 antibody. As seen in Figure 4.3, there was an increase in CD38 expression
on treatment with ATRA as well as combination treatment of ATRA-ATO. There
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Figure 4.2: Change in cellular morphology induced by different treat-
ments in the presence or absence of MEK1/ inhibitor PD98059.
Wrights stained images showingmorphological changes at 96h
after different treatments are shown here. Panel A: In the con-
trol (untreated) case, mostly round cells were observed. Ad-
dition of All Trans Retinoic Acid (ATRA) lead to differenti-
ated cells, seen here as the distorted cells (Panel C). Differ-
entiation was more apparent in the combination treatment of
ATRA and Arsenic Trioxide (ATO), whereas ATO alone treat-
ment case shows a morphology similar to the control case, al-
though a smaller number of cells are seen in this case (Panel D
and B respectively). The effect of addition of MEK1 inhibitor
PD98059 is seen in Panel E and F.
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was no increase in CD38 expression in the case when cells were treated with
ATO alone, when compared with the control case. There was no synergy seen
in CD38 expression however, when we compared ATRA treatment with ATRA-
ATO combination treatment at 24 h or at an earlier time point of 6h. These
results suggested that ATO had no effect on CD38 expression, in combination
with ATRA or by itself. Another cell surface marker, CD11b was used to mea-
sure the effect of Arsenic Trioxide (ATO) on ATRA induced cell differentiation.
Measurement of CD11b expression was done by immunofluorescence using an
APC-conjugated CD11b antibody. ATRA has been known to induce CD11b ex-
pression in HL-60 cells and other leukemic cell lines on its own [229, 230]. Effect
of ATO on CD11b expression in HL-60 cells was determined by comparing ex-
pression levels in HL-60 untreated cells (control), cells treated with ATRA alone,
cells treated with a combination of ATRA and ATO and cells treated with ATO
alone. Measurements were taken at 48h and 74h time points using flow cytome-
try. Compared to untreated control cells, ATRA-treated cells showed an increase
in CD11b expression, as expected. However, CD11b expressionwas consistently
higher in the case of ATRA-ATO combination when compared with the ATRA
alone case (Fig 4.3, Panel B). The difference between CD11b expression was sta-
tistically significant at both 48h (p = 0.0006) and 72h (p = 0.016), indicating that
the differentiationmachinery was affected by ATO during its both early and late
stages. In contrast, the cells treated with ATO alone did not show an increase
when compared with the untreated control case, indicating that ATO alone does
not affect CD11b expression.
Increase in Reactive Oxygen Species (ROS) is one of the functional markers
of differentiation. p47PHOX is one of the essential components of ROS generating
machinery which gets activated in differentiated cells. We probed the effect of
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Figure 4.3: Arsenic Trioxide (ATO) enhanced ATRA-induced CD11b ex-
pression, but not CD38 expression. Panel A shows that there
was no enhancement in CD38 expression in the combination
treatment, but CD11b (Panel B) expression showed a synergis-
tic increase in the ATRA-ATO combined treatment case. The
y-axis shows percentage of CD38 positive cells (Panel A) and
CD11b positive cells (Panel B) at indicated time points when
compared with untreated cells with gates set to exclude 95%
of the cells in the control case. (C) shows the representative
CD11b histograms of untreated (control) and cells treated with
ATRA, ATRA-ATO combination and ATO alone at 48h.
93
ATO on p47PHOX to establish that it directly affects the differentiation machinery
in HL-60 cells.
4.5.3 Arsenic Trioxide enhances ATRA induced differentiation
by upregulating p47PHOX
To determine whether the differentiation machinery is directly affected by the
ATO treatment, we investigated the effect of ATO and ATRA on p47PHOX.
p47PHOX is an essential component of the NADPH-oxidase complex which gen-
erates Reactive Oxygen Species (ROS) in neutrophils in response to agonists
like phorbol-12-myristate-13-acetate (PMA) and Tumor Necrosis Factor (TNF)
[239]. p47PHOX is cytosolic, but upon its activation it translocates to the mem-
brane where it acts as the scaffold for formation of the NADPH oxidase com-
plex [231, 232]. Due to its central role in generating ROS, an increased amount
of p47PHOX is a indicator of a higher differentiated state of the cell. We ana-
lyzed and compared the expression of p47PHOX in untreated cells (control), cells
treated with ATRA, combination treatment of ATRA-ATO and ATO treatment
alone. The control cells and ATO treatment alone cases did not show p47PHOX at
24h or 48h (See Fig. 4.4). Consistent with the trend seen in activation of MAPK
proteins, an enhanced expression was seen in case of the combination treatment
as compared to ATRA treatment alone. Also, the difference in expression of
p47PHOX between ATRA and ATRA-ATO treatments was more prominent at 48h
than at 24h. This result suggests that ATO synergizes with ATRA to directly af-
fect the differentiation machinery in HL-60 cells, even though it does not seem
to activate it on its own. Another interesting result was that we did not a signal
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Figure 4.4: Arsenic Trioxide (ATO) leads to an increase in ATRA-induced
expression in p47PHOX. Western analysis of total expression of
p47PHOX is shown at 24h and 48h timepoints.
in the control (untreated) and ATO treatment alone. This corroborates with the
results of the DCF assay which measured the inducible oxidative metabolism, a
functional marker of terminal differentiation in HL-60 cells which showed that
the ATO treatment alone did not lead to generation of ROS.
4.5.4 Arsenic Trioxide (ATO) enhances ATRA induced func-
tional differentiation
To confirm the functional significance of the induced p47PHOX expression, TPA
inducible oxidative metabolism, a late functional differentiation marker that
characterizes mature myelo-monocytic cells, was measured. When treated with
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ATRA, HL-60 cells typically exhibit a functional inducible Reactive Oxygen
Species (ROS) response. As before, cells were treated with ATO or ATRA alone
or in combination. Inducible oxidative metabolism was measured by flow cy-
tometry using 2’,7’-dichloroduhydrofluorescein diacetate (H2DCFDA), a cell-
permeant indicator of reactive oxygen species that is nonfluorescent until the ac-
etate groups are removed by intercellular esterases when oxidation takes place
within the cell. As shown by Fig 4.5 (A), HL-60 cells treated with a combination
of ATRA-ATO showed increased functional differentiation at both 48h and 72h
time-points when compared with cells treated with ATRA alone. For example,
at 72h, 85.3 % of cells treated with ATO plus ATRA were able to produce ROS
induced by TPA, compared to 60.9 % of cells treated with ATRA alone. The en-
hancement in ROS in case of ATO-ATRA was statistically significantly different
than that of ATRA alone with 95% confidence (p = 0.024) at 72h. In the case of
cells treated with ATO alone, there was no significant increase in ROS induction
upon TPA treatment, indicating that ATO alone was unable to induce functional
differentiation of HL-60 cells. This is consistent with the inability of ATO to in-
duce the other differentiation markers measured. These results indicate that
even though ATO by itself is unable to induce differentiation of HL-60 cells, it
works synergistically to enhance ATRA induced differentiation. In the case of
cells treated with ATO alone, there was no significant increase in DCF induction
upon TPA treatment, suggesting that ATO alone was not able to induce differ-
entiation in HL-60 cells. These results indicate that even though ATO by its own
is not able to induce differentiation in HL-60 cells, it works synergistically to en-
hance ATRA induced differentiation. This result is consistent with the CD11b
expression pattern seen in Fig. 4.3 which also showed enhanced ATRA induced
expression upon ATO treatment.
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Figure 4.5: Arsenic Trioxide enhances ATRA-induced differentiation of
HL-60 cells as well as NB4 cells. (A) shows the percent-
age of cells (y-axis) with capability for inducible oxidative
metabolism at the indicated time points. Cells were treated
with TPA to induce oxidative metabolism. The percentage of
positive cells with TPA, when gates were set to exclude 95%
of control cells (without TPA), is shown. There was no statis-
tically significant difference in the percentage of differentiated
cells in the ATRA alone versus ATRA-ATO combination treat-
ments at 48h. However, at 72h the difference in DCF positive
% cells was statistically significant between ATRA and ATRA-
ATO combination treatment (p = 0.024). (B) shows the same for
NB4 cells.
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Similar enhancement in differentiation was obtained for NB4 cells in the
combination treatment. There were some key differences however between the
response of HL60 cells and NB4 cells. For e.g., NB4 cells showed much higher
sensitivity towards ATO and massive apoptosis was observed in the cultures
with ATO concentration more than 0.5 µM. Therefore a lower dose of ATO (0.5
µM) and ATRA (0.25 µM) was administered to NB4 cells in culture. This dosage
was such as to preserve the ratio of ATRA to ATO same as that in HL-60 cells
(2:1). Another difference in the response of the two cell lines was that almost
100% of the cells showed terminal differentiation at 72h in NB4 cells. Therefore,
inducible oxidative mechanism was measured at earlier time points, i.e. 24h
and 48h. An increase in terminal differentiation was observed at 24h and 48h in
the combination treatment case, when compared to the ATRA alone case. Using
a one-tailed t-test, we concluded that differentiation in the ATRA alone case was
statistically less than that in the combination case at 48h (p = 0.046) (See Figure
4.5, Panel B). This result suggests that mechanisms involved in enhancement of
differentiation in the combination are not HL-60 specific.
4.5.5 Arsenic Trioxide (ATO) leads to reduced growth in HL-60
cells
Apersistent feature of HL-60 cells treatedwith Arsenic Trioxide (ATO)was their
slower growth rates as compared with control (untreated) cells and All Trans
Retinoic Acid (ATRA) treated cells. As seen from Fig. 4.5.5, addition of ATRA
alone also decreased cell growth rate when compared with the untreated cells.
However, addition of ATO had a more drastic effect on growth rate of cells than
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ATRA, as cultures with ATO alone or the combination treatment of ATRA-ATO
were seen to grow much slower than the cultures with ATRA alone. Micro-
scopic images of the cultures at 72h showed differentiated cells in the ATRA and
ATRA-ATO (Fig. 4.2) combination treatments, cells in the ATO alone cultures
were not much different from the untreated cells morphologically. These results
suggest ATO treatment alone, although leads to reduction in growth rate does
not induce differentiation by itself. Three possible reasons for decrease in cell
growth rates were hypothesized and tested, a decrease in cell growth rate could
be due to apoptosis upon addition of ATO. Alternatively, an increase in the per-
centage of cells arrested in the G0/G1 phase could lead to overall decrease in
cell growth rates or finally, an overall decrease in proliferative processes inside
the cells could lead to a dilation of cell cycle and hence decrease in the cell dou-
bling rates. We looked at phosphorylation of a key kinase Akt as a marker of
metabolic processes inside the cell, cell-cycle assay using PI (Propidium Iodide)
staining was used to measure the percentage of cells arrested in various treat-
ments, whereas cleavage of PARPwas used to determine the extent of apoptosis
in various treatment cases.
4.5.6 Arsenic Trioxide dependent cleavage of PARP is abro-
gated by ATRA
To test our first hypothesis, i.e., if reduced growth rates are due to increased
apoptosis, we looked at Poly (ADP)-ribose polymerase (PARP) cleavage. PARP
acts as a molecular nick sensor and marks sections of damaged DNA for repair.
PARP is a substrate for caspase-3 and caspase-7 which cleave it into two frag-
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Figure 4.6: There is a decrease in cell growth rate upon addition of ATO.
Cells growth rates were measured over a period of 72h after
treatments. The cells were seeded at an initial concentration of
0.2 million cells/mL. Addition of ATRA also leads to decreased
growth rate, however ATO addition has a more significant ef-
fect by itself or in combination with ATRA. # and *, the cell
growth rates in ATO and ATRA-ATO combination treatment
were statistically significantly different at both 48h (p = 0.006)
and 72h (p = 0.013). †,
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Figure 4.7: ATRA abrogates the apoptotic effect of ATO in HL-60 cells.
Western analysis of cleaved and uncleaved PARP at 24 and 48 h
is shown here. The different lanes are control (untreated) cells,
and cells treated with ATRA, combination of ATRA-ATO, and
ATO alone.
ments, a major fragment of 89 kDa and minor fragment of 24 kDa. Cleavage
of PARP is a marker of proteolytic activity of caspase and measures progres-
sion of apoptosis. It has been shown that a high dose of ATO (10µM) leads to
cleavage of PARP after 12h [240], which continues upto 24h in HL-60 cells and
NB4 cells. In NB4 cells, a low dose (2 µM) ATO can lead to cleavage of PARP
at 72h. However, it was also seen that chemical agents such as lipoic acid and
N-acetylcysteine were able to block ATO induced cleavage of PARP and thus
rescuing the cells from apoptosis, without affecting degradation of PML-RARα
protein [223]. Figure 4.7 shows the SDS-PAGE analysis of the uncleaved and
cleaved PARP. Our results suggest that there was some transient apoptosis in
the ATO alone treatment case, but it did not continue at 48h. More importantly,
we did not see apoptosis in the combination case of ATRA-ATO treatment. This
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result shows that the effect of ATRA is to rescue cells from apoptosis caused by
ATO. Thus we concluded that the decrease in growth rates in the combination
treatment case is not due to death of cells. Next we tested if the decrease in
growth rates was because of increase in the percentage of cells arrested in the
G1/G0 phase using the Propidium Iodide (PI) cell-cycle arrest assay.
4.5.7 Arsenic Trioxide (ATO) did not accelerate ATRA induced
cell-cycle arrest in HL-60 cells
ATRA treatment in HL-60 cells leads to myeloid differentiation as well as arrest
of cells in G1/G0 phase. To determine the effect of Arsenic Trioxide (ATO) on
cell-cycle arrest, the percentage of arrested cells was measured by flow cytome-
try in untreated (control) HL-60 cells, cells treated with ATRA, cells treated with
ATRA-ATO combined and cells treated with ATO alone. Treatment with ATRA
showed an increase in the percentage of cells arrested in G0/G1 phase, as seen
before [229]. Treatment with ATO alone however, did not show an increase in
the percentage of cells arrested as compared to the control case at 72h (see Fig.
4.8 (A)). The combination treatment also increased the percentage of cells ar-
rested in the G0/G1 cell cycle phase. However, when compared with the ATRA
induced cell-cycle arrest, the combination treatment did not lead to a statisti-
cally significant increase in the percentage of arrested cells. This indicates that
the effect of ATO on cell-cycle arrest is minimal, both when acting alone or in
combination with ATRA. The effect of ATO treatment on cell cycle arrest was
studied at earlier time points also (24h and 48h, results not shown) and simi-
lar results were obtained. Thus, even though ATO treatment leads to enhanced
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Figure 4.8: (A) Arsenic Trioxide did not accelerate ATRA-induced G0 ar-
rest. The percentage of G1/G0, S and G2/M cells at 72 h
after the treatment is shown for control (untreated), ATRA,
ATRA-ATO combination treated and ATO alone treated cells.
Y-axishere shows the percentage of cells in the different cell-
cycle phases at 72h. *, treatment with ATRA or ATRA-ATO
lead to statistically significant increase in percentage of cells in
G1/0 w.r.t. control, as expected. (B) Representative DNA his-
tograms for untreated (control) cells, cells treated with ATRA,
cells treated with ATRA-ATO combination and cells treated
ATO alone are shown at 72 h.
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differentiation in HL-60 cells, our study indicates that it does not contribute to
their arrest in the G0/G1 phase. Finally we tested our hypothesis that the re-
duced growth rate in ATO cells could be a result of overall slowing down of the
proliferative mechanisms in the cells, leading to an increased cell cycle which
would explain lower cell growth rate without an increase in apoptotic cells. To
test this hypothesis we probed the activation levels of a key protein kinase, PKB
or Akt which is involved in many important cellular signaling pathways related
to growth.
4.5.8 Arsenic Trioxide (ATO) in combination with ATRA leads
to decreased activation of Akt
The role of Akt phosphorylation (Ser-473/Thr-308) in cellular proliferation has
been well documented [172]. In HL-60 cells, it has been shown that a consti-
tutively active PI3K/Akt axis was responsible for resistance to ATO-induced
apoptosis. Chemical inhibition of Akt activation was also seen to impart sen-
sitivity to ATRA induced differentiation in HL-60 cells [241]. Previous stud-
ies have shown evidence of synergistic action between ATO and a flavinoid,
quercetin in downregulating Akt phosphorylation in human leukemia cell lines
such as U937 [242]. The cooperation between Quercetin and ATO was low in
NB-4 cells, indicating that the synergy is cell-line dependent. We investigated
the effect of the combination treatment of ATRA and ATO on Akt phosphory-
lation (Ser-473/Thr-308). As seen from Fig. 4.9, the combination treatment of
ATRA and ATO leads to a decrease in Akt phosphorylation at both 24h and
48h. This decrease is seen at both the phosphorylation residues, Ser-473 and
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Figure 4.9: Arsenic Trioxide (ATO) in combination with ATRA leads to a
decrease in the phosphorylation of Akt at the Ser-473 and Thr-
308 residues. Western analysis of activation of Akt is shown
here. (A) shows the activation at the Ser-473 residue whereas
(B) shows the activation at the Thr-308 residues at 24h and 48h.
Thr-308, and is more prominent at 48h than at 24h. Since, we used only the nu-
clear fraction in Akt phosphorylation studies, Histone 3 was used as a loading
control. Akt is a central kinase involved in many important cellular processes
like proliferation, survival, growth as well as protein translation. For e.g., Akt
upon phosphorylation and activation, activates mTOR which plays a key role
in formation of the 80S translation initiation complex. Our results suggest that
the due to reduction in Akt phosphorylation, there is a decrease in rates of pro-
liferative processes in the cell leading to an overall decrease in cell growth rate.
However, this result does not explain the fact that we saw a decrease in cell
growth in the ATO alone treatment case without an apparent decrease in Akt
phosphorylation, suggesting that there are other factors at play.
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CHAPTER 5
MODELING AND ANALYSIS OF RETINOIC ACID INDUCED
DIFFERENTIATION OF UNCOMMITTED PRECURSOR CELLS
5.1 Abstract
Manipulation of differentiation programs has therapeutic potential in a spec-
trum of human cancers and neurodegenerative disorders. In this study, we in-
tegrated computational and experimental methods to unravel the response of
a lineage uncommitted precursor cell-line, HL-60, to Retinoic Acid (RA). HL-
60 is a human myeloblastic leukemia cell-line used extensively to study human
differentiation programs. Initially we focused on the role of the BLR1 recep-
tor in RA-induced differentiation and G1/0-arrest in HL-60. BLR1, a putative
G protein coupled receptor expressed following RA exposure, is required for
RA-induced cell-cycle arrest and differentiation and causes persistent MAPK
signaling. A mathematical model of RA-induced cell-cycle arrest and differen-
tiation was formulated and tested against BLR1 wild-type (wt) knock-out and
knock-in HL-60 cell-lines with and without RA. The current model described
the dynamics of 729 proteins and protein complexes interconnected by 1356 in-
teractions. An ensemble strategy was used to compensate for uncertain model
parameters. The ensemble of HL-60 models recapitulated the positive feedback
between BLR1 and MAPK signaling. The ensemble of models also correctly
predicted Rb and p47phox regulation and the correlation between p21-CDK4
formation and G1/0-arrest following exposure to RA. Finally, we investigated
the robustness of theHL-60 network architecture to structural perturbations and
generated experimentally testable hypotheses for future study. Taken together,
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the model presented here was a first step toward a systematic framework for
analysis of programed differentiation. These studies also demonstrated that
mechanistic network modeling can help prioritize experimental directions by
generating falsifiable hypotheses despite uncertainty.
5.2 Introduction
A molecular understanding of proliferation and differentiation could lead to
new treatments for cancer, spinal cord injuries or neurodegenerative disorders.
However, the molecular basis of these fundamental programs has yet to be fully
unraveled. To rationally reprogram these networks we must first understand
their connectivity and regulation. One strategy toward this goal is to analyze the
proliferation and differentiation behavior of a model system. Lessons learned in
simple systems could perhaps inform analysis of more complex programs. One
such model system for the study of differentiation is the lineage uncommitted
humanmyloblastic cell line HL-60. HL-60 is an archetype in-vitro differentiation
model studied since the late 1970’s [243, 244, 245]. Depending upon the stim-
ulus, HL-60 undergoes G1/0-arrest followed by either myeloid or monocytic
differentiation. Retinoic Acid (RA) or Dimethyl Sufoxide (DMSO) causes G1/0-
arrest and myeloid differentiation. On the other hand, 1,25-dihydroxy vitamin
D3 (D3) or sodium butyrate causes arrest with monocytic differentiation. Stim-
uli such as RA or D3 drives MEK-dependent activation of the ERK1/2-MAPK
pathway [218, 246, 247, 248]. ElevatedMAPK signaling persists until cells G1/0-
arrest and terminally differentiate. The onset of G1/0 arrest and terminal differ-
entiation requires approximately 48 hr. During this period, HL-60 cells undergo
approximately two division cycles [249, 250, 251, 252]. Interestingly, during the
107
first 24 hours of treatment, called a precommitment period, cells are primed
to differentiate without lineage specificity. Lineage specificity is determined
in the second 24 hr period. Disruption of MEK signaling leads to failure of
ERK2 activation and HL-60 differentiation. Activation of both Retinoic Acid
Receptor (RAR) and Retinoid X Receptor (RXR) is necessary for RA-induced
G1/0-arrest, MAPK signal activation [253, 254, 255] and myeloid differentiation
[246, 247, 248, 256]. RA-induced differentiation is contingent on the early tran-
scriptional up-regulation of BLR1 (Burkitt’s Lymphoma Receptor-1). BLR1, also
known as CXCR5, is a putative serpentine heterotrimeric Gq protein-coupled
receptor, with a sequence similar to IL-8 receptors [257]. It was first discovered
in a screen for differentially expressed genes that conferred metastatic capabil-
ity to human B-cell lymphomas [257, 258]. BLR1 was identified as an early RA
(or D3)-inducible gene in HL-60 cells using differential display [245, 259], sug-
gesting it had a broader function than lymphocyte regulation. Studies of the
BLR1 promoter identified a 5’ 17bp GT box approximately 1 kb upstream of
the transcriptional start that conferred RA responsiveness [260]. Over expres-
sion of BLR1 in HL-60 cells enhanced ERK2 activation in both RA-untreated
and treated cells and accelerated RA- and D3-induced differentiation and G1/0-
arrest. Alternatively, BLR1 homologous knockout cells failed to produce a sus-
tained MAPK response, arrest or differentiate. However, activation of MAPK
signaling via constitutively active Raf over-expression was able to rescue the
differentiation response. Furthermore, inhibiting MAPK activation via a Raf in-
hibitor or siRNA knockdown resulted in decreased BLR1 expression, and loss
of differentiation and arrest [219]. Thus, RA-induced BLR1 expression appears
to contribute to sustained ERK2 activation and propulsion of induced differen-
tiation and G0 arrest.
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To analyze RA-induced arrest and differentiation in HL-60 we integrated
experimental and computational methods. Many have suggested that the
integration of experimental and computational research is required to un-
ravel critical questions facing modern cell biology [261, 262]. Toward this
end, mathematical modeling has become an important tool to understand
biological complexity [3]. A common method of modeling biological path-
ways is to formulate coupled Ordinary Differential Equations (ODEs). ODE
models have been constructed for a range of signal transduction processes
[263, 264, 171, 23, 265, 266, 267, 268, 269]. However, to formulate and solve these
models both the network structure and parameter estimates are required. Yeast
Two-Hybrid (Y2H) [270, 271, 272, 273], Fluorescence Resonance Energy Trans-
fer (FRET) [274] or Chromatin Immunoprecipitation (ChIP)-DNA microarray
techniques [275, 276, 277, 278] have all been used to identify network interac-
tions. Although error prone [279, 280], these techniques along with traditional
low-throughput Immunoprecipitation have been the basis for most experimen-
tal network discovery. Computational motif discovery [281, 282, 283], high-
throughput network reconstruction [284, 285, 286, 287] or text processing [288],
have also contributed significantly to network identification. The integration
of these studies has led to comprehensive on-line network databases such as
STRING [289], NetworKIN [290, 291] or KEGG [292, 293, 294]. However, while
network structural knowledge continues to evolve, the identification of model
parameters remains a fundamental challenge.
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5.3 Materials and Methods
5.3.1 Cell culture, RA treatment and western blot analysis.
Human myeloblastic leukemia cells (HL-60) were grown in a humidified atmo-
sphere of 5% CO2 at 37 C and maintained in RPMI 1640 supplemented with
5% fetal bovine serum (Invitrogen). The cells were cultured in constant expo-
nential growth as previously described [295]. The experimental cultures were
initiated at a cell density of 0.2×106 cells/ml. RA (Sigma) was dissolved in 100%
ethanol with a stock concentration of 5 mM, and used at a final concentration
of 1µM as previously described [295]. For Western blot analyses, 1.2 × 107 cells
were lysed using 400µl of M-Per lysis buffer (Pierce) and lysates were cleared
by centrifugation at 16,950 × g in a microcentrifuge for 20 min at 4oC. Equal
amounts of protein lysates (20µg) were resolved by 8% SDS-PAGE at 90 volts,
transferred to nitrocellulose membranes, and probed with a primary and sec-
ondary antibodies for visualization. Antibody solutions contained 10µL of the
appropriate antibody and 1g bovine serum albumin dissolved in 20mL 1X TBS,
0.1% Tween. The primary Retinoblastoma (Rb) antibody was purchased from
Zymed. A GAPDH antibody (Cell Signaling, Beverly, MA) was used to check
uniform loading. Anti-rabbit and anti-mouse horseradish peroxidase-linked
secondary antibodies (Cell Signaling, Beverly, MA) were used for visualization.
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5.3.2 Formulation and solution of the model equations.
The HL-60 model was formulated as a set of coupled Ordinary Differential
Equations (ODEs):
dx
dt
= S · r (x,p) x (to) = xo (5.1)
The symbol S denotes the stoichiometric matrix (729 × 1356). The quantity x
denotes the concentration vector of proteins or protein complexes (729× 1). The
term r (x,p) denotes the vector of reaction rates (1356 × 1). Each row in S de-
scribed a protein while each column described the stoichiometry of network in-
teractions. Thus, the (i, j) element of S, denoted by σi j, described how protein i
was involved in rate j. If σi j < 0, then protein iwas consumed in r j. Conversely,
if σi j > 0, protein i was produced by r j. Lastly, if σi j = 0, there was no protein i
in rate j. We assumed mass-action kinetics for each interaction in the network.
The rate expression for protein-protein interaction or catalytic reaction q:
∑
j∈{Rq}
σ jqx j →
∑
p∈{Pq}
σpqxp (5.2)
was given by:
rq
(
x, kq
)
= kq
∏
j∈{Rq}
x−σ jqj (5.3)
The set
{
Rq
}
denotes reactants for reaction q. The quantity
{
Pq
}
denotes the set
of products for reaction q. The kq term denotes the rate constant governing the
qth interaction. Lastly, σ jq, σpq denote stoichiometric coefficients (elements of
the matrix S). We treated every interaction in the model as non-negative. All re-
versible interactions were split into two irreversible steps. The mass-action for-
mulation, while expanding the dimension of the initiation model, regularized
the mathematical structure. The regular structure allowed automatic generation
of the model equations. Mass-action kinetics also regularized the model param-
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eters. Unknown model parameters were one of only three types, association,
dissociation or catalytic rate constants. Thus, although mass-action kinetics in-
creased the number of parameters and species, they reduced the complexity of
model analysis. In this study, we did not consider intracellular concentration
gradients. However, we accounted for membrane, cytosolic and nuclear species
by explicitly incorporating separate protein species.
5.3.3 Simulation protocol.
A pseudo steady-state was used as the starting point (t = 0 hr) for all simula-
tions presented in this study. For example, when calculating the response of
HL-60 to the addition of RA, we first ran the model to steady-state and then
simulated the addition of RA. We assumed that a pseudo steady-state was a
reasonable approximation of the population average behavior of HL-60 grow-
ing in the exponential phase. The steady-state was estimated numerically by
repeatedly solving the model equations and estimating the difference between
two subsequent time points:
‖x (t + ∆t) − x (t) ‖2 ≤  (5.4)
The quantities x (t) and x (t + ∆t) denote the simulated concentration vector at
time t and t + ∆t, respectively. The quantity ‖ · ‖2 denotes the L2 vector norm. In
this study, we used ∆t = 50 hrs of simulated time and  = 0.01 for all simulations.
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5.3.4 Estimating an ensemble of model parameters.
The 1462 unknown model parameters (1356 kinetic constants and 106 non-zero
initial conditions) were estimated using the experimental studies preformed by
Wang and Yen [219]. The experimental work focused on the existence of a BLR1-
MAPK positive feedback loop and included time course data and genetically
engineered cell-lines to capture perturbations in both the BLR1 and MAPK sig-
naling axis. The initial parameter guess p0 was used to generate an ensemble of
parameters that maximized the likelihood of describing the training data. The
difference between the measured and simulated value of species j at time or
condition i, denoted by xˆi, j and x(pk)i, j respectively, was quantified by the nor-
malized mean squared error, η:
η (pk) =
1
N
∑
i, j
(xˆi, j − β jx (pk)i, j)2
σˆ2i, j
, (5.5)
where sum was carried out over all species j and observations i. The quanti-
ties N and σˆi, j denote the total number of observations and the measurement
error of species j at time or condition i, respectively. If no experimental error
was reported, we assumed a standard deviation equal to 10% of the reported
observation. In cases where the quantification of the stimulus or observation
was unclear an augmented error of 20%-100% was applied to compensate for
the added uncertainty. The scaling factor β j was chosen to minimize the nor-
malized squared error for a given experiment and species j [296]:
β j =
∑
i(xˆi, jxi, j/σˆ2i, j)∑
i(xi, j/σˆi, j)2
. (5.6)
Because of the scaling factor, the concentration units on simulation results were
arbitrary (consistent with the arbitrary units associated with the majority of the
training data). There was insufficient training data to properly constrain the
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model parameters. To account for parametric uncertainty, a monte-carlo ap-
proach similar to Battogtokh et al. [167] was used to generate an ensemble
of parameters. Consider a set of model parameters pi. Let the likelihood that
model simulations with parameters pi describe the training data be defined as:
φ(pi) ≡ exp{−η(pi)T }, (5.7)
where η(pi) denotes the simulation error associated with parameter set pi. The
quantity T is a parameter used to tune the rate of acceptance. Further let the
acceptance probability, P(p′i+1|pi), of a new parameter set, p′i+1, be φ(p
′
i+1)
φ(pi)
if φ(p′i+1) <
φ(pi) and 1 otherwise. P denotes the probability that p′i+1 will be accepted as the
starting point for consecutive monte-carlo steps. Parameter sets were generated
by applying a small additive random perturbation in log space:
logp′i+1 = logpi +N (0, ν) (5.8)
where N (0, ν) is a normally distributed random number with zero mean and
variance ν. The perturbation was applied in log space to account for the large
variation in parameter scales and to ensure positivity. Monte-carlo trajecto-
ries were generated starting from p0 where ν =0.05 or 0.1 and T =1 or 0.5.
The autocorrelation function of each trajectory was calculated. The number of
monte-carlo steps between parameter sets which were added to the ensemble
was taken to be the number of steps after which the autocorrelation function
dropped to 5% of its initial value. This was done to ensure independence be-
tween sets in the ensemble. To compensate for noise in the autocorrelation func-
tion an exponential fit was applied. We generated 2377 possible parameter sets
from which we selected the 100 sets with the highest likely-hood for inclusion
in the final ensemble.
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5.3.5 Robustness analysis of the HL-60 architecture.
Robustness coefficients of the form:
α
(
i, j, to, t f
)
=
(∫ t f
to
xi (t) dt
)−1 (∫ t f
to
x( j)i (t) dt
)
(5.9)
were calculated to understand the regulatory connectedness of the HL-60 net-
work. The robustness coefficient α
(
i, j, to, t f
)
is the ratio of the integrated con-
centration of a network output in the presence (numerator) and absence (de-
nominator) of structural or operational perturbation. Here t0 and t f denote
the initial and final simulation time respectively. The network output was
taken to be the network states. The quantity i denotes the index for a marker
or reference species while j denotes the perturbation index, respectively. If
α
(
i, j, to, t f
)
> 1, then the perturbation increases the output concentration. Con-
versely, if α
(
i, j, to, t f
)
 1 the perturbation decreases the output concentration.
Lastly, if α
(
i, j, to, t f
)
∼ 1 the perturbation does not influence the output con-
centration. Because of computational constraints, we calculated the robustness
coefficients using a sub-ensemble (N = 47) selected from the full ensemble (N
= 100). The sub-ensemble had a CV distribution similar to the full ensemble
(Fig. 6.4.1B, circles). While we sampled a sub-ensemble, this subset had a diver-
sity similar to the full ensemble. Thus, we expect results calculated using the
sub-ensemble will be similar to the full ensemble.
5.4 Results
In this study, we tested the sufficiency of the BLR1-MAPK architecture to re-
capitulate persistent MAPK activation and to predict qualitative molecular fea-
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tures of RA-induced arrest and differentiation in HL-60. The model was orga-
nized around the regulation of seven transcription factors by Erk1/2 and PKCα
and the subsequent RA-induced transcriptional program (Table 5.1). The signal-
ing and transcription factor network architecture was assembled by aggregating
information from literature.
Table 5.1: Transcription factor, corresponding kinase and transcription factor
target genes used in the transcription subnetwork.
TF Kinase Targets Citation
ETS ERK IRF, SRPK, RhoGDI, p47Phox, CD45, EIF2AK, SIIIp15 [297, 298]
BRN – IRF, SRPK, RhoGDI, p47Phox, CD45, EIF2AK, SIIIp15 [297]
CREB PKC IRF, SRPK, RhoGDI, p47Phox, CD45, EIF2AK, SIIIp15, BLR1 [297, 219]
Oct1 – IRF, SRPK, RhoGDI, p47Phox, CD45, EIF2AK, SIIIp15, BLR1 [297, 219]
NFATc3 ERK BLR1 [299]
E2F – CycE, E2F [300]
AP1 ERK CycD [298]
Model parameters and structure (if required) were re-identified to make the
model HL-60 specific. The composite network included: steroid/hormone acti-
vated nuclear transcription factor receptors [301, 259]; MAPK driven transcrip-
tion factor activation [302, 263, 171]; BLR1 mediated G coupled-protein recep-
tor signaling [269, 303, 304]; PI3K/AKT/TOR mediated translation initiation
[172, 154]; and G1/0 mammalian cell cycle regulation [161]. All molecular in-
teractions, including transcription and translation, were modeled as elementary
reactions using mass action kinetics. Mass balance equations describing the dy-
namics of network components were formulated as a system of non-linear Or-
dinary Differential Equations (ODEs). While we assumed spatial homogeneity,
we differentiated between cytosolic, membrane and nuclear localized processes
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Figure 5.1: Schematic overview of BLR1-MAPK positive feedback loop
driving RA induced HL-60 arrest and differentiation.
using segregated compartments. In total, the model described 729 species and
1356 interactions (Fig. 5.1). The model had 1462 unknown parameters (1356
kinetic constants and 106 initial conditions). The kinetic constants were of three
types, association, dissociation or catalytic rate constants. Identification of these
unknown model parameters posed a significant challenge. We addressed this
challenge by identifying an ensemble of parameter sets consistent with the train-
ing data instead of a single best fit but uncertain parameter set. The ensemble
of HL-60 models recapitulated the positive feedback between BLR1 and MAPK
signaling. The ensemble of models was also capable of making important pre-
dictions. For example, the model ensemble correctly predicted Rb and p47phox
regulation and the correlation between p21-CDK4 formation and G0 arrest. Fi-
nally, we investigated the robustness of the HL-60 network subjected to struc-
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tural perturbations and generated experimentally testable hypothesis for future
study.
5.4.1 Estimating an ensemble of HL-60 models.
Signal transduction models often exhibit complex behavior [305, 306, 307, 308].
It is often not possible to identify model parameters, even with extensive train-
ing data [309]. Thus, despite identification standards [310] and the integra-
tion of model identification with experimental design [311], parameter esti-
mation remains challenging. In this study, an ensemble of plausible model pa-
rameters was estimated from the study of Wang and Yen [219]. Ensemble ap-
proaches have successfully addressed uncertainty in systems biology and other
fields like weather prediction [167, 312, 269, 296, 313]. Their central value is
the ability to constrain model predictions despite uncertainty. For example,
Sethna and coworkers showed in a model of growth factor signaling that pre-
dictions were possible using ensembles despite incomplete parameter informa-
tion (sometimes only order of magnitude estimates) [306]. They further showed
that model ensembles were predictive using many different mathematical mod-
els [314]. The data sets used for model training and validation along with the
model error are summarized in Table 5.2.
Table 5.2: Quantification of model training and validation error.
Species Figure Purpose Cite
BLR1 mRNA Fig. 3 A training [219]
pRaf Fig. 3 B training [219]
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Table 5.2 (Continued)
TF Kinase Targets Citation
pMek Fig. 3 C training [219]
pERK Fig. 3 D training [219]
BLR1 mRNA Fig. 4 A and B training [219]
pRaf Fig. 4 C training [219]
Rb mRNA Fig. C top Validation [315]
Rb Fig. C bottom Validation in house
Cyclin D Fig. C top Validation [315]
IRF Table 1 Validation [297]
SPRK2 Table 1 Validation [297]
RhoGDI Table 1 Validation [297]
p47Phox Table 1 Validation [297]
CD45 Table 1 Validation [297]
PRK Table 1 Validation [297]
Weused the time-course ofMAPK activation and BLR1 expression following
RA treatment to generate the HL-60 ensemble (Fig. 5.4). In addition, measure-
ments of the MAPK-BLR1 signaling axis in genetically engineered HL-60 cell-
lines were also used (Fig. 5.5). We used a maximum likelihood random-walk
strategy similar to Battogtokh et al. [167] to identify the ensemble (Fig. 6.4.1A).
We generated 2377 possible parameter sets and selected themost likely sets (N =
100) for inclusion in the ensemble. The median binding affinity for interactions
in the model (calculated over the ensemble) was approximately 100 nM, while
the median kcat ' 0.5 s−1. Thus, although no specific constraint was applied, the
parameters were physiologically reasonable. Additionally, the correlation be-
tween ensemble parameter sets showed that we sampled from at least two local
minima (Fig. 5.3). This suggested that the ensemble was diverse and explored
multiple possible local solutions. Seventy-two percent of parameters in the en-
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Figure 5.2: Parameter identification strategy. (A)Multiple monte-carlo tra-
jectories were used to randomly explore parameter space. The
simulation likelihood was used to generate a family of param-
eter sets used in the simulation study. We generated N = 2377
possible parameter sets and selected the 100 sets with the high-
est likelihood for inclusion in the ensemble. (B) Coefficient of
Variation (CV; standard deviation of a parameter relative to its
mean value) for the parameter ensemble used in this study.
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Figure 5.3: Correlation between parameter sets in theHL-60 ensemble. Re-
gions of red indicate high correlation, while blue regions de-
note low correlation.
semble had a Coefficient of Variation (CV) of less than 100% (Fig. 6.4.1B). Thus,
the order of magnitude of approximately three-quarters of the model parame-
ters was identified from the training data. Unconstrained parameters typically
involved processes not activated by RA or not associated with BLR1 signaling.
121
5.4.2 The ensemble of HL-60 models recapitulated RA-induced
BLR1 expression and MAPK activation.
Wang and Yen demonstrated that RA-induced BLR1 expression was necessary
for sustainedMAPK activation [219]. In this study, we explored whether a BLR1
control element was sufficient for sustained MAPK activation. We incorporated
a putative BLR1-MAPK feedback architecture supported by literature. Yen and
coworkers established that RA treatment induces BLR1 expression through a
non-canonical retinoic acid-responsive element (RARE) in the BLR1 promoter
[260]. However, the mechanism by which BLR1 drives Raf1 activation in HL-60
remains uncertain. There is evidence suggesting that BLR1 acts as a Gq protein-
coupled receptor [316, 317]. Moreover, Kolch et al. showed that protein kinase
C activator (PKCα) phosphorylated Raf1, at several sites, in NIH 3T3 fibrob-
lasts [304]. This suggested the hypothesis that BLR1 activates PKCα through
its Gq protein-coupled receptor activity and PKCα in turn phosphorylates Raf1.
We encoded this connectivity by re-identifying the Gq protein-coupled recep-
tor model of Song and Varner [269] in HL-60. To complete the loop, MAPK
family members must be connected in some way with BLR1 expression. Com-
ponents of the BLR1 transcriptional activator complex e.g., NFATc3 and CREB
can be phosphorylated by ERK, JNK or p38 MAPK family members [318]. In
the model we encoded the simplest of the possible routes, namely the phos-
phorylation of NFATc3 by pERK1/2. The in-vivo phosphorylation of NFATc3
by ERK1/2 has been shown in a variety of blood cell types [318]. The HL-60
connectivity recapitulated RA-induced sustained MAPK activation and feed-
back between BLR1 and MAPK (Fig. 5.4 and Fig. 5.5). The ensemble of HL-
60 models, following the addition of RA, captured the transient expression of
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Figure 5.4: Model simulations over the parameter ensemble captured the
sustained activation of MAPK following RA exposure (1µM)
at time = 1 hour. Dashed lines denote the simulation mean.
Shaded regions denote one ensemble standard deviation. (A)
Experimental and simulated levels of BLR1 mRNA following
RA exposure. (B) Time profile of phosphorylated RAF1 ac-
tivation following RA exposure. (C) Simulated versus mea-
sured phosphorylated MEK activation following RA exposure.
(D) Simulated versus measured phosphorylated ERK follow-
ing RA exposure.
BLR1 (Fig. 5.4A). BLR1 then drove Raf1 phosphorylation through its hypoth-
esized Gq protein-coupled activity (Fig. 5.4B). Activated Raf1 was then free to
activate downstream MAPK kinases (Fig. 5.4C and 5.4D). The median train-
ing error for RA-induced BLR1/MAPK signaling was ∼ 2, where pERK1/2 was
the least constrained species (Table 5.2). An error of 1.0 indicated the model
accuracy was equal to experimental error (assumed to be ± 20% for the train-
ing blots). Thus, the model recapitulated three of the four species to within
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Figure 5.5: The model recapitulated RA-induced feedback between BLR1
expression and MAPK activation. (A) Simulated BLR1 expres-
sion normalized to wildtype (WT) with Raf overexpression (+,
50% increase in Raf initial condition) and inhibition (KD, 50%
decrease in Raf initial condition) 12 hr after the addition of RA.
(B) Simulated BLR1 expression normalized to wildtype (WT)
with Raf overexpression (+) and inhibition (KD) 72 hr after the
addition of RA. (C) Simulated phosphorylated Raf levels nor-
malized to wildtype (WT) with BLR1 overexpression (+, 50%
increase in BLR1 gene initial condition) and knockout (KO,
BLR1 gene initial condition set to zero) 12 hr after the addition
of RA. (D) Model training data adapted from Wang and Yen.
First row: effect of Raf knockdown (left) and overexpression
(right) on the expression of BLR1 (Northern). Second row: ef-
fect of BLR1 knockout and overexpression of the level of phos-
phorylated Raf (S621) (left) and the effect of the Raf inhibitor,
GW5074 on BLR1 overexpression 12 and 24 hr after the addi-
tion of RA.
a neighborhood around the experimental error. The ensemble of models also
recapitulated aspects of BLR1/MAPK signaling following Raf1 and BLR1 per-
turbations (Fig. 5.5). Because the perturbation magnitudes were not reported,
we assumed ±50% for all changes, excluding the BLR1 homologous knockout.
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A 50% increase in Raf1 expression increased BLR1 transcription after 12 hr of
RA exposure (Fig. 5.5A). Conversely, a 50% decrease in Raf1 activation reduced
the BLR1message 72 hr post RA treatment (Fig. 5.5B). The perturbation of BLR1
played a similar role to Raf1. A 50% increase in BLR1 expression increased Raf1
activation (Fig. 5.5C, lane two), while a BLR1 knockout blocked RA-induced
Raf1 activation (Fig. 5.5C, lane three). The BLR1-MAPK perturbation simula-
tions were qualitatively consistent with experimental measurements (Fig. 5.5D).
However, while the direction of the simulated shifts was consistent with mea-
surements, the time-scale did not match for all cases. The time-scale of Raf1
activation following perturbations to BLR1 directly corresponded to measure-
ments. On the other hand, the time-scale of the response of BLR1 to changes in
Raf1 activation was not directly comparable to measurements.
5.4.3 The HL-60 ensemble predicted RA-induced expression
shifts and qualitative features of G1/0 cell-cycle arrest.
We tested the ability of the model to predict qualitative features of RA-induced
differentiation not included in the training data (Table 5.2).
Table 5.3: Predicted and measured RA-induced protein expression shifts at 3, 12
and 24 hrs after the addition of RA.
Protein 3hr 12hr 24hr
TF Kinase Targets Citation
Cyclin D - + -
IRF - - -
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Table 5.3 (Continued)
Protein 3hr 12hr 24hr
TF Kinase Targets Citation
SPRK2 + + +
RhoGDI + - -
p47Phox + + +
CD45 + - -
PRK + + -
We compared simulations of RA-induced protein expression with a panel of
proteins found to be important following RA treatment [297]. In total, we cap-
tured approximately half of the significant RA-induced protein shifts at three
different time points (Table 5.3). For example, the model ensemble predicted the
up-regulation of p47Phox, a component of oxidative metabolism important in
the functional differentiation of mature myeloid cells [319]. The model ensem-
ble also predicted that Rb protein levels decreased following RA treatment (Fig.
5.6B). Down-regulation of the Rb protein level was consistent with western blot
measurements 24 hrs after RA treatment (Fig. 5.6B, lower inset). Interestingly,
Rb protein levels decreased despite a stable mRNA signal (Fig. 5.6B, top in-
set). The model thus correctly predicted an unanticipated experimental obser-
vation. The model ensemble predicted that competition for translational ma-
chinery resulted in the decreased Rb protein levels. Other factors not present in
the model, for example, RA-induced degradation mechanisms could also play
a role. In addition to shifts in Rb and p47Phox expression, the model ensemble
also predicted other RA-induced cell-cycle responses. For example, the model
ensemble predicted increased association of p21 with the CDK4-cyclin D com-
plex following RA-treatment (Fig. 5.6A). Increased p21-CDK4-cyclin D levels
were consistent with previous data on the kinetics of RA-induced G1/0-arrest
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Figure 5.6: Computationally predicted markers of RA-induced pheno-
typic shift. (A) Predicted p21-CDK4-cyclinD complex forma-
tion was consistent with percentage of G1/0-arrested cells (in-
sert). (B) Effect of RA on Rb expression. Rb transcript (top) re-
mains constant while Rb protein (bottom) decreases. Rb tran-
script consistent with Northern analysis (top insert) while Rb
protein levels were consistent with Western analysis (bottom
insert).
(Fig. 5.6A, inset). However, there was some discrepancy between the previous
arrest studies and the cyclin D expression data, as cyclin D expression levels
were not consistently predicted (Table 5.3).
5.4.4 Robustness analysis identified essential nodes in RA-
induced arrest and differentiation of HL-60.
Signal transduction architectures often contain redundancy, feedback and
crosstalk. These and other features make signaling networks robust to pertur-
bation. However, robust networks which are highly optimized for specific tasks
may also contain hidden fragility [61]. Here, we generated falsifiable predic-
tions about the fragility or robustness of structural features of the HL-60 net-
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work using robustness analysis. We hypothesized that the concentration pro-
files of the network components following the addition of RA was indicative
of network function. We calculated the direction of RA-induced concentration
shifts for 729 markers following the deletion of 106 network components (Fig.
5.7A). Robustness coefficients were calculated over the ensemble to minimize
parametric artifacts. The structural perturbations included the deletion of 80
constitutively expressed proteins, the genes for 20 regulated proteins or the re-
moval of calcium, ATP, etc. We rank-ordered the results from least (rank = 1)
to most (rank = 106) effective knock-down (x-axis) and least (rank = 1) to most
(rank = 729) effected marker (y-axis). Effectiveness was defined as the num-
ber of expression shifts caused or the number of perturbations a marker was
effected by.
Themajority of structural perturbations resulted in only small changes in the
network output following the addition of RA. The HL-60 network architecture
was approximately scale-free (Fig. 5.8). A hub and spoke topology was consis-
tent with the sparseness of the perturbation simulation results. Approximately
80% of the entries in the robustness matrix were equal to zero (Fig. 5.7A, green).
For those species that did influence the network state, there was an approxi-
mately 30% correlation between connectivity and influence. Globally, the single
largest impact was made by removing components of translation initiation and
RNA polymerase (RNAp) from the model. For example, deletion of RNAp re-
sulted in 468 statistically significant shifts, or 64% of the network components.
This was consistent with the obvious expectation that stopping protein synthe-
sis would interrupt the progress of induced differentiation. Interestingly, while
deletion of translation components effected many markers, there were only a
limited number of perturbations that impacted translation. This suggested that
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Figure 5.7: Robustness analysis. (A) Qualitative coupling results. Re-
moved species are along the x-axis from lowest to largest im-
pact and observedmodel species are along the y-axis from least
to most effectived. Blue (red) markers depict a statistical de-
crease (increase) in area under the curve within a 90% confi-
dence interval. (B) Coupling coefficients (area under the curve
from the simulation with species removed over wild-type sim-
ulation) for three markers of differentiation: phosphorylated
ERK, p47phox expression and p21-CDK4 complex.
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Figure 5.8: The HL-60 network architecture exhibits scale free properties.
translation was a fragile core subsystem similar to fragile subsystems in other
‘bow-tie’ type networks [320]. Anecdotally, RNAp was also the most connected
component with 191 connections (connected to approximately 26% of the net-
work species). However, the Spearman rank correlation between connectivity
and knock-down effectiveness was only 0.32. This suggested there was a lim-
ited relationship between the direct connectivity of a node and the functional
consequences of its removal. Deletion of other structural elements with much
lower connectivity also produced global variation. For example, deletion of blr1
or the blr1 transcription factor complex effected on average 280 markers, or 38%
of the network. BLR1 or components of its transcriptional activator complex
had an average connectivity of 11, or just 1.5% of the network. Small molecules
such as calcium ions, ATP and GDP were also structurally critical, on average
effecting 185 markers. Interestingly, MAPK species appeared nearly midway
through the ordered list with ERK at rank 43/106 and MEK at rank 46/106. The
most influential MAPK component was Raf1 at rank 59/106.
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No single structural deletion led to enhanced differentiation of HL-60 fol-
lowing RA exposure. We considered three markers to represent a significant
tendency towards HL-60 differentiation and G1/0-arrest: ERK-T203Y205 phos-
phorylation represented sustained MAPK signaling; the p21-CDK4 complex
represented initial aspects of cell cycle arrest; p47phox expression represented
early aspects of the inducible reactive oxygen species machinery. Of the 106
deletions, none consistently up-regulated all three markers. Twenty-two net-
work components (or 21% of those tested) were essential for differentiation
(Fig. 5.7B). Seventeen of these involved translation and RNAp. The remain-
ing five targets were members of the BLR1 transcription factor complex includ-
ing RAR/RXR. Analysis of the shifts for the individual markers following the
structural perturbations suggested functional relationships in the network. For
example, deletion of 32 components (or 30% of those explored) reduced ERK-
pp formation (Fig. 5.7B, top panel). These included BLR1, RXR/RAR, proteins
in the Gq protein-coupled cascade connecting BLR1 with Raf1, upstream ki-
nases and MAPK phosphatases. Thirty-six perturbations (or 34% of those ex-
plored) influenced p21-CDK4 formation (Fig. 5.7B, center panel). In addition
to those perturbations associated with pERK1/2, deletion of components in-
volved with cyclin D expression also influenced p21-CDK4-cyclin D levels. For
example, deletion of the phosphatase responsible for de-phosphorylating AP1-
p (transcription factor for cyclin D) increased p21-CDK4 levels. Twenty-seven
perturbations (or 25% of those explored) shifted p47Phox expression (Fig. 5.7B,
bottom panel). These structural perturbations were largely associated with the
regulation of the transcription factors driving p47Phox expression.
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5.5 Discussion
Agrand challenge in tumor biology continues to be an understanding of the reg-
ulation of cell division and differentiation. The primary obstacle to understand-
ing these programs has been their complexity and scale. Interrogating these
complex systems species by species is intractable due to the number of species
and their interactions. A computational approach that allows in-silico analysis
versus experimental surveying would be a tool of widespread utility to push
passed this hurdle. Perhaps, one such tool is mechanistic pathway modeling.
The ultimate objective of this study was to develop a mathematical model of
hormone/growth factor regulated cell division and differentiation. The math-
ematical model is eventually intended to be a cell-type agnostic tool generally
applicable to any cell-type where division and differentiation are hormonally
regulated. However, to develop an initial framework towards this goal we have
focused model development on the archetype in vitro cell line HL-60. Upon
RA treatment HL-60 undergoes growth arrest and myeloid differentiation. Our
basic hypothesis has been that RA-induced cell differentiation is regulated by
BLR1which signals through a RAF/MEK/ERK axis. In turn, theMAPK cascade
activates a limited number of transcription factors who then drive the expres-
sion of proteins mediating the phenotypic shift [260]. The current network in-
corporates these basic signaling features. We established that a literature based
positive feedback loop between BLR1 and MAPK signaling was sufficient to
generate the BLR1 expression and MAPK activation profiles observed experi-
mentally (Fig. 5.4 and Fig. 5.5). Furthermore, we demonstrated that the current
model was capable of making important predictions including the regulation of
Rb and p47phox along with the correlation between the p21-cdk4 complex and
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G0 arrest. Robust networks or systems maintain performance despite structural
or operational perturbations.
In this study, we performed robustness analysis to estimate which architec-
tural features of the HL-60 network promoted or destroyed differentiation. This
analysis also generated falsifiable predictions on the role of individual model
species and global insight into the network itself. For example, the core trans-
lation machinery was a robust yet fragile subsystem. Deletion of translation
components effected roughly 60% of the entire network (Fig. 5.7A). However,
translation was robust in that removal of other network species had little im-
pact on its function. The majority of translation, save met-tRNA and eIF5, were
in the lower third of effected markers. However, while necessary, the trans-
lation subnetwork may not be experimentally interesting. To focus on phe-
notypic conversion we considered three markers of programed differentiation
and G1/0-arrest: pERK1/2, p21-CDK4-cyclin D and p47phox. These markers
were representative of sustained MAPK activity, cell cycle arrest and early ROS
machinery, respectively. Simulations of RA-induced phenotypic change in the
wild-typemodel showed these markers were reliable compared to experimental
data. None of the structural perturbations considered consistently up-regulated
all three markers. This suggested that no single structural perturbation en-
hanced the effect of RA and that, given the current network, no components
were blocking differentiation. Structural perturbations that consistently down-
regulated all threemarkers were considered targets that would prevent differen-
tiation. Again the translational core machinery along with RNAp proved to be
necessary for differentiation. Beyond these global inhibitors, we also found that
deletion of RAR, RXR, BLR1, NFATc3, Oct1 and CREB (Fig. 5.7B) also down-
regulated differentiation. RAR and RXR were obvious candidates for mitigat-
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ing the RA differentiation response [321]. Removal of BLR1 has previously been
shown to prevent differentiation [219] and was indeed a motivating factor in
the original model design. NFATc3, Oct1, and CREB were all required for tran-
scriptional activation of the BLR1 gene andwere therefore of similar importance
[260]. This study identified key differentiation regulators, however, the list was
not complete. For example, Yen et al. showed that Raf and MEK activation was
also required for differentiation [219, 218]. In the current network, ERK1/2 dele-
tion repressed only two (pERK1/2 and p21-CDK4) of the three differentiation
markers, not effecting p47phox. While ERK1/2 may regulate p47phox expres-
sion, ERK1/2 may also impact inducible ROS response at other points in the
network. A more detailed model, including other differentiation markers, is
required to fully unravel the key species in the differentiation program.
The initial model presented here was a step toward a systematic frame-
work for the organization and prediction of programed differentiation. How-
ever, there are several mathematical and experimental issues that should be
addressed in subsequent studies. For example, a common criticism of large
complex mathematical models is the poorly characterized effect of model un-
certainty. Model uncertainty has two forms. Structural uncertainty is uncer-
tainty in the biology, while parametric uncertainty is incomplete knowledge of
model parameters. We used an ensemble approach to overcome parametric un-
certainty. Consistent with previous ensemble studies [306], the HL-60 ensem-
ble predicted the expression of a panel of markers found previously to be im-
portant [297]. These predictions were successful despite the large uncertainty
in the model parameters. However, the prediction error rate was significant.
This suggested that structural uncertainty was also important. It is likely that
structural uncertainty was present both in terms of missing interactions (false
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negatives) and incorrect interactions (false positives). We partially mitigated
structural uncertainty by associating each interaction with experimental studies
or previously validated network models. However, in some cases connectivity
had to be hypothesized from literature. For example, the connectivity between
BLR1 signaling and Raf1 activation was hypothesized from studies in fibrob-
lasts. G coupled-protein receptor (GCPR) signaling and the subsequent acti-
vation of PKCα was modeled as a sequential series of activating events. This
basic architecture was sufficient to generate an RA-induced sustained MAPK
signal. However, this connectivity remains to be validated in HL-60. To validate
the proposed architecture, our laboratory is employing biochemical strategies to
characterize intermediate complexes in the BLR1 signaling axis. False negative
structural defects also represent a significant challenge. Current computational
and biological limitations render a full cell model intractable. Thus, the choice
of scope is an important aspect to modeling protein interaction networks. In this
study, we focused MAPK-BLR1 positive feedback. Inclusion of other signaling
pathways or a more advanced transcriptional regulation network will be re-
quired to capture the RA-induced expression shifts missed here as well as other
HL-60 differentiation data. The framework provided in this study is amenable
to expansion. The inclusion of more experimental data and a more detailed net-
work architecture could improve predictive power of the model and provide an
in silico tool for understanding programed cellular differentiation.
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CHAPTER 6
ANALYSIS OF THEMOLECULAR NETWORKS IN ANDROGEN
DEPENDENT AND INDEPENDENT PROSTATE CANCER REVEALED
FRAGILE AND ROBUST SUBSYSTEMS
6.1 Abstract
Androgen ablation therapy is currently the primary treatment for metastatic
prostate cancer. Unfortunately, in nearly all cases androgen ablation fails to per-
manently arrest cancer progression. As androgens like testosterone are with-
drawn, prostate cancer cells lose their androgen sensitivity and begin to prolif-
erate without hormone growth factors. In this study, we constructed and an-
alyzed a mathematical model of the integration between hormone growth fac-
tor signaling, androgen receptor activation and the expression of cyclin D and
Prostate Specific Antigen in human LNCaP prostate adenocarcinoma cells. The
objective of the study was to investigate which signaling systems were impor-
tant in the loss of androgen dependence. The model was formulated as a set
of ordinary differential equations which described 212 species and 384 interac-
tions including both the mRNA and protein levels for key species. An ensemble
approach was chosen to constrain model parameters and to estimate the im-
pact of parametric uncertainty on model predictions. Model parameters were
identified using 14 steady-state and dynamic LNCaP data sets taken from liter-
ature sources. Alterations in the rate of Prostatic Acid Phosphatase expression
was sufficient to capture varying levels of androgen dependence. Analysis of
the model provided insight into the importance of network components as a
function of androgen dependence. The importance of androgen receptor avail-
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ability and the MAPK/Akt signaling axes was independent of androgen status.
Interestingly, androgen receptor was important even in androgen independent
LNCaP cells. Translation became progressively more important in androgen
independent LNCaP cells. Further analysis suggested a positive synergy be-
tween the MAPK and Akt signaling axes and the translation of key proliferative
markers like cyclin D in androgen independent cells. Taken together, the results
support the targeting of both the Akt andMAPK pathways. Moreover, the anal-
ysis suggested that direct targeting of the translational machinery, specifically
eIF4E, could be efficacious in androgen independent prostate cancers.
6.2 Introduction
Prostate cancer is the most common cancer in men and the second leading cause
of cancer-related death in the United States [322]. It has been known since
the 1940s that androgens, such as testosterone, are required for prostate can-
cer growth [323]. Accordingly, androgen ablation in combination with radia-
tion or traditional chemotherapy remains the primary non-surgical treatment
for androgen-dependent prostate cancer. Androgen ablation initially leads to
decreased tumor growth and reduced secretion of biomarkers such as Prostate
Specific Antigen (PSA) [324, 325, 326]. However, in nearly all cases androgen
ablation fails to permanently arrest cancer progression. As testosterone is with-
drawn, malfunctioning prostate cells lose their sensitivity to androgen and be-
gin to proliferate without hormone growth factor signals. These testosterone in-
sensitive cells can then lead to Androgen-Independent Prostate Cancer (AIPC)
[327]. The AIPC phenotype is closely related to metastasis and decreased sur-
vival. Unfortunately, current treatments formetastatic AIPC have demonstrated
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onlymodest survival advantages [328]. Thus, an effective therepy for metastatic
AIPC represents an unmet medical need and an ideal target for systems biology.
AIPC is characterized by androgen action in the absence of androgen stim-
ulation. At the core of androgen action is the regulation of Androgen Receptor
(AR) by hormones such as testosterone. AR is a cytosolic steroid hormone recep-
tor belonging to the superfamily of ligand activated transcription factors. Other
members of this family include Vitamin A/D, estrogen, progesterone and thy-
roid hormone receptors [329, 330]. In healthy prostate epithelial cells, androgens
activate AR and drive an AR-dependent gene expression program. Sexual an-
drogens such as testosterone typically circulate in the blood, bound to proteins
such as the Sex Hormone Binding Globulin (SHBG) protein. Free testosterone
enters prostate cells where the 5α-reductase enzyme converts it to activated di-
hydrotestosterone (DHT) [331]. Both cytosolic testosterone and DHT can bind
AR, however DHT has a higher affinity for AR. Binding of DHT to AR promotes
cytosolic AR activation and the translocation of activated AR to the nucleus.
Nuclear AR drives the expression of target genes including PSA by binding to
AR-responsive promoter elements [332, 333]. Because of its ligand dependence,
one would expect AR activation and AR-driven gene expression to be absent
without hormone stimulation. However, AIPC often has higher PSA expression
and increased cell-proliferation compared to its androgen-dependent counter-
part even without stimulation [334, 335].
AIPC’s increased proliferation and PSA secretion in the absence of androgen
suggests a failure in the regulation of androgen receptor activation. Feldman
and Feldman reviewed several possible AR regulatory pathways perhaps re-
sponsible for androgen action in the absence of hormone stimulation [336]. One
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hypothesis, referred to as the hypersensitivity pathway, suggests that AR may
bemore sensitive to androgen in AIPC. This would allowAR activation andAR-
driven gene expression at much lower levels of extracellular testosterone sig-
nals. Another hypothesis, referred to as the promiscuous pathway, suggests that
AR can be activated by non-androgen antagonists. A third hypothesis, explored
here, suggests that AR can be activated by other pathways, for example, the Mi-
togen Activated Protein Kinase (MAPK) cascade. Several studies support this
cross-talk hypothesis, sometimes referred to as the outlaw pathway. Culig et al.
showed in DU-145 human prostatic tumor cells that growth factors e.g., IGF-I,
KGF, and EGF could drive AR activation without androgen [337]. Nazareth and
Weigel showed in human prostate PC-3 cells that AR could also be activated by
the protein kinase A activator, forskolin in the absence of androgen [338]. Other
studies have suggested a connection between Her2 induced activation of the
primaryMAPK cascade andAR activation [339]. For example, Her2 overexpres-
sion was positively correlated with diminished sensitivity to androgen ablation,
increased AR dependent PSA expression, increased AR activation, increased tu-
mor mass and shortened tumor latency [340, 339, 341, 335]. Thus, one would
expect regulators of Her2 activation, for example the different forms of the 100
kDa glycoprotein Prostatic Acid Phosphatase (PAcP), could be important factors
in androgen dependence and tumor grade [342, 343, 344, 345, 346, 347]. Intracel-
lular PAcP (cPAcP) whose expression is AR responsive, downregulates Her2 by
dephosphorylation. On the other had, secreted PAcP (sPAcP) promotes modest
Her2 activation by an unknown mechanism [347].
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6.3 Materials and Methods
Formulation and solution of the model equations.
The prostate model was formulated as a set of coupled Ordinary Differential
Equations (ODEs):
dx
dt
= S · r (x,k) x (to) = xo (6.1)
The symbol S denotes the stoichiometric matrix (212 × 384). The quantity x
denotes the species concentration (212 × 1). The term r (x,p) denotes the vector
of reaction rates (384 × 1). Each row in S described a species while each column
described the stoichiometry of network interactions. Thus, the (i, j) element of
S, denoted by σi j, described how protein iwas involved in rate j. If σi j < 0, then
protein i was consumed in r j. Conversely, if σi j > 0, protein i was produced by
r j. Lastly, if σi j = 0, protein iwas not involved in rate j.
We assumed mass-action kinetics for each interaction in the network. The
rate expression for protein-protein interaction or catalytic reaction q:
∑
j∈{Rq}
σ jqx j →
∑
p∈{Pq}
σpqxp (6.2)
was given by:
rq
(
x, kq
)
= kq
∏
j∈{Rq}
x−σ jqj (6.3)
The set
{
Rq
}
denotes reactants for reaction q. The quantity
{
Pq
}
denotes the set
of products for reaction q. The kq term denotes the rate constant governing the
qth interaction. Lastly, σ jq, σpq denote stoichiometric coefficients (elements of
the matrix S). We treated every interaction in the model as non-negative. All re-
versible interactions were split into two irreversible steps. The mass-action for-
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mulation, while expanding the dimension of the prostate model, regularized the
mathematical structure. The regular structure allowed automatic generation of
the model equations. In addition, an analytical Jacobian (A) and matrix of par-
tial derivatives of the mass balances with respect to the model parameters (B)
were also generated. Mass-action kinetics also regularized the model param-
eters. Unknown model parameters were one of only three types, association,
dissociation or catalytic rate constants. Thus, although mass-action kinetics in-
creased the number of parameters and species, they reduced the complexity of
model analysis. In this study, we did not consider intracellular concentration
gradients. However, we accounted for membrane and cytosolic proteins by ex-
plicitly incorporating separate membrane and cytosolic protein species. We did
not consider a separate nuclear compartment.
6.3.1 Simulation protocol.
An approximate steady-state was used as the starting point (t = 0 hr) for all
simulations presented in this study. For example, when calculating the response
of LNCaP to the addition of DHT, we first ran the model to steady-state and
then simulated the addition of DHT. Although no individual cell is likely to be
at steady-state we assumed that steady-state was a reasonable approximation
of the population average behavior of LNCaP cells growing in the exponential
phase. The steady-state was estimated numerically by repeatedly solving the
model equations and estimating the difference between two subsequent time
points:
‖x (t + ∆t) − x (t) ‖2 ≤  (6.4)
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The quantities x (t) and x (t + ∆t) denote the simulated concentration vector at
time t and t + ∆t, respectively. The quantity ‖ · ‖2 denotes the L2 vector norm. In
this study, we used ∆t = 50 hrs of simulated time and  = 0.01 for all simulations.
6.3.2 Estimation of the prostate model parameter ensemble.
An initial set of model parameters, denoted by p0, was chosen by hand to repli-
cate the training data. The training data consisted of 14 time-series and steady-
state data sets taken from literature sources (Table C.2). The initial parameter
guess p0 was used to generate an ensemble of parameters that maximized the
likelihood of describing the training data. The difference between the measured
and simulated value of species j at time or condition i, denoted by xˆi, j and x(pk)i, j
respectively, was quantified by the normalized mean squared error, η:
η (pk) =
1
N
∑
i, j
(xˆi, j − β jx (pk)i, j)2
σˆ2i, j
, (6.5)
where the sum was carried out over all species j and observations i. The quan-
tities N and σˆi, j denote the total number of observations and the measurement
standard deviation of species j at time or condition i, respectively. If no exper-
imental error was reported, we assumed a standard deviation equal to 10% of
the reported observation. In cases where the quantification of the stimulus or
observation was unclear an augmented error of 20%-100% was applied to com-
pensate for the added uncertainty. β j is a scaling factor which is required when
considering experimental data that is accurate only to a multiplicative constant
(assumed here to be the case form immunoblotting analysis). The scaling factor
was chosen to minimize the normalized squared error between a given experi-
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ment and species j [166]:
β j =
∑
i(xˆi, jxi, j/σˆ2i, j)∑
i(xi, j/σˆi, j)2
. (6.6)
Because of the scaling factor, the concentration units on simulation results were
arbitrary (consistent with the arbitrary units on the majority of the training
data). All simulation outputs reported in this study were scaled by the cor-
responding β j. There was insufficient training data to properly constrain the
420 model parameters. To account for parametric uncertainty, a monte-carlo
approach similar to Battogtokh et al. [167] was used to generate an ensemble
of parameters. Consider a set of model parameters pi. Let the likelihood that
model simulations with parameters pi describe the training data be defined as:
φ(pi) ≡ exp{−η(pi)
α
}, (6.7)
where η(pi) denotes the simulation error associated with parameter set pi. The
quantity α is a parameter used to tune the rate of acceptance. Further let the
acceptance probability, P(p′i+1|pi), of a new parameter set, p′i+1, be φ(p
′
i+1)
φ(pi)
if φ(p′i+1) <
φ(pi) and 1 otherwise. P denotes the probability that p′i+1 will be accepted as pi
for consecutive monte-carlo steps. Parameter sets were generated by applying
a small additive random perturbation in log space:
logp′i+1 = logpi +N (0, ν) (6.8)
where N (0, ν) is a normally distributed random number with zero mean and
variance ν. The perturbation was applied in log space to account for the large
variation in parameter scales and to ensure positivity. Monte-carlo trajecto-
ries were generated starting from p0 where ν =0.05 or 0.1 and α =1 or 0.5.
The autocorrelation function of each trajectory was calculated. The number of
monte-carlo steps between parameter sets which were added to the ensemble
was taken to be the number of steps after which the autocorrelation function
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dropped to 5% of its initial value. This was done to ensure independence be-
tween sets in the ensemble. To compensate for noise in the autocorrelation func-
tion an exponential fit was applied. The final ensemble contained 107 parameter
sets, which produced an ensemble η of 5.25.
6.3.3 Sensitivity analysis of the prostate network.
Overall State Sensitivity Coefficients (OSSC) were used to estimate which struc-
tural elements of the prostate network were sensitive [23]. OSSC values were
determined by first calculating the first-order sensitivity coefficients at time tk:
si j (tk) =
∂xi
∂p j
∣∣∣∣∣∣
tk
(6.9)
First-order sensitivity coefficients were computed by solving the matrix differ-
ential equation:
ds j
dt
= A (t) s j + b j (t) j = 1, 2, . . . , P (6.10)
subject to the initial condition s j(t0) = 0. In Eqn. 6.10, j denotes the parameter
index, P denotes the number of parameters in the model, A denotes the Jaco-
bian matrix, and b j denotes the jth column of the matrix of first-derivatives of
the mass balances with respect to the parameter values (denoted by B). An an-
alytical Jacobian and matrix of first-derivatives of the mass balances w.r.t the
parameters:
A =
∂fx
∂x
∣∣∣∣∣∣
(x∗,p∗)
B =
∂fx
∂p
∣∣∣∣∣∣
(x∗,p∗)
(6.11)
were generated from the model equations. The quantity fx = S · r (x,p) and
(x∗,p∗) denotes a point along the unperturbed model solution. The sensitivity
equations required that we solve the model equations to evaluate the A and B
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matrices. Thus, we formulated the sensitivity problem as an extended kinetic-
sensitivity system of equations [188]: x˙s˙ j
 =
 S · r (x,p)A (t) s j + b j (t)
 j = 1, 2, . . . , P (6.12)
where x˙ = dx/dt and s˙ j = ds j/dt. We solved the kinetic-sensitivity system for
multiple parameters in a single calculation using the LSODE routine of OC-
TAVE (www.octave.org). The first-order sensitivity coefficients were then used
to calculate the OSSC value for parameter j:
O j (t) =
p j
Ns
( NT∑
k=1
Ns∑
i=1
[
1
xi
∂xi
∂p j
∣∣∣∣∣∣
tk
]2)1/2
(6.13)
The terms NT , Ns denote the number of time points considered and the state
dimension of the model, respectively. To account for parametric uncertainty,
OSSC values were calculated over the parameter ensemble. Parameters were
ranked-ordered (1 ≤ θ j ≤ 384) based upon the magnitude of the OSSC value.
Large values of θ j indicated fragile or important interactions in the prostate net-
work architecture. Conversely, small values of θ j indicated robustness.
Each model in the ensemble was run to approximately steady state. At
steady-state, 10nM DHT was added and the first order sensitivity coefficients
were calculated for 100 seconds of simulated time. OSSC values were then
calculated and the rank ordering determined. We collected interactions whose
rank was at least one standard deviation above the mean rank calculated over
all parameters. Highly ranked interactions were statistically significantly dif-
ferent between LNCaP clones if the null hypothesis could be rejected with 95%
confidence via a t-test. To estimate significance, we performed a two variable
unequal variance double tail t-test using the MATLAB (R) statistical toolbox
(2007a, The Mathworks, Natick, MA).
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6.3.4 Robustness analysis of functional protein markers.
Robustness coefficients of the form:
α
(
i, j, to, t f
)
=
(∫ t f
to
xi (t) dt
)−1 (∫ t f
to
x( j)i (t) dt
)
(6.14)
were calculated to understand the regulatory connectedness of functional pro-
tein markers in the LNCaP network. The robustness coefficient α
(
i, j, to, t f
)
is
the ratio of the integrated concentration of a network output in the presence
(numerator) and absence (denominator) of structural or operational perturba-
tion. Here t0 and t f denote the initial and final simulation time respectively.
Simulations were taken of C-81 from approximate steady-state at t0, 10nM of
DHT was added at 1 hour and t f was taken to be 72 hours after DHT addition.
The network output was taken to be the network states. The quantity i denotes
the index for a marker or reference species while j denotes the perturbation in-
dex, respectively. If α
(
i, j, to, t f
)
> 1, then the perturbation increases the output
concentration. Conversely, if α
(
i, j, to, t f
)
 1 the perturbation decreases the out-
put concentration. Lastly, if α
(
i, j, to, t f
)
∼ 1 the perturbation does not influence
the output concentration.
6.3.5 Calculation of steady-state synergy coefficients.
To understand the connectedness of subsystems in the prostate network fol-
lowing ERK and/or Akt knockdowns we computed synergy coefficients of the
form:
∆ j =
δx j,Erk+Akt − (δx j,Erk + δx j,Akt)
x j,total
(6.15)
The quantity x j,total denotes the steady-state concentration (flux) of species (inter-
action) j in wild-type C-81. The quantity δx j,Erk (δx j,Akt) denotes the steady-state
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concentration (flux) of species (interaction) j in the presence of an Akt (ERK)
knock-out minus the basal value of quantity j. The term δx j,Erk+Akt denotes the
steady-state concentration (flux) of species (interaction) j in wild-type C-81. If
∆ j > 0, the quantity j has a positive synergy with Akt and ERK. In other words,
the steady-state concentration (flux) of species (interaction) j in the wild-type
was greater than the sum of the individual contributions in single Akt or ERK
knock-downouts. Conversely, if ∆ j < 0, the quantity j has a negative synergy
with Akt and ERK. Lastly, if ∆ j ∼ 0 then there is no connection between quan-
tity j and the Akt/ERK signaling axes.
6.4 Results
The objective of this study was to determine which signaling components were
important in AI versus AD LNCaP cells. Toward this objective, we constructed
and analyzed a mechanistic mathematical model of the androgen response of
three different LNCaP prostate adenocarcinoma sub-lines. We investigated
MAPK-dependent outlaw activation of AR in AD (C-33), mid-range (C-51) and
AI (C-81) LNCaP cells [348, 334]. Our network model included: nuclear hor-
mone and transmembrane growth factor receptor activation; transcriptional ac-
tivity via the MAPK subsystem [302, 263, 171] together with outlaw activation
of AR via MAPK [336, 339]; PI3K/AKT/TOR mediated translation initiation
[172, 154]; the transcriptional and translational regulation of PSA, cyclin D and
PAcP expression [341, 335]; and the regulation of Her2 activity by PAcP [347]
(Fig. 6.4).
The network described 212 species and 384 interactions (Table C.1). Tran-
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Figure 6.1: Schematic overview of the interaction network used in mod-
eling the androgen response in prostate epithelial cells. The
model architecture was formulated by aggregating molecular
modules into a single network (see insert for high level details).
scription and translation were modeled using elementary reactions based on
literature. Constitutive and regulated expression of PSA, cyclin D and the
two forms of PAcP were considered in the model. The total level of all
other model proteins was constant. We modeled the molecular interactions
using mass action kinetic processes within an ordinary differential equation
(ODE) framework. ODEs are a common method of modeling biological path-
ways and have been used to model a range of signal transduction processes
[263, 264, 171, 23, 265, 266, 267, 268, 269, 349]. Mass action kinetics have also
been used extensively, for example, to model receptor tyrosine kinase signaling
[349], blood coagulation [268], pain networks [269] or Toll like receptor signaling
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[350, 351]. They have also been a key component in the success of perturbation-
response approaches which have shown that simple linear rules often govern
the response behavior of biological networks [352]. The ODE model was deter-
ministic and captured only population averaged behavior. While we assumed
spatial homogeneity, we differentiated between cytosolic and membrane local-
ized processes. We used mass-action kinetics to describe the rate of each molec-
ular interaction. Thus, the 384 kinetic model parameters were mainly associ-
ation, dissociation or catalytic rate constants. With one exception, model pa-
rameters were estimated and validated using LNCaP training data taken from
literature sources (Table C.2). However, we were unable to estimate unique
model parameters. Instead, we estimated a family or ensemble of parameters
that was consistent with the training data. The ensemble allowed us to estimate
the model uncertainty associated with the many poorly characterized parame-
ters. We analyzed the model ensemble to better understand which architectural
features were important in androgen dependent versus independence cells.
6.4.1 Estimating the ensemble of prostate model parameters.
Signal transduction models often exhibit complex behavior [305, 306, 307, 308].
It is often not possible to identify model parameters, even with extensive train-
ing data [309]. Thus, despite identification standards [310] and the integration
ofmodel identificationwith experimental design [311], parameter estimation re-
mains challenging. In this study, an ensemble of plausible model parameters was
estimated from AI and AD LNCaP sub-clones. Ensemble approaches have suc-
cessfully addressed uncertainty in systems biology and other fields like weather
prediction [167, 312, 269, 166, 313]. Their central value is the ability to con-
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Figure 6.2: Identification and properties of the prostate model ensemble.
A: Steady state PSA level as a function of cPAcP and sPAcP ex-
pression. The circles represent the values used to model the C-
51 and C-81 LNCaP clones. All values are relative to C-33. B:
Coefficient of Variation (CV; standard deviation of a parame-
ter relative to its mean value) for the parameter ensemble used
in this study. C: Parameter identification strategy. Multiple
monte-carlo trajectories were used to randomly explore param-
eter space.
strain model predictions despite uncertainty. For example, Sethna and cowork-
ers showed in a model of growth factor signaling that predictions were possible
using ensembles despite incomplete parameter information (sometimes only or-
der of magnitude estimates) [306]. They further showed that model ensembles
were predictive using many different mathematical models [314]. The 420 un-
known model parameters (384 kinetic constants and 36 non-zero initial condi-
tions) were estimated using 14 time-series and steady-state training sets taken
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from literature sources (Table S2). The parameter identification procedure used
a maximum likelihood random-walk strategy with a correlation constraint to
identify a diverse family of likely parameter sets (Fig. 6.4.1C). We generated
3210 possible parameter sets and selected 107 of these for inclusion in the final
ensemble. The selection wasmade to minimize the correlation between possible
sets (materials and methods). The majority of parameters had a Coefficient of
Variation (CV) of greater than 100%. Thus, although the model qualitatively re-
capitulated the training data, many of the parameters were poorly constrained
(Fig. 6.4.1B). However, parameters involved with key features such as cyclin-D
and PSA expression were relatively well constrained (CV ≤ 50%). The low devi-
ation of these parameters could be attributed to the abundance of PSA/cyclin D
training data. Alternatively, it may suggest that these mechanisms had a large
impact on model behavior. A single network structure described both Andro-
gen Dependent (AD) and Androgen Independent (AI) training data with only
two experimentally justified parameter changes. The parameters controlling
the expression rate of cellular PAcP (cPAcP) and secreted PAcP (sPAcP) were
reduced by a factor of 0.01 and 0.5, respectively, for the C-81 and C-51 cell-lines
compared to C-33 (Fig. 6.4.1A). The PAcP expression scaling factors were cho-
sen to correspond with measured steady-state PAcP expression ratios for the
different cell-lines [353]. The kinetic parameters and non-zero initial conditions
for C-33 are given in Table C.1 and Table C.3, respectively.
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6.4.2 The ensemble of AI/AD LNCaP models recapitulated an-
drogen action and the activity of the outlaw pathway.
AR can be activated by both hormone dependent and independent pathways. In
this study, we considered both the traditional hormone dependent and MAPK
mediated AR activation. We selected training data sets to constrain each mode
of AR activation and the subsequent AR-driven gene expression program. The
data of Lee et al.,was used to constrain the relationship between PSA expression
andAR activation in AI andAD cells [335]. ActivatedARwasmodeled as both a
transcriptional activator of PSA expression [354] and a transcriptional represser
of PAcP expression [341]. The model recapitulated the qualitative features of
PSA expression at the protein level for C-81 and C-33 (Fig. 6.3B). Additionally,
the basal and increased level of PSA mRNA following Her2 overexpression in
C-33 was also well described (Fig. 6.4). The PSA mRNA data was taken from a
separate LNCaP study [339]. The C-33 simulations recapitulated the observed
lower PSA expression (∼ 4 fold) compared to C-81 in the absence of androgen
(Fig. 6.3B, initial point). Following DHT stimulation (10nM at t = 1 hr) PSA
expression increased for both clones. However, the increase was more signif-
icant for C-33 (Fig. 6.3B). The study of Meng et al. was used to constrain the
relationship between AR activation and PAcP expression [341]. The addition of
DHT to C-33 cells decreased PAcP expression and increased Her2 phosphory-
lation (Fig. 6.3A). The model recapitulated the positive feedback between Her2
induced MAPK activation and androgen action. Several studies have demon-
strated that MAPK can activate AR in the absence of hormone stimulation. Ac-
tivated AR transcriptionally down-regulates cPAcP expression which in turn
increases Her2 activation. Both Her2 dimerization along with the traditional
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Figure 6.3: Simulation results for the addition of 10nm DHT at 1 hour to
C-33 and C-81 LNCaP clones. A: Her2 phosphoralation (cir-
cles) and cPAcP expression (squares) for C-33 cells following
the addition of DHT. B: PSA expression following the addition
of DHT to C-81 (squares) and C-33 (circles) LNCaP clones.
0
0.5
1
1.5
2
2.5
3
m
RN
A 
PS
A 
(A
.U
.)
Her2 (nominal)
Model (C-33)
Measured (C-33)
Her2 (overexpression)
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Figure 6.5: Simulation results for key species under androgen free condi-
tions. A: Effect of HER2 and MEK overexpression on LNCaP
C-33 steady state PSA levels. The inhibition of MEK blocks
the effect HER2 overexpression. B: Effect of HER2 and MEK
inhibition on LNCaP C-33 steady state PSA levels. The inhibi-
tion of either HER2 or MEK blocks high AIPC PSA levels. C:
Effect of PAcP isoforms on LNCaP steady state cyclin D lev-
els. Experimental data adapted from Lingappa and coworkers
(Prosetta Corporation, unpublished data). D: Transient activa-
tion of ERK via ligand dependent EGF signaling (8nM EGF at
t = 60s) in HeLa cells. Inset: Simulated phosphorylated ETS
(ETSp) levels following the addition of 8nM EGF in the pres-
ence and absence of Her2.
EGFR-growth factor pathway can activate MAPK, leading to a positive feed-
back loop. However, typical growth factor induced MAPK activation is tran-
sient whereas de-regulated Her2 induced MAPK activation is persistent. The
MAPK module in the model described both activation pathways. Growth fac-
tor dependent MAPK activation was constrained by dynamic measurements of
phosphorylated ERK (ERKpp) levels following stimulation of EGFR with 8nM
EGF (Fig. 6.5D). The EGF induced ERKpp data was taken fromHeLa cells [171].
However, we expect transient EGF-induced MAPK activation in LNCaP cells
will be qualitatively similar to HeLa given the conserved nature of mitogenic
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signaling. We constrained Her2 induced MAPK activation using cyclin D pro-
tein expression data in C-33 and C-81 cells without androgen following PAcP
expression (Fig. 6.5C). Cyclin D expression was coupled to ERK through the
ETS and AP1 transcription factors, both of which activate cyclin D expression
[298]. Her2 induced MAPK activation led to a persistent ETSp signal compared
to ETS activation following EGFR-induced MAPK activation (Fig. 6.5D, inset).
Nominally, C-33 cells have lower cyclin D expression compared to C-81 (Fig.
6.5C, lane 1 and 4). The difference in cyclin D expression between C-33 and
C-81 cells was qualitatively consistent with increased C-81 proliferation [334].
While the expression of cPAcP in C-81 reduced cyclin D levels (Fig. 6.5C, lane
2), sPAcP expression resulted in no change (Fig. 6.5C, lane 3). Furthermore, the
model predicted a dose dependent increase in C-33 cyclin D levels 24 hours after
addition of DHT (Fig. 6.6A). Although the cyclin D increase is only notable in
response to high levels of DHT (10 or 100nM) the prediction is qualitatively con-
sistent with experimental data not included in the ensemble calculations [355].
To further constrain the relationship between MAPK, Her2 and AR activation,
we used the Her2 perturbation study of Lee et al. [335] in the ensemble calcu-
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lations. Because the perturbation magnitudes were not reported, we assumed
±50% for all changes. Where possible, this assumption was validated by analyz-
ing the correspondingWestern blots using the GelEval software package (v1.22,
Frog Dance Software). The ±50% perturbation magnitude was approximately
consistent with the published blots. A 50% increase in Her2 led to an approx-
imately 50% increase in PSA expression in C-33 without androgen (Fig. 6.5A,
lanes 1 and 3). While a 50% decrease in Her2 in C-81 led to a similar decrease in
PSA secretion (Fig. 6.5B, lanes 1 and 2). Further disruption of Her2 effectively
blocked PSA expression in C-81 without androgen (Fig. 6.5B, lane 3). A 50%
reduction of MEK, one of the three primary protein kinases in MAPK, resulted
in reduced PSA expression in C-81 (Fig. 6.5B, lane 4). While a 50% increase
of MEK in C-33 increased PSA expression by 5-fold (Fig. 6.5A, lane 2). The
combination of MEK inhibition and Her2 activation (50% increase in Her2 and
a 50% decrease in MEK) decreased PSA expression in C-33 (Fig. 6.5A, lane 4).
Furthermore, the model predicted an increase in C-33 PSA levels 72 hours after
a 2nM addition of the androgen testosterone. Simulations performed with 10%
of the AR initial condition predicted an approximate 50% decrease in testos-
terone stimulated PSA (Fig. 6.6B). The reduced PSA levels are consistent with
reported experimental data on AR antisense knock-downs in androgen depen-
dent LNCaP cells [356]. This data was not included in the ensemble calculations.
Taken together, the model replicated qualitative features of the relationship be-
tween MAPK, AR activation and androgen action. In addition, the qualitative
agreement between model and experiments for PSA and cyclin D expression
suggested that the transcription and translation subsystem models were oper-
ating correctly.
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6.4.3 Sensitivity analysis revealed key subsystems in AI and
AD cells.
Sensitivity analysis identified interactions important in C-33, C-51 andC-81 cells
(Fig. 6.7 and Table C.4). We calculated overall State Sensitivity Coefficients (OS-
SCs) for the three LNCaP clones over the parameter ensemble (materials and
methods). The OSSC values were ranked-ordered based on their absolute mag-
nitude. The dissociation of AR from Heat Shock Proteins (HSP), components of
the Akt signaling axis and MAPK activation were important (top 2% of sensi-
tive interactions) irrespective of androgen status. Sequestered AR was unable
to become activated by androgens or MAPK. Thus, increased AR-HSP dissocia-
tion promoted increased AR activation and AR-driven gene expression. Several
components of the MAPK cascade were also important including Ras binding
to GAP and Raf, and the dephosphorylation of ERK. The sensitivity of MAPK
was not unexpected. ERK was critical to outlaw activation of AR. Moreover,
ERK activation was modeled as being Ras dependent. We also found the Akt
signaling axis to have components in the top 2% of sensitive interactions ir-
respective of androgen status. For example, the formation of PIP3, an early
step in the PI3K/Akt signaling axis regulated by PTEN, was found to be highly
sensitive in all clones. Looking beyond the upper 2% of sensitive interactions,
additional common mechanisms were identified. These included AR interac-
tions with DHT, recruitment of adapter molecules by Her2, activation of ERK
by MEKpp and additional regulation of PIP3 formation by PTEN.
Translation interactions became more fragile while transcription became
more robust with increasing androgen independence. Her2 auto-activation and
Her2 cPAcP interactions were also increasingly important with increasing an-
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Figure 6.7: Sensitivity analysis of the model parameters. A: Compari-
son of the mean OSSC parameter ranks for the C-33 and C-81
LNCaP models. B: Comparison of the mean OSSC parame-
ter ranks for translation mechanisms (including the role of Akt
signaling in translation initiation) in C-33 versus C-81 LNCaP
clones. C: The final mechanism in PSA transcription becomes
increasingly more robust w.r.t cancer aggressiveness, as indi-
cated by a significant reduction in mean OSSC Rank. D: The
final mechanism in PSA translation (translation termination)
was increasingly fragile w.r.t cancer aggressiveness, as indi-
cated by a significant increase in mean OSSC rank.
drogen independence. The difference in the importance of interactions in AI
versus AD LNCaP clones was estimated by computing shifts in the sensitivity
rankings (Table C.5). In addition to considering C-33 and C-81, we analyzed
a third clone, C-51, which was moderately androgen dependent. There were
117 statistically significant shifts (52 more and 65 less sensitive) between the
C-81 and C-33 clones. However, only 14 shifts were larger than one standard
above the mean shift. Of the 14 large shifts, 50% involved PSA and PAcP trans-
lation while the remainder were associated with Her2 and cPAcP. Conversely,
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PSA transcription becamemore robust with increasing androgen independence.
Similarly, when comparing C-33 to C-51, PSA translation and Her2 activity be-
came more sensitive with increasing androgen independence. Inspection of the
importance of the final step in PSA transcription and translation among the in-
dividual models in the ensemble showed a shift away from transcription (Fig.
6.7C) toward translation (Fig. 6.7D) across the population of models. The in-
creasing importance of translation was not limited to PSA, although PSA was
the most significant example. Globally, 16 of the 52 interactions that were more
sensitive in C-81 involved translation while only 4 of 52 involved transcription.
No translationmechanisms becamemore robust in C-81 compared to C-33. Sim-
ilar to PSA, translation of other key proteins such as cPAcP became more sensi-
tive in C-81 versus C-33. Of the statistically significant shifts, 7/9 of the cPAcP
translation interactions were more sensitive in C-81. Additionally, both mech-
anisms for the phosphorylation of 4E-BP1 by TOR kinase, a key step in trans-
lation initiation that liberates eIF4E, were also more importance in C-81. Taken
together, the sensitivity analysis suggested that the fragility of the translational
subsystem directly correlated to androgen independence.
To quantify the effects of perturbing key species in C-81 clones we preformed
robustness analysis on four functional protein markers. The initial conditions
of seven key protein species were altered by a factor of 10, .1 or 0 for knock-in,
knock-down or knock-out perturbations, respectively. We then calculated the
effect of these perturbation on cyclin D and PSA expression levels along with
ERK and AR activation levels. Perturbation of Raf, MEK or ERK had similar
effects on the functional markers with ERK being the most notable (Fig 6.8 lanes
1, 2 and 3). Trivially, ERK perturbations directly effected ERK activation lev-
els. However, more importantly, ERK perturbations greatly effected cyclin D
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Figure 6.8: Robustness analysis of functional protein markers. The expres-
sion level of seven key proteins was altered by a factor of 10,
.1 or 0 (knock-in, knock-down or knock-out) and robustness
coefficients.
expression levels. ERK knock-ins approximately doubled cyclin D while ERK
knock-outs reduced cyclin D to less then one third of wild-type levels. The
functional markers were robust to perturbations in AKT and TOR with differ-
ing effects on ERK activity and slight decreases in expression levels upon AKT
or TOR knock-out (Fig 6.8 lanes 4 and 5). Furthermore, the translation initiation
factor eIF4E demonstrated a limiting reagent behavior in the expression of both
cyclin D and PSA while perturbations in 4E-BP1 had little effect (Fig 6.8 lanes
6 and 7). However, the 4E-BP1 results could be an artifact of artificially high
background levels of eIF4E as no direct eIF4E measurements were included in
the training data. Knock-in simulations of eIF4E demonstrated an 8.7 and 5.2
fold increase in cyclin D and PSA expression. Reduction of eIF4E resulted in
a 89% loss of expression and, full knock-out simulations predicted a complete
loss of cyclin D and PSA.
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6.4.4 The MAPK and Akt pathways synergistically activated
cyclin D expression.
Complex systems composed of interacting subsystems can display emergent
properties that are not explained by the individual subsystems alone [357]. In
cancer biology, it is common to speak of signal transduction pathways as if they
were isolated. In reality, these components are highly interconnected and can
interact in a variety of ways sometimes leading to unpredictable behavior. In
this study, we explored whether the MAPK and Akt signaling axes synergisti-
cally activated the expression of cyclin D. We compared the steady-state cyclin
D expression in Akt and ERK knock-outs with wild-type C-81 cells in the ab-
sence of androgens. At steady-state, the MAPK and Akt pathways synergisti-
cally (∆cycD > 0) activated cyclin D expression in C-81 cells without androgen
(Fig. 6.9A). Thus, steady-state cyclin D expression was greater in wild-type cells
(Akt+-ERK+) than the linear combination of cyclin D expression in Akt−-EKT+
and Akt+-ERK− cells. The above-additive (superlinear) cyclin D expression was
statistically significant within a 95% confidence interval. However, the rela-
tively large standard deviation suggested that cyclin D expression variedwidely
across the ensemble. To address this, we inspected every model in the ensemble
and found that each predicted an above-additive increase in cyclin D expres-
sion (data not shown). Superlinear cyclin D expression may be the result of
positive synergy between the MAPK and translation subsystems. To elucidate
the underlying mechanisms responsible for synergy we expanded the analy-
sis to include all modeled species (both proteins and protein complexes) and
rates. Many functional network subunits demonstrated no statistically signifi-
cant deviations from additive behavior (Fig. 6.9C, grey). However, 22 species
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Figure 6.9: Synergy analysis between the ERK and Akt signaling axes in
LNCaP C-81 cells. The double ERK and Akt knock-out was
used as the control. A: The difference in steady state cyclin D
expression (compared to the control) with the knock-in of Akt
(left), ERK (center) and both (right). B: Species and interactions
that demonstrated a positive (negative) synergy are shown as
green (red) in the connectivity diagram. Species or interactions
not effected are shown in grey. C: The full connectivity diagram
qualitatively clustered in functional groups. Positive (negative)
synergy are shown in green (red) in the connectivity diagram.
(79 interactions) were negatively coupled to Akt/ERK (∆ j < 0; Fig. 6.9B, red)
while 14 species (37 interactions) had a positive synergy (∆ j > 0; Fig. 6.9B,
green). Synergy between the MAPK and Akt signaling subsystems negatively
effected transcription factor activation. Phosphorylated ERK (ERKpp) activated
AR (pAR), and the transcription factors AP1 and ETS all showed a below addi-
tive response (Fig. 6.9B). Conversely, positive synergy was almost exclusively
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limited to translation interactions. The binding of eIF4E, 40S and 60S ribosomes
to form the mRNA initiation complex, elongation and termination steps all had
positive synergy with ERK/Akt knockdowns (Fig. 6.9B).
6.5 Discussion
A critical milestone in prostate cancer progression is the onset of androgen in-
dependence. In this study, we formulated and analyzed an ensemble of mathe-
matical models of the androgen response of AI and AD LNCaP prostate cancer
epithelial cells. The model ensemble was identified using 14 different steady-
state and dynamic data sets taken from literature. With the exception of one
study, all the training data was generated in LNCaP cell-lines. We estimated
which molecular subsystems were important in AI versus AD cells using sen-
sitivity analysis. For example, the assembly and regulation of Her2 adapter
complexes and the regulation of ERK were sensitive irrespective of androgen
status. The dissociation of AR from HSP was also in the top 2% of sensitive in-
teractions for both C-33 and C-81. On the surface, the importance of AR in C-81
was surprising as the proliferation of C-81 is androgen independent. However,
AR can be activated independently of androgen, thus, the presence of androgen
is not required for androgen action [336, 358]. The differentiating factor between
the AI and ADmodels described here was the expression rate of PAcP conform-
ers. We demonstrated the ability of decreased PAcP expression to describe the
PSA levels of increasingly androgen independent sub-lines. Moreover, inter-
actions involving Her2 auto-phopshporylation, cPAcP availability and cPAcP
phosphatase activity were significantly more fragile in C-81 versus C-33. These
results suggest that the regulation of the phosphorylation state of Her2 by cPAcP
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may be a critical interaction controlling androgen action in the absence of hor-
mone signals. Experimentally this has been demonstrated as forced expression
of PAcP is sufficient to suppress C-81 xenograft tumor growth [359].
Model analysis suggested that translation interactions were more fragile and
transcription more robust in AI versus AD cells. Globally, 16 of the 52 interac-
tions that were more sensitive in C-81 involved translation while only 4 of 52
involved transcription. Moreover, no translation mechanisms became more ro-
bust in AI versus AD cells. The importance of translation in more aggressive
cancers (increasing androgen independence) may be due, in-part, to synergies
between the Akt and MAPK pathways. Simulations of ERK and/or Akt knock-
outs showed an above-additive response almost exclusively limited to trans-
lation upon the simultaneous reinstitution of Akt and ERK. In-vivo studies of
AIPC have demonstrated positive synergies between the MAPK and Akt path-
ways. Gao et al. observed above-additive tumor growth rates in castrated and
mock nude male mice upon the forced expression of constitutively active Akt
and B-RafV600E [360]. These experiments suggest that cell proliferation may be
regulated by a complex integration of the MAPK and Akt signaling axes. Our
robustness analysis suggested that independent perturbations in TOR and AKT
may have little or no effect on AIPC. However, we observed the possibility of
an inverse relationship between TOR and ERK activation. This suggests that if
TOR or Akt were to be independently targeted, AKT might be a more suitable
therapeutic target. Additionally, we observed that perturbations in Raf, MEK
and ERK had a similar effect on cyclin D but not PSA expression, with ERK
being more pronounced. Current therapeutics such as trastuzumab or gefi-
tinib, which target either Her2 or EGFR respectively, have had little efficacy
against hormone-refractory prostate cancers [361, 362]. Our results suggest that
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a possible factor in their lack of effectiveness is that they fail to address syn-
ergy between growth factor signaling, MAPK activation and the Akt signaling
axes. Our analysis also demonstrated that translation mechanisms were gener-
ally more sensitive in increasingly androgen independent models. The transla-
tion results suggest that the direct targeting of the translation machinery may be
useful for the treatment of AIPC. Our robustness analysis identified eIF4E as a
limiting reagent in the expression of both cyclin D and PSA in C-81 clones. Soni
et al. demonstrated the effectiveness of directly targeting eIF4E in breast can-
cer. Down-regulation of eIF4E resulted in decreased cyclin D expression and
decreased growth rate without the deleterious effect of inhibitors such as ra-
pamycin which act further upstream [363]. Previous modeling studies from our
laboratory have also demonstrated the importance of translation beyond cyclin
D [161]. However, the current model has only a basic description of transla-
tion initiation. Moreover, translation parameters were only indirectly trained
from the PSA mRNA and protein data. Thus, while the initial robustness and
sensitivity results are encouraging more studies are needed.
Analysis of the ensemble of AI models suggested the Akt and MAPK path-
ways synergistically enhanced cyclin D expression by up-regulating translation.
Cyclin D is expressed early in the cell cycle and a point of convergence in the
proliferative action of multiple receptors [364]. Many studies have identified a
direct correlation between cyclin D regulation and prostate cancer, as well as
breast and non-small cell lung cancer [365, 366, 367]. Balk et al. demonstrated
that increased cyclin D expression in PTEN−/− LNCaP cells following DHT addi-
tion was largely because of increased translation [368]. PTEN loss and presum-
ably the activation of Akt has been implicated with increased translation and
the resistance to therapeutics which target Her2 and EGFR [369, 370]. However,
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the underlying mechanism responsible for the increased translation in the Balk
et al. study was not solely AKT dependent. Early translation activation was due
to PI3K/Akt signaling but TOR activation at later time points was Akt indepen-
dent. One key difference between the modeling and the Balk et al. study was the
binding of activated AR with the regulatory subunit of PI3K. This interaction,
which was not included in the model, was at least partially responsible for TOR
activation and the eventual liberation of eIF4E. In addition to direct AR binding,
PI3K (and subsequently TOR) can be activated through receptor adaptor com-
plexes such as those associated with Her2. In the model, PI3K was activated
by androgen (in the absence of growth factor) because of the down-regulation
of cPAcP expression by activated AR. Upregulated PI3K then drove Akt depen-
dent activation of TOR which led to enhanced liberation of eIF4E from 4E-BP1.
Thus, while the initiating events driving TOR activation were different, the sub-
sequent up-regulation of cyclin D translation was similar. This suggests that the
model prediction of a complex synergy between interacting signaling axes may
be valid. It also suggests a falsifiable hypothesis that cPAcP could be critical to
enhanced translation following androgen stimulation.
The role of mechanistic mathematical modeling in drug design remains un-
clear. A common criticism of such techniques has been the poorly characterized
effect of model uncertainty. Model uncertainty has two forms. Structural un-
certainty is defined as uncertainty in the biology, while parametric uncertainty
is defined as incomplete knowledge of parameter values. In this study, para-
metric uncertainty was minimized by considering a family of consistent models
instead of a single best-fit but uncertain model. While model ensembles of-
ten poorly constrain individual parameter values, they may robustly constrain
model predictions [314]. Structural uncertainty was addressed by considering
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only molecular interactions supported by experimental evidence. However, the
current model contained some abstracted pathways and should be expanded
to include additional biology. For example, the analysis highlighted the impor-
tance of translation. However, the current model contains a limited description
of initiation factor activation and the assembly of the 80S initiation complex. A
more detailed translation interaction network could further refine which trans-
lation components were important in AI versus AD cells. Another example is
the mechanism by which AR transcriptionally regulates the expression of target
genes. In the current model we ignored the role of transcriptional co-regulators
and assumed activated AR functioned alone. While this is a reasonable first
approximation, well known co-repressors and activators [371] such as ARA70
[372] should be included. The regulation and activity of these co-regulators may
be different in AI versus AD cells and could enhance the list of differentially im-
portant targets. Additionally, a nuclear compartment and enhanced cell cycle
and cell death subnetworks should be added to themodel. These additional net-
works could be critical to understanding cell proliferation and survival effects
in AI versus AD cells. For example, androgen and AR are known to regulate
several components of the G1-phase of the cell cycle in prostate cells, not just
cyclin D [373]. Moreover, the model describes the activation of Akt in the con-
text of translation initiation, but not its well know survival functions [374, 375].
Lastly, given the importance of EGFR and Her2 induced MAPK activation in
the current study and the therapeutic emphasis on receptor inhibition we plan
to include a more complete receptor signaling network. Other receptors, IGFR
and IL-6R have also been implicated in prostate cancer [376, 377, 378]. Under-
standing the signaling associated with these receptors and their downstream
targets should be considered and will provide a better representation of how
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intra- extra-cellular communication drives cell fate decisions. Furthermore, the
application of advanced sampling techniques may allow for a more exhaustive
investigation of parameter space. For example, multi-objective optimization en-
semble techniques could be used to balance conflicts in the training data [269].
Additionally, understanding the topological details of the cost function in an
extended parameter space could provide statistical information on kinetic rates
and initial conditions. Other techniques, for example the calculation of the mu-
tual information matrix, could also provide insight into correlations between
model interactions. Also, computation of second order sensitivity coefficients
would allow the identification of possible synergies in the model. Thus, we ex-
pect that deeper insight could be generated by extending the network structure
and through the application of advanced model analysis tools.
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CHAPTER 7
CONCLUDING REMARKS AND FUTURE DIRECTIONS
7.1 Conclusions
This objective of this thesis was to understand the molecular mechanisms con-
trolling critical cellular functions such as growth, reproduction and cell differen-
tiation computationally and gain valuable insight which could be used directly
in treatment strategies for various cancers. Towards this aim we first studied
three different published models of cell cycle to show the validity of our model-
ing and analysis methods. Our computational analysis of these well-established
systems suggested that cell-cycle models follow the Highly Optimized Toler-
ance (HOT) paradigm. They exhibit the “robust yet fragile” property, a com-
mon phenomenon exhibited by all evolved networks. Our work on these mod-
els also revealed a list of fragile proteins, which correlated well with the targets
currently pursued in clinical trials. Thus, we showed that computationally de-
rived novel targets are of potential therapeutic value. Our analysis of one of the
cell cycle models revealed protein translation as a major fragile sub-sytem. We
constructed a detailed mechanistic model of protein translation initiation and
validated it using a novel ensemble approach. The ensemble approach allowed
us to overcome several different challenges and offered many advantages over
the traditional approach used in literature. For e.g., kinetic rates of biological
interactions are often not exactly known and can vary order-of-magnitudes in
their values. By using an ensemble of parameters we can better capture this di-
versity in rates and explore a variety of scenarios. Because of our approach we
were able to faithfully replicate both steady state in vivo and dynamic in vitro
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data within a common framework. It also enabled us to overcome the handicap
of parametric uncertainty, a hallmark of suchmodels. Innovative analysis meth-
ods such as coupling coefficients and in silico knockout and over-expression ex-
periments allowed us to analyze the entire model on a system wide scale. We
discovered the critical role of proteins such as Akt and eIF4E, emerging due to
an interplay of connected sub-systems. A study of signaling pathways of im-
portance in Prostate cancer was done to understand the change in the nature of
the biological system as it underwent a transition towards increasing androgen
independence. In the prostate study, we introduced a computational method to
quantify the interdependence between any two states using coupling or robust-
ness analysis. Our results revealed a synergy between the MAPK and the Akt
pathway and the increasing importance of protein translation as cells moved
towards androgen independence. Molecular mechanisms playing an impor-
tant role in cell differentiation were studied in detail both computationally and
experimentally. An experimental study elucidating the effects of Arsenic Tri-
oxide on a myeloblastic cell line (HL-60) revealed that cellular differentiation
is directly affected by sustained activation of MAPK. Our studies showed that
Arsenic Trioxide cooperated with All Trans Retinoic Acid (ATRA) to enhance
cellular differentiation. The increase in differentiation was a result of concomi-
tant increase in the activation of components of MAPK signaling cascade. Our
studies revealed a synergistic response in case of combined Arsenic Trioxide
and ATRA treatment and suggested a direct role of sustained MAPK activation
in cell differentiation logic. With computational modeling and analysis of dif-
ferentiation program in HL-60 cells, we presented a systematic framework to
study programmed differentiation. That the model was able to recapitulate ex-
perimental results qualitatively, despite structural and parametric uncertainty
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suggests that our approach can be extended to study other cellular programs
with confidence.
7.2 Future Directions
This thesis established a detailed framework for the study of cellular programs
of critical importance in cancers. The tools presented here are easily extend-
able to a variety of biological systems and the computational tools developed
are model agnostic. We would like to see the present work advanced both on
a biological as well as computational level. With the advent of highly power-
ful computers, modeling ultra-scale networks is perhaps no longer intractable.
Therefore, we would like to see much more biological details being added to
the our networks. Specifically, the translation initiation network now describes
the response to a generic growth factor input, we would like it to be tailored
to model specific kinds of growth factors, e.g., Platelet Derived Growth Factors
(PDGF) and Insulin. Similarly, adding components such as phosphorylation
events of eIF4E and other binding partners of mTOR would give the model
a much more solid biological basis. Addition of a full translation network to
the present prostate cancer study and the HL-60 model to understand differ-
entiation would contribute towards making them more faithful representations
of underlying real events. As the response of cell surface markers like CD38
and CD11b is measured to study differentiation experimentally, addition of
these markers and their interactions is needed to make the model more realistic.
Apart from addition of biological complexity, novel mathematical and compu-
tational techniques would be required to handle and analyze these complex net-
works. Towards this end, application of fast solvers routines such as SUNDIALS
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(https://computation.llnl.gov/casc/sundials/main.html) would help in reduc-
ing the computation time associated with solving and analyzing the models.
This becomes a critical issue as the size of networks grows geometrically. An-
other area of possible improvement is the method to select parameter sets in
the ensemble method. Incorporation of optimization techniques such as multi-
objective thermal annealing sampling method would allow us to select more
diverse parameter sets. This approach can thus allow us to explore more di-
versity in kinetic rate constants. Our experimental study was focussed on the
co-operation between Arsenic Trioxide and Retinoic Acid to enhance cell differ-
entiation. Our study also revealed that addition of Arsenic Trioxide leads to a
reduction in the growth rate of HL-60 cells. Investigating the mechanistic basis
of this decreased growth rate would help in clearly establishing the reasons be-
hind stunted growth in HL-60 cells and would elucidate the effects of Arsenic
Trioxide on cell differentiation programs better. As treatment with Arsenic Tri-
oxide in case of relapsed cancers has shown positive results clinically, a labora-
tory study on the effects of Arsenic Trioxide on RA resistant cell lines is needed
to fully understand the mechanisms behind its efficacy. The ultimate goal of
this study is to computationally provide novel targets of therapeutic value in
cellular systems. Towards this aim, it is important that the targets generated in
silico are regularly tested in the laboratory to ultimately enhance clinical efficacy
and increase therapeutic options.
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APPENDIX A
CHAPTER 1 OF APPEDIX
Table A.1: Comparison of OSSCs calculated for G1/S model of Qu et al.,.
Reaction Cluster OSSC-BDF OSSC-FD OSSC-ODE15s
µ ± σ µ ± σ µ ± σ
Dephosphorylation of aCDC25 I 0.6252 ± 0.2980 0.6314 ± 0.2667 0.6942 ± 0.2518
Degradation of aCycE-Cdk2 I 0.5854 ± 0.3452 0.6373 ± 0.3403 0.6756 ± 0.3423
Concentration of E2F I 0.5710 ± 0.3247 0.6744 ± 0.3062 0.6469 ± 0.2958
Synthesis of CycE I 0.4583 ± 0.3364 0.5131 ± 0.3476 0.6063 ± 0.3502
Generation of aCKIs II 0.4513 ± 0.2577 0.5297 ± 0.2540 0.5494 ± 0.2320
Concentration of pRb II 0.4429 ± 0.2982 0.5224 ± 0.2827 0.5238 ± 0.2725
Phosphorylation of iCDC25 II 0.4442 ± 0.3245 0.4349 ± 0.2905 0.4803 ± 0.2856
Synthesis of iCDC25 II 0.3952 ± 0.1934 0.4535 ± 0.2015 0.4801 ± 0.1690
Synthesis of CycD II 0.3367 ± 0.2230 0.3984 ± 0.2340 0.4376 ± 0.2411
Formation of iCycE-Cdk2 II 0.3590 ± 0.2275 0.4053 ± 0.2656 0.4271 ± 0.2417
Dephosphorylation of iCKIs II 0.3841 ± 0.2557 0.4101 ± 0.2428 0.4271 ± 0.2361
Degradation of iCDC25 II 0.3198 ± 0.2129 0.3711 ± 0.2436 0.3789 ± 0.2239
Formation of CycE-Cdk2-CKI II 0.3410 ± 0.1997 0.3655 ± 0.2106 0.3706 ± 0.1731
Dissociation of CycE-Cdk2 complex II 0.3023 ± 0.2626 0.3343 ± 0.2946 0.3428 ± 0.3002
Degradation of CycE II 0.2671 ± 0.2791 0.3163 ± 0.3165 0.3250 ± 0.3262
Phosphorylation of aCKIs II 0.2909 ± 0.2459 0.2705 ± 0.2017 0.3182 ± 0.2099
Degradation of CKIs II 0.2678 ± 0.2556 0.2985 ± 0.2803 0.2921 ± 0.2618
Formation of CycD-Cdk4/6 III 0.1987 ± 0.1312 0.2325 ± 0.1410 0.2639 ± 0.1485
Dissociation of CycE-Cdk2-CKI III 0.2623 ± 0.2512 0.2647 ± 0.2722 0.2585 ± 0.2563
Degradation of CycD III 0.1867 ± 0.1654 0.2194 ± 0.1786 0.2575 ± 0.1910
Phosphorylation of CDC25 by aCycE-Cdk2 III 0.2096 ± 0.2617 0.2472 ± 0.3047 0.2322 ± 0.2888
iCycE-Cdk2→ aCycE-Cdk2 III 0.2057 ± 0.2446 0.2358 ± 0.2828 0.2318 ± 0.2893
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Table A.1 (Continued)
Reaction Cluster OSSC-BDF OSSC-FD OSSC-ODE15s
µ ± σ µ ± σ µ ± σ
Formation of CycD-Cdk4/6-CKI III 0.1801 ± 0.1130 0.2054 ± 0.1164 0.2268 ± 0.1232
Rate constant for pRb dephosphorylation III 0.3945 ± 0.3126 0.2016 ± 0.1152 0.2260 ± 0.1164
Degradation of iCKI III 0.1678 ± 0.1646 0.1644 ± 0.1642 0.2077 ± 0.1815
E2F dependent CycE expression III 0.2219 ± 0.2849 0.2432 ± 0.3064 0.2064 ± 0.3020
Dissociation of CycD-Cdk4/6-CKI III 0.1867 ± 0.1654 0.1993 ± 0.1443 0.2046 ± 0.1376
aCycE-Cdk2 regulated pRb phosphorylation III 0.1551 ± 0.1055 0.1812 ± 0.1122 0.2008 ± 0.1127
Rate constant for CKI phosphorylation III 0.1638 ± 0.2232 0.1998 ± 0.2602 0.1911 ± 0.2547
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Table A.2: Comparison of OSSCs for the G2-DNA damage model of Aguda.
Reaction Cluster OSSC-BDF OSSC-FD OSSC-ODE15s
µ ± σ µ ± σ µ ± σ
pMPF→MPF, catalyzed by aCdc25 I 0.8759 ± 0.1475 0.8910 ± 0.1271 0.9924 ± 0.0739
aCdc25→ iCdc25 II 0.7676 ± 0.1442 0.7703 ± 0.1181 0.8845 ± 0.0920
Generation of preMPF II 0.9413 ± 0.1214 0.9720 ± 0.0838 0.8684 ± 0.1130
iCdc25cyto. →iCdc25nuc. II 0.9270 ± 0.1164 0.9417 ± 0.0938 0.8356 ± 0.1014
iCdc25→ aCdc25, catalyzed by MPF II 0.5728 ± 0.2291 0.5010 ± 0.1422 0.2835 ± 0.1517
Generation of p21 III 0.4860 ± 0.1784 0.5031 ± 0.1949 0.2835 ± 0.1517
Degradation of p21 III 0.4833 ± 0.1760 0.4854 ± 0.1838 0.2812 ± 0.1481
p21 + MPF→ p21-MPF III 0.3382 ± 0.1406 0.3413 ± 0.1504 0.2017 ± 0.1248
p21-MPF→ p21 + MPF III 0.3352 ± 0.1373 0.3254 ± 0.1438 0.1979 ± 0.1172
Generation of 14-3-3σ protein III 0.3434 ± 0.1250 0.3802 ± 0.1459 0.1913 ± 0.1060
Degradation of 14-3-3σ protein III 0.3421 ± 0.1247 0.3625 ± 0.1390 0.1909 ± 0.1059
Wee1→Wee1P, catalyzed by MPF III 0.3214 ± 0.1338 0.3274 ± 0.1489 0.1739 ± 0.0878
Wee1P→Wee1 III 0.3078 ± 0.1306 0.2993 ± 0.1381 0.1666 ± 0.0855
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Table A.3: Comparison of OSSCs for Tyson and Novak model. Three different
numerical methods were used to solve the sensitivity equations; OSSC-BDF: 3rd
order fixed step-size backward differencemethod (implicit); OSSC-FD: forward-
finite difference (explicit); and OSSC-ODE15s: 5th order variable step-size back-
ward difference routine (implicit) from theMatlab (TheMathworks, NatickMA)
ODE suite.
Reaction Cluster OSSC-BDF OSSC-FD OSSC-ODE15s
µ ± σ µ ± σ µ ± σ
Translational efficiency () I 0.7904 ± 0.3264 0.8647 ± 0.2372 0.6657 ± 0.3816
Activation of ‘IE’(k31) I 0.6026 ± 0.3071 0.6026 ± 0.3071 0.5361 ± 0.3843
Generation of CycB(k1) I 0.5650 ± 0.3015 0.4993 ± 0.2299 0.5002 ± 0.3471
Cdh1 degradation(k4) I 0.4043 ± 0.2443 0.3805 ± 0.2361 0.4997 ± 0.3765
Degradation of ‘IEP’(k32) II 0.4958 ± 0.2863 0.3576 ± 0.2219 0.4759 ± 0.3417
Generation of Cdh1 (k′3) II 0.4434 ± 0.2934 0.3021 ± 0.1895 0.4482 ± 0.3853
CycA mediated degradation of Cdh1
(γA)
II 0.3567 ± 0.2381 0.3734 ± 0.2263 0.3985 ± 0.3823
Degradation of ‘PPX’(k34) II 0.2266 ± 0.1621 0.2788 ± 0.1995 0.2835 ± 0.2604
Generation of dephosphatase PPX (k33) III 0.2224 ± 0.1652 0.2152 ± 0.1616 0.2572 ± 0.2240
Activation of Cdc20 (k13) III 0.2441 ± 0.3096 0.2557 ± 0.2616 0.2202 ± 0.2782
CycE dependent CycE:Kip1 dissocia-
tion (k8)
III 0.0463 ± 0.0798 0.0041 ± 0.0058 0.1989 ± 0.2545
CycE:Kip1 dissociation giving Kip1
(k′8)
III 0.0463 ± 0.0798 0.0105 ± 0.0635 0.1988 ± 0.2545
CycE dependent Kip1 accumulation
(ψE)
III 0.0438 ± 0.0744 0.0078 ± 0.0371 0.1861 ± 0.2386
Cdh1 dependent degradation of Cyc B
(k′2)
III 0.1143 ± 0.1189 0.0865 ± 0.1405 0.1759 ± 0.1690
Generation of Cyc B (k′1) III 0.1486 ± 0.0760 0.1333 ± 0.0672 0.1751 ± 0.1649
Degradation of Cdc20 (k14) III 0.2402 ± 0.2678 0.1898 ± 0.2238 0.1692 ± 0.2057
Total E2F (E2FT ) III 0.1460 ± 0.1282 0.4249 ± 0.2385 0.1524 ± 0.1424
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Table A.3 (Continued)
Reaction Cluster OSSC-BDF OSSC-FD OSSC-ODE15s
µ ± σ µ ± σ µ ± σ
Delay of DRGs (k18) III 0.0463 ± 0.1020 0.0003 ± 0.0006 0.1461 ± 0.1720
Expression CycA, catalyzed by aE2F
(k29)
III 0.1697 ± 0.1366 0.2639 ± 0.1444 0.1334 ± 0.1525
aE2F (k7)mediate CycE expression III 0.0367 ± 0.0625 0.0035 ± 0.0038 0.1325 ± 0.1489
Formation of ‘GM’ (k27) III 0.0911 ± 0.1014 0.1276 ± 0.0863 0.1307 ± 0.1474
Degradation of Cdc20 (J4) III 0.0649 ± 0.0743 0.0743 ± 0.1348 0.1281 ± 0.1151
CycB dependent degradation of Cdh1
(γB)
III 0.0902 ± 0.1296 0.0478 ± 0.0563 0.1281 ± 0.1331
Synthesis of p27Kip1 (k5) III 0.0272 ± 0.0447 0.0032 ± 0.0041 0.1274 ± 0.1232
Synthesis of DRG products (k17) III 0.0442 ± 0.0992 0.0003 ± 0.0005 0.1205 ± 0.1754
Maximum specific growth rate (µ) III 0.1231 ± 0.1431 0.1724 ± 0.1096 0.1176 ± 0.1490
CycE dependent decrease in Kip1 (k6) III 0.0264 ± 0.0432 0.0030 ± 0.0038 0.1161 ± 0.1161
Decrease in E2F (k23) III 0.0713 ± 0.0734 0.2138 ± 0.2094 0.1130 ± 0.1080
Degradation of Cdc20 (k12) III 0.0686 ± 0.0969 0.0308 ± 0.0419 0.1091 ± 0.1041
Degradation of free E2F (aE2F (k22)) III 0.0683 ± 0.0654 0.2401 ± 0.2031 0.1065 ± 0.1038
Total PP1T (PP1T ) III 0.0220 ± 0.0394 0.0001 ± 0.0002 0.1011 ± 0.1034
Synthesis of CycB (J1) III 0.0577 ± 0.0356 0.0594 ± 0.0378 0.0999 ± 0.1341
Degradation of ‘GM’ (k28) III 0.0841 ± 0.0957 0.1025 ± 0.0688 0.0961 ± 0.1092
CycE/A activation of PP1 (K21) III 0.0206 ± 0.0370 0.0001 ± 0.0002 0.0945 ± 0.0972
Cdh1 dependent CycB degradation
(k2)
III 0.0706 ± 0.0676 0.0547 ± 0.0447 0.0911 ± 0.1137
CycD dependent E2F:Rb dissociation
(k20)
III 0.0224 ± 0.0402 0.0022 ± 0.0208 0.0878 ± 0.0941
CycE dependent activation of PP1 (φE) III 0.0183 ± 0.0324 0.0011 ± 0.0104 0.0865 ± 0.0911
Degradation of ‘IEP’ (J32) III 0.0467 ± 0.0551 0.0313 ± 0.0428 0.0853 ± 0.0774
Degradation of CycD and CycD:Kip1
(k10)
III 0.0174 ± 0.0307 0.0002 ± 0.0004 0.0852 ± 0.0889
GF dependent synthesis of CycD (k9) III 0.0171 ± 0.0304 0.0012 ± 0.0104 0.0805 ± 0.0874
Degradation of ERG (k16) III 0.0129 ± 0.0227 7.194×10−7 ± 1.728×10−6 0.0802 ± 0.0912
Total pRb concentration (RbT ) III 0.0179 ± 0.0321 0.0068 ± 0.0530 0.0780 ± 0.0817
PP1 dependent pRb activation (k19) III 0.0179 ± 0.0321 0.0001 ± 0.0002 0.0772 ± 0.0807
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Table A.3 (Continued)
Reaction Cluster OSSC-BDF OSSC-FD OSSC-ODE15s
µ ± σ µ ± σ µ ± σ
CycB dependent Cdc20 formation (k11) III 0.0138 ± 0.0230 0.0023 ± 0.0171 0.0770 ± 0.0826
Formation of Cdh1 (J3) III 0.0153 ± 0.0224 0.0118 ± 0.0136 0.0710 ± 0.1542
Formation of CycE-Cdk2-Kip1 (k25) III 0.0142 ± 0.0246 0.0004 ± 0.0006 0.0695 ± 0.0687
Cdc20 dependent CycB degradation
(k′′2 )
III 0.0697 ± 0.1035 0.0489 ± 0.0944 0.0685 ± 0.1210
Formation of ERGs (k15) III 0.0124 ± 0.0222 8.593×10−7 ± 2.233×10−6 0.0662 ± 0.0759
DRG dependent formation of ERG(J15) III 0.0208 ± 0.0399 4.998×10−7 ± 8.465×10−7 0.0649 ± 0.0997
CycB dissociation of CKI complex(ηB) III 0.0170 ± 0.0328 0.0003 ± 0.0004 0.0598 ± 0.0787
CycD-Cdk4/6-Kip1 association(k24) III 0.0110 ± 0.0199 0.0002 ± 0.0004 0.0469 ± 0.0563
CycE dissociation of CKI complex(ηE) III 0.0099 ± 0.0134 0.0021 ± 0.0022 0.0461 ± 0.0510
Cdh20 depdendent Cdh1 formation
(k3)
III 0.0732 ± 0.1007 0.0607 ± 0.1165 0.0439 ± 0.0851
CycE dependent pRb phosphorylation
(λE)
III 0.0098 ± 0.0173 7.812×10−5 ± 1.044×10−4 0.0413 ± 0.0467
Cyclin dependent pRb phosphoryla-
tion (k26)
III 0.0112 ± 0.0199 0.0001 ± 0.0002 0.0383 ± 0.0470
CycB dependent pRb phosphorylation
(λB)
III 0.0123 ± 0.0238 5.447×10−5 ± 1.567×10−4 0.0333 ± 0.0515
Cdc20 dependent CycA degradation
(k30)
III 0.0182 ± 0.0289 0.0138 ± 0.0184 0.0329 ± 0.0458
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Table B.1: Reactions and parameter values for the cap-dependent and cap-
independent Initiation model developed in this study. For each parameter, the
ensemble mean and one standard deviation are reported.
Reaction k f ± σ kb ± σ kc ± σ Source
(nM−1min−1) (min−1) (min−1)
Formation of the activated receptor complex
∅ GF 2.6×10−5 ± 0.0 3.6×10−5 ± 0.0 –
∅ R 1.6×10−5 ± 0.0 9.7×10−5 ± 0.0 –
GF+R GF-R 1.8 ± 3.6×10−1 2.4×10−1 ± 4.4×10−2 – [170, 171, 172]
2*GF-R GF-R-2 3.9 ± 7.1 6.6 ± 1.2 – [170, 171, 172]
GF-R-2 GF-R-2-P 6.3×101 ± 1.1×101 6.5×10−1 ± 1.1×10−1 – [170, 171, 172]
∅ G 5.6×10−5 ± 0.0 5.3×10−5 ± 0.0 –
∅ So 1.2×10−4 ± 0.0 1.2×10−4 ± 0.0 –
G+So G-So 9.4×10−2 ± 1.6×10−2 6.1×10−3 ± 1.1×10−3 – [170, 171, 172]
GF-R-2-P+G GF-R-2-P-G 1.8×10−2 ± 3.8×10−3 3.29 ± 4.3×10−1 – [170, 171, 172]
GF-R-2-P-G+So GF-R-2-P-G-So 3.0×10−1 ± 4.7×10−2 3.86 ± 7.1×10−1 – [170, 171, 172]
GF-R-2-P+G-So GF-R-2-P-G-So 2.9×10−1 ± 4.7×10−2 6.3×10−1 ± 1.5×10−1 – [170, 171, 172]
∅ Ras 3.5×10−5 ± 0.0 1.2×10−4 ± 0.0 –
Ras+GDP R-GDP 6.5×10−1 ± 1.1×10−1 3.76 ± 7.1×10−1 – [170, 171, 172]
GF-R-2-P-G-So+R-GDP
GF-R-2-P-G-So-R-GDP 2.3×10−1 ± 4.1×10−2 3.2 ± 5.6×10−1 – [170, 171, 172]
GF-R-2-P-G-So-R-GDP→
GF-R-2-P-G-So-R-GTP (Act-R) – – 61 ± 8.6 [170, 171, 172]
∅ Sh 2.4×10−5 ± 0.0 3.9×10−5 ± 0.0 –
∅ GB 8.9×10−5 ± 0.0 1.6×10−6 ± 0.0 –
GF-R-2-P+Sh GF-R-2-P-Sh 5.6 ± 1.0 3.8×101 ± 5.9 – [170, 171, 172]
GF-R-2-P-Sh-G GF-R-2-P-Sh+G 1.9×10−1 ± 3.0×10−2 3.10 ± 4.7×10−1 – [170, 171, 172]
GF-R-2-P-Sh-G+So GF-R-2-P-Sh-G-So 6.1×10−1 ± 1.2×10−1 3.74 ± 6.2×10−1 – [170, 171, 172]
GF-R-2-P-Sh+G-So GF-R-2-P-Sh-G-So 6.0×10−1 ± 9.6×10−2 3.79 ± 7.6×10−1 – [170, 171, 172]
GF-R-2-P-Sh-G-So+GB
GF-R-2-P-Sh-G-So-GB 6.2×10−1 ± 9.4×10−2 3.8 ± 7.9×10−1 – [170, 171, 172]
GF-R-2-P-Sh-G-So-GB+R-GDP
GF-R-2-P-Sh-G-So-GB-R-GDP 2.1×10−1 ± 3.7×10−2 3.1×101 ± 7.1 – [170, 171, 172]
GF-R-2-P-Sh-G-So-GB-R-GDP→
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Table B.1 (Continued)
Reaction k f ± σ kb ± σ kc ± σ Source
(nM−1min−1) (min−1) (min−1)
GF-R-2-P-Sh-G-So-GB-R-GDP (Act-R) – – 61 ± 9.7 [170, 171, 172]
Activation of Akt and TOR
∅ PI3K 2.8×10−5 ± 0.0 7.4×10−5 ± 0.0 –
PI3K+GF-R-2-P-Sh-G-So-GB-R-GTP PI3K-Act-R 5.9 ± 1.1 3.4×10−1 ± 6.9×10−2 – [170, 171, 172]
PI3K+GF-R-2-P-G-So-R-GTP PI3K-Act-R 6.0 ± 1.1 2.1 ± 4.5×10−1 – [170, 171, 172]
PI3K-Act-R Act-PI3K+R 6.5 ± 1.1 1.2×10−4 ± 6.2×10−4 – [170, 171, 172]
∅ PTEN 4.8×10−5 ± 0.0 1.7×10−5 ± 0.0 –
∅ PIP2 7.7×10−5 ± 0.0 1.2×10−4 ± 6.0.0 –
∅ PIP3 1.1×10−5 ± 0.0 1.1×10−4 ± 0.0 –
PIP2+Act-PI3K PIP2-Act-PI3K 9.2 ± 1.7 1.0×10−1 ± 1.9×10−2 – [173, 172]
PIP2-Act-PI3K→ PIP3+Act-PI3K 7.4 ± 1.9 – – [173, 172]
PIP3+PTEN PIP3-PTEN 8.6 ± 1.6 5.2×10−1 ± 1.1×10−1 – [173, 172]
PIP3-PTEN→ PIP2+PTEN 9.1 ± 1.4 – –
∅ Akt 1.1×10−4 ± 0.0 9.8×10−5 ± 0.0 – [173, 172]
∅ Pdk1 1.0×10−4 ± 0.0 7.6×10−5 ± 0.0 – [173, 172]
PIP3+Akt PIP3-Akt 9.7 ± 1.8 2.7×10−1 ± 5.2×10−2 – [173, 172]
PIP3-Akt→ PIP3+Aktm 8.1 ± 1.4 – – [173, 172]
PIP3+Pdk1 PIP3-Pdk1 8.2 ± 1.6 1.1×10−1 ± 1.8×10−2 – [173, 172]
PIP3-Pdk1→ PIP3+Pdk1m 8.0 ± 1.3 – – [173, 172]
Pdk1m+Aktm Pdk1m-Aktm 9.0 ± 1.9 5.3×10−1 ± 1.0×10−1 – [173, 172]
Pdk1m-Aktm → Pdk1+aAkt – – 8.3 ± 1.5 [173, 172]
∅ TOR 3.5×10−5 ± 0.0 9.5×10−5 ± 0.0 –
aAkt+TOR aAkt-TOR 4.2 ± 8.1×10−1 6.2 ± 1.1 – [174]
aAkt-TOR Akt+aTOR 8.67 ± 1.56 2.26×10−5 ± 1.1×10−4 – [174]
∅ TSC1 9.3×10−5 ± 0.0 5.2×10−5 ± 0.0 –
∅ TSC2 6.3×10−5 ± 0.0 6.2×10−5 ± 0.0 – [132]
TSC1+TSC2 TSC1-TSC2 8.65 ± 1.49 3.3×10−1 ± 6.5×10−2 – [132]
∅ R-GDP 9.6×10−5 ± 0.0 1.0×10−4 ± 0.0 –
∅ R-GTP 1.0×10−4 ± 0.0 4.3×10−5 ± 0.0 –
R-GTP+TSC1-TSC2 R-GTP-TSC1-TSC2 1.6×10−1 ± 2.9×10−2 1.86 ± 3.0×10−1 – [132]
R-GTP-TSC1-TSC2 R-GDP+TSC1-TSC2 4.5×10−1 ± 6.8×10−2 6.9×10−5 ± 3.5×10−4 – [132]
R-GTP+TOR R-GTP-TOR 1.3×10−2 ± 2.9×10−3 1.0×101 ± 1.71 – [132]
R-GTP-TOR→ R-GTP+aTOR – – 2.25 ± 4.6×10−1 [132]
TSC1-TSC2+aAkt TSC1-TSC2-aAkt 2.1×10−1 ± 3.8×10−2 6.72 ± 1.27 – [132]
TSC1-TSC2-aAkt→ TSC1-TSC2-P+aAkt 9.9×10−2 ± 1.7×10−2 – – [132]
4E-BP1 and eIF4E reactions
∅ 4E-BP1 7.8×10−6 ± 0.0 7.8×10−5 ± 0.0 –
4E-BP1-4E 4E-BP1+4E 6.57 ± 1.11 9.6×10−1 ± 1.7×10−1 – [175, 176, 177]
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Table B.1 (Continued)
Reaction k f ± σ kb ± σ kc ± σ Source
(nM−1min−1) (min−1) (min−1)
4E-BP1+aTOR 4E-BP1-aTOR 1.1×10−1 ± 1.6×10−2 1.27 ± 2.3×10−1 – [175, 176, 177]
4E-BP1→ 4E-BP1-P+aTOR – – 5.2×101 ± 1.0×101 [175, 176, 177]
4E-BP1-4E+aTOR 4E-BP1-4E-aTOR 4.3×10−1 ± 7.9×10−2 3.9×10−1 ± 7.6×10−2 – [175, 176, 177]
4E-BP1-4E-aTOR→ 4E-BP1-P+4E+aTOR – – 2.0×10−1 ± 4.3×10−2 [175, 176, 177]
Formation of 43S complex
∅ 40SI 1.1×10−4 ± 0.0 1.2×10−5 ± 0.0 –
∅ p70 1.0×10−4 ± 0.0 2.6×10−5 ± 0.0 –
p70+aTOR p70-aTOR 8.74 ± 1.28 1.09 ± 1.9×10−1 – [178]
p70-aTOR→ ap70+aTOR 8.00 ± 1.31 – – [178]
ap70+40SI  ap70-40SI 7.52 ± 1.28 6.5×10−1 ± 1.5×10−1 –
ap70-40SI → ap70+40S 4.78 ± 7.9×10−1 – –
∅ 2 4.2×10−5 ± 0.0 3.6×10−5 ± 0.0 –
∅ GTP 9.4×10−5 ± 0.0 1.0×10−4 ± 0.0 –
∅ mtRNA 1.1×10−4 ± 0.0 3.6×10−5 ± 0.0 –
2+GTP 2-GTP 9.71 ± 1.59 7.6×10−2 ± 1.3×10−2 – [168, 129]
2-GTP+mtRNA 2-GTP-mtRNA 3.2×10−1 ± 6.1×10−2 5.3×10−1 ± 1.0×10−1 – [168, 129]
∅ 3 2.0×10−5 ± 0.0 8.6×10−6 ± 0.0 –
∅ 1 1.2×10−4 ± 0.0 1.0×10−4 ± 0.0 –
∅ 1A 1.2×10−4 ± 0.0 3.5×10−5 ± 0.0 –
∅ 5 9.5×10−5 ± 0.0 3.0×10−5 ± 0.0 –
∅ 5B 8.7×10−5 ± 0.0 6.5×10−5 ± 0.0 –
40S+3 40S-3 6.92 ± 1.55 6.4×10−2 ± 1.3×10−2 – [168, 129]
40S-3+1 40S-3-1 8.80 ± 1.92 4.2×10−2 ± 9.8×10−3 – [168, 129]
40S-3-1+1A 40S-3-1-1A 3.9×10−2 ± 6.4×10−3 5.9×10−2 ± 1.0×10−2 – [168, 129]
5+5B 5-5B 1.0×101 ± 1.85 6.8×10−2 ± 1.0×10−2 – [379]
40S-3-1-1A+5-5B 40S-3-1-1A-5-5B 1.0×101 ± 1.52 1.0×10−2 ± 1.7×10−3 – [379]
2-GTP-mtRNA+40S-3-1-1A-5-5B 2-GTP-mtRNA-
40S-3-1-1A-5-5B (43S)
7.17 ± 1.04 5.0×10−1 ± 9.2×10−2 – [379]
Formation of the Cap Binding Complex (CBC) and it’s binding to mRNA
∅ 4E 6.2×10−8 ± 0.0 1.1×10−4 ± 0.0 –
∅ 4G 3.2×10−5 ± 0.0 1.0×10−4 ± 0.0 –
∅ 4A 1.0×10−4 ± 0.0 6.6×10−5 ± 0.0 –
4A+4G+4E 4A-4G-4E 7.7×10−1 ± 1.4×10−1 4.6 ± 9.7×10−1 – [168, 129]
∅ 4B 1.5×10−5 ± 0.0 3.3×10−5 ± 0.0 –
∅ 4H 5.7×10−5 ± 0.0 8.3×10−5 ± 0.0 –
4A-4G-4E+4B+4H 4A-4G-4E-4B-4H (CBC) 9.8 ± 2.0 3.7×10−1 ± 7.1×10−2 – [168, 129]
∅ PB 5.8×10−5 ± 0.0 2.6×10−5 ± 0.0 –
∅mRNAC 7.8×10−8 ± 0.0 8.3×101 ± 1.5×101 –
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PB+mRNAC mRNAC -PB 1.4×101 ± 2.16 9.15 ± 1.43 –
CBC+mRNAC -PB CBC-mRNAC -PB 8.96 ± 1.49 2.4×10−2 ± 4.4×10−3 –
Formation of the 48S complex and scanning
CBC-mRNAC -PB+43S  CBC-mRNAC -PB-43S
(48S)
5.78 ± 9.1×10−1 3.3×10−1 ± 7.9×10−2 –
48S→ 48S-AUG – – 6.8×10−1 ± 1.0×10−1
Hydrolysis of GTP and release of eIF2-GDP
48S-AUG+5 48S-AUG-5 3.3 ± 5.4×10−1 4.9×10−1 ± 1.0×10−1 – [379, 380]
48S-AUG-5+5B 48S-AUG-5-5B 6.20 ± 1.04 2.3×10−2 ± 3.6×10−3 – [379, 380]
48S-AUG+5-5B 48S-5-5B-AUG-5-5B 6.34 ± 1.21 5.1×10−1 ± 9.2×10−2 – [379, 380]
48S-(2-GTP)-5-5B-AUG-5-5B → 48S-(2-GDP)-5-5B-
AUG-5-5B
– – 6.66 ± 1.33 [379, 380]
48S-(2-GDP)-5-5B-AUG-5-5B → 48S-5-5B-AUG-5-
5B+2-GDP
7.1×101 ± 1.2×101 – – [379, 380]
Conversion of eIF2-GDP to eIF2-GTP
∅ eIF2B 1.1×10−4 ± 0.0 7.5×10−5 ± 0.0 –
2-GDP+eIF2B 2-GDP-eIF2B 5.9×10−1 ± 1.2×10−1 7.9×10−2 ± 1.3×10−2 –
2-GDP-eIF2B→ 2-GTP+eIF2B 3.6×10−1 ± 6.3×10−2 – –
Addition of 60S and Puromycin Assay
∅ 60S 2.2×10−5 ± 0.0 6.9×10−7 ± 0.0 – [164]
48S-5-5B-AUG-5-5B+60S  48S-5-5B-AUG-5-5B-
60S (80S)
4.40 ± 7.4×10−1 9.0×10−2 ± 1.7×10−2 – [164]
80S 80S+5+5B 1.0×101 ± 1.62 4.6×10−3 ± 7.4×10−4 – [164]
80S 80S+3+1+1A 4.49 ± 7.4×10−1 1.1×10−1 ± 1.9×10−2 – [164]
80S+GTP→ 80S-star+GDP – – 1.0×10−1 ± 1.9×10−2 –
80S-star+Puro 80S-star-Puro 1.1×10−3 ± 2.8×10−4 6.6×101 ± 1.3×101 – [164]
80S-star-Puro→ Cap-Met-Puro – – 1.1×101 ± 1.98 [164]
80S+Puro 80S-Puro 1.0×10−3 ± 1.9×10−4 1.0×102 ± 1.7×101 – [164]
80S-Puro→ Cap-Met-Puro – – 3.3×10−1 ± 5.9×10−2 [164]
Effect of physiological stress, e.g., hypoxia
∅mRNAI 6.7×10−5 ± 0.0 9.7×101 ± 2.0×101 –
mRNAI+PBmRNAI -PB 8.43 ± 1.80 8.8×10−1 ± 1.5×10−1 –
∅ Stress 3.0×10−5 ± 1.5×10−4 6.7×10−5 ± 3.4×10−4 –
Stress+4G Stress-4G 9.89 ± 1.80 6.2×10−2 ± 1.1×10−2 – [381]
Stress-4G→ 4GC – – 9.46 ± 1.67 [381]
4E-BP1-P+Stress 4E-BP1-P-Stress 8.5×10−1 ± 1.4×10−1 9.4×10−2 ± 1.6×10−2 – [382]
182
Table B.1 (Continued)
Reaction k f ± σ kb ± σ kc ± σ Source
(nM−1min−1) (min−1) (min−1)
4E-BP1-P-Stress→ 4E-BP1 – – 9.2×10−1 ± 1.7×10−1 [382]
∅ I1 8.2×10−5 ± 0.0 3.2×10−5 ± 0.0 –
∅ I2 7.4×10−5 ± 0.0 4.0×10−5 ± 0.0 –
4A+4GC+4B+4H+I1+I2  4A-4GC -4B-4H-I1-I2
(IBC)
4.67 ± 8.4×10−1 1.6×10−2 ± 2.7×10−3 – [383]
IBC+mRNAI -PB IBC-mRNAI -PB 5.57 ± 8.0×10−1 3.3×10−4 ± 3.2×10−4 –
IBC-mRNAI -PB+43S IBC-mRNAI -PB-43S (48SI ) 5.31 ± 8.6×10−1 2.5×10−1 ± 3.8×10−2 –
48SI → 48SI -AUG – – 7.1×10−1 ± 1.1×10−1 –
48SI -AUG+5 48SI -AUG-5 6.57 ± 1.00 2.8×10−1 ± 5.1×10−2 –
48SI -AUG-5+5B 48SI -AUG-5-5B 5.50 ± 1.04 8.7×10−1 ± 1.5×10−1 –
48SI -AUG+5-5B 48SI -AUG-5-5B 1.0×101 ± 2.05 1.0×10−1 ± 1.8×10−2 –
48SI -(2-GTP)-AUG-5-5B → 48SI -(2-GDP)-AUG-5-
5B
– – 6.56 ± 1.17 –
48SI -(2-GDP)-AUG-5-5B→ 48SI -AUG-5-5B+2-GDP – – 3.82 ± 7.3×10−1 –
48SI -AUG-5-5B+60S 48SI -AUG-5-5B-AUG-60S 4.18 ± 8.3×10−1 2.4×10−1 ± 4.3×10−2 –
48SI -5-5B-AUG-60S→ 48SI -AUG-60S+5-5B – – 1.12 ± 2.1×10−1 –
48SI -AUG-60S → 48SI -AUG-60S (IRES 80S)
+1+1A+3
4.7×10−1 ± 8.4×10−2 5.3×10−5 ± 2.7×10−4 – –
Characterization with Puromycin Assay
IRES 80S+GTP→ IRES 80S-star+GDP – – 1.0×10−1 ± 2.3×10−2 [164]
IRES 80S-star+Puro IRES 80S-star-Puro 1.0×10−3 ± 2.0×10−4 6.4×101 ± 1.2×101 – [164]
IRES 80S-star-Puro→ IRES-Met-Puro – – 1.0×101 ± 1.64 [164]
80S+Puro IRES-80S-Puro 1.0×10−3 ± 1.8×10−4 1.0×102 ± 1.9×101 – [164]
IRES-80S-Puro→ IRES-Met-Puro – – 3.1×10−1 ± 4.5×10−2 [164]
Reactions of the Rheb-GTP/GDP, TSC subsystem
R-GTP+TSC1 R-GTP-TSC1 7.7×10−2 ± 1.7×10−2 1.0×101 ± 1.89 – [384]
R-GTP-TSC1→ R-GDP+TSC1 1.04 ± 2.0×10−1 – – [384]
R-GTP+TSC2 R-GTP-TSC2 6.0×10−1 ± 1.2×10−1 3.16 ± 5.6×10−1 – [384]
R-GTP-TSC2→ R-GDP+TSC2 – – 71.0×101 ± 2.56 [384]
TSC1+aAkt TSC1-aAkt 2.2×10−1 ± 3.2×10−2 6.61 ± 1.22 –
TSC1-aAkt→ TSC1-P+aAkt – – 1.0×10−1 ± 1.7×10−2 [384]
TSC2+aAkt TSC2-aAkt 2.2×10−1 ± 4.4×10−2 6.99 ± 1.45 –
TSC2-aAkt→ TSC2-P+aAkt – – 1.0×10−1 ± 2.0×10−2 [384]
R-GTP R-GDP 1.0×10−2 ± 1.9×10−3 1.0×10−2 ± 1.9×10−3 –
aTOR→ TOR – – 1.1×101 ± 1.96
Rheb+GDP R-GDP 1.07 ± 1.8×10−1 9.8×10−2 ± 1.7×10−2 – [384]
Rheb+GTP R-GTP 1.03 ± 2.0×10−1 1.0×10−1 ± 1.9×10−2 – [384]
∅ Rheb 2.7×10−5 ± 0.0 1.2×10−4 ± 0.0 –
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Reactions of PI3K (Wortmannin) and mTOR inhibitors (Rapamycin)
WxWi 1.0×102 ± 2.5×101 1.0×10−1 ± 1.7×10−2 –
Rx Ri 1.0×102 ± 1.7×101 1.0×10−1 ± 2.0×10−2 –
Ri+TOR Ri-TOR 1.0×101 ± 2.27 9.9×10−3 ± 1.9×10−3 –
Wi+PI3KWi-PI3K 1.0×101 ± 1.66 1.0×10−2 ± 1.7×10−3 –
Ri+aTOR Ri-aTOR 1.0×101 ± 1.89 1.0×10−2 ± 1.8×10−3 –
Wi+Act-PI3KWi-Act-PI3K 1.0×101 ± 1.96 1.0×10−2 ± 1.8×10−3
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Table C.1: Prostate model interactions and parameters for the C-33, C-51 and
C-81 LNCaP clones.
Reactions kon ko f f kcat cite
EGF+EGFR
 EGFR-EGF 2.215E0±3.1E0 1.3E-3±1.9E-3 - [171]
2*EGFR-EGF
 EGFR-EGF-2 3.701E-1±3.586E-1 1.708E-1±1.377E-1 - [171]
EGFR-EGF-2
 EGFR-EGF-2-p 1.864E0±2.444E0 2.707E-2±7.107E-2 - [171]
2*Her2
 Her2-2 4.98E-2±2.815E-2 1.756E-1±2.654E-1 - ?
Her2-2
 Her2-2-p 2.032E-2±2.204E-2 1.472E-5±1.213E-5 - [385]
EGFR-EGF-2-p+Grb2
 EGFR-EGF-2-p-Grb2 1.068E0±3.282E0 7.018E-1±4.517E-1 - [302]
EGFR-EGF-2-p-Grb2+Sos
 EGFR-EGF-2-p-Grb2-Sos 4.244E-1±6.357E-1 3.506E0±5.793E0 - [302]
EGFR-EGF-2-p-Grb2-Sos
 EGFR-EGF-2-p+Grb2-Sos 1.159E0±2.35E0 5.034E-2±6.075E-2 - [302]
Grb2+Sos
 Grb2-Sos 4.104E-3±2.773E-3 2.548E-4±2.191E-4 - [302]
EGFR-EGF-2-p-Grb2-Sos+Ras-GDP
 EGFR-EGF-2-p-Grb2-Sos-
Ras-GDP
2.183E-2±1.842E-2 8.377E-1±9.551E-1 - [263, 386]
EGFR-EGF-2-p-Grb2-Sos-Ras-GDP → EGFR-EGF-2-p-Grb2-
Sos+Ras-GTP
- - 4.28E0±3.525E0 [263, 386]
Her2-2-p+Grb2
 Her2-2-p-Grb2 1.976E-2±2.734E-2 9.558E-1±8.677E-1 - ?
Her2-2-p-Grb2+Sos
 Her2-2-p-Grb2-Sos 2.395E-1±2.953E-1 1.49E0±2.296E0 - ?
Her2-2-p-Grb2-Sos
 Her2-2-p+Grb2-Sos 3.623E-2±2.45E-2 5.343E-2±5.586E-2 - ?
Her2-2-p-Grb2-Sos+Ras-GDP
 Her2-2-p-Grb2-Sos-Ras-GDP 3.053E-2±1.959E-2 4.568E-1±3.063E-1 - ?
Her2-2-p-Grb2-Sos-Ras-GDP→ Her2-2-p-Grb2-Sos+Ras-GTP - - 5.685E0±5.969E0 ?
EGFR-EGF-2-p+Shc
 EGFR-EGF-2-p-Shc 6.682E-1±7.743E-1 2.79E0±1.557E0 - [302]
EGFR-EGF-2-p-Shc→ EGFR-EGF-2-p-Shc-p - - 1.327E1±1.083E1 [302]
EGFR-EGF-2-p-Shc-p
 EGFR-EGF-2-p+Shc-p 1.464E0±1.058E0 6.464E-3±8.466E-3 - [302]
Shc-p→ Shc - - 5.153E0±5.371E0 [302]
EGFR-EGF-2-p-Shc-p+Grb2
 EGFR-EGF-2-p-Shc-p-Grb2 6.308E-2±4.851E-2 8.773E-1±6.182E-1 - [302]
EGFR-EGF-2-p-Shc-p-Grb2+Sos 
 EGFR-EGF-2-p-Shc-p-Grb2-
Sos
2.065E-1±3.931E-1 2.176E-1±2.282E-1 - [302]
EGFR-EGF-2-p-Shc-p-Grb2-Sos 
 EGFR-EGF-2-p+Shc-p-Grb2-
Sos
9.887E-1±1.048E0 1.562E-3±1.142E-3 - [302]
Shc-p+Grb2-Sos
 Shc-p-Grb2-Sos 3.755E-2±4.72E-2 1.613E-1±1.613E-1 - [302]
EGFR-EGF-2-p-Shc-p-Grb2-Sos+Ras-GDP 
 EGFR-EGF-2-p-
Shc-p-Grb2-Sos-Ras-GDP
3.412E-2±3.79E-2 2.066E-1±2.164E-1 - [263, 386]
EGFR-EGF-2-p-Shc-p-Grb2-Sos-Ras-GDP → EGFR-EGF-2-p-Shc-
p-Grb2-Sos+Ras-GTP
- - 4.399E0±7.045E0 [263, 386]
Her2-2-p+Shc
 Her2-2-p-Shc 1.208E-1±1.537E-1 9.921E0±2.087E1 - ?
Her2-2-p-Shc→ Her2-2-p-Shc-p - - 2.995E1±6.778E1 ?
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Her2-2-p-Shc-p
 Her2-2-p+Shc-p 4.703E0±1.342E1 3.983E-3±4.616E-3 - ?
Her2-2-p-Shc-p+Grb2
 Her2-2-p-Shc-p-Grb2 5.805E-2±7.916E-2 1.127E0±1.51E0 - ?
Her2-2-p-Shc-p-Grb2+Sos
 Her2-2-p-Shc-p-Grb2-Sos 1.359E-1±1.23E-1 2.241E0±7.899E0 - ?
Her2-2-p-Shc-p-Grb2-Sos
 Her2-2-p+Shc-p-Grb2-Sos 9.861E-1±1.159E0 1.294E-2±3.787E-2 - ?
Her2-2-p-Shc-p-Grb2-Sos+Ras-GDP 
 Her2-2-p-Shc-p-Grb2-
Sos-Ras-GDP
1.749E-2±1.219E-2 6.129E-1±1.44E0 - ?
Her2-2-p-Shc-p-Grb2-Sos-Ras-GDP → Her2-2-p-Shc-p-Grb2-
Sos+Ras-GTP
- - 1.882E1±4.063E1 ?
Her2-2-p+cPAcP
 Her2-2-p-cPAcP 1.707E1±1.581E1 5.325E-2±3.92E-2 - ?
Her2-2-p-cPAcP→ Her2-2+cPAcP - - 2.012E1±2.021E1 [346]
Her2-2+sPAcP
 Her2-2-sPAcP 8.951E0±9.414E0 1.248E-3±7.101E-4 - [346]
Her2-2-sPAcP→ Her2-2-p+sPAcP - - 2.288E1±2.252E1 †
Ras-GTP+GAP
 Ras-GTP-GAP 1.032E-1±1.526E-1 1.149E0±1.23E0 - †
Ras-GTP-GAP→ Ras-GDP+GAP - - 4.785E-1±3.57E-1 [386]
Ras-GTP+Raf
 Ras-GTP-Raf 5.455E-3±4.49E-3 2.097E-2±1.256E-2 - [386]
Ras-GTP-Raf→ Ras-GTP+Raf-p - - 5.858E0±6.133E0 [171]
Raf-p+Pase1
 Raf-p-Pase1 5.166E-1±5.821E-1 1.77E0±1.446E0 - [171]
Raf-p-Pase1→ Raf+Pase1 - - 3.978E0±2.632E0 [171]
MEK+Raf-p
MEK-Raf-p 6.055E-2±5.209E-2 9.006E-2±1.189E-1 - [171]
MEK-Raf-p→MEK-p+Raf-p - - 1.409E1±2.857E1 [171]
MEK-p+Raf-p
MEK-p-Raf-p 2.145E-1±6.272E-1 1.056E-1±1.282E-1 - [171]
MEK-p-Raf-p→MEK-pp+Raf-p - - 2.949E0±2.16E0 [171]
ERK+MEK-pp
 ERK-MEK-pp 1.677E-3±1.72E-3 4.956E-1±3.873E-1 - [171]
ERK-MEK-pp→ ERK-p+MEK-pp - - 1.095E1±1.112E1 [171]
ERK-p+MEK-pp
 ERK-p-MEK-pp 2.09E-3±1.47E-3 3.124E0±8.012E0 - [171]
ERK-p-MEK-pp→ ERK-pp+MEK-pp - - 8.435E0±6.538E0 [171]
MEK-p+Pase2
MEK-p-Pase2 1.04E-3±1.072E-3 7.569E0±1.607E1 - [171]
MEK-p-Pase2→MEK+Pase2 - - 7.221E-1±8.541E-1 [171]
MEK-pp+Pase2
MEK-pp-Pase2 6.319E-2±4.223E-2 4.293E0±2.501E0 - [171]
MEK-pp-Pase2→MEK-p+Pase2 - - 2.617E-2±2.29E-2 [171]
ERK-p+Pase3
 ERK-p-Pase3 2.408E0±2.499E0 3.366E-1±2.34E-1 - [171]
ERK-p-Pase3→ ERK+Pase3 - - 2.7E0±4.156E0 [171]
ERK-pp+Pase3
 ERK-pp-Pase3 5.008E-2±3.168E-2 5.499E0±8.337E0 - [171]
ERK-pp-Pase3→ ERK-p+Pase3 - - 2.789E0±5.206E0 [171]
EGFR-EGF-2-p-Grb2-Sos+ERK-pp 
 EGFR-EGF-2-p-Grb2-Sos-
ERK-pp
2.239E0±2.85E0 6.502E-4±5.11E-4 - [305]
EGFR-EGF-2-p-Grb2-Sos-ERK-pp → EGFR-EGF-2-p-
Grb2+Sos+ERK-pp
- - 1.351E0±1.222E0 [305]
Her2-2-p-Grb2-Sos+ERK-pp
 Her2-2-p-Grb2-Sos-ERK-pp 1.856E0±1.211E0 1.559E-1±2.128E-1 - ?
Her2-2-p-Grb2-Sos-ERK-pp→ Her2-2-p-Grb2+Sos+ERK-pp - - 3.075E0±3.738E0 ?
EGFR-EGF-2-p-Shc-p-Grb2-Sos+ERK-pp 
 EGFR-EGF-2-p-Shc-
p-Grb2-Sos-ERK-pp
1.185E0±1.099E0 8.315E-4±6.405E-4 - [305]
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EGFR-EGF-2-p-Shc-p-Grb2-Sos-ERK-pp→ EGFR-EGF-2-p-Shc-p-
Grb2+Sos+ERK-pp
- - 1.231E1±4.931E1 [305]
Her2-2-p-Shc-p-Grb2-Sos+ERK-pp 
 Her2-2-p-Shc-p-Grb2-Sos-
ERK-pp
3.378E0±5.412E0 3.747E-1±8.356E-1 - [171]
Her2-2-p-Shc-p-Grb2-Sos-ERK-pp → Her2-2-p-Shc-p-
Grb2+Sos+ERK-pp
- - 5.262E0±9.916E0 [171]
EGF→ EGFi - - 0E0±0E0 [171]
EGFR
 EGFRi 1.179E-2±1.056E-2 1.599E-1±2.308E-1 - [171]
EGFR-EGF→ EGFR-EGFi - - 1.579E-1±3.334E-1 [171]
EGFRi+EGFi
 EGFR-EGFi 1.041E0±1.185E0 1.251E-1±4.785E-1 - ‡
EGFR-EGF-2→ EGFR-EGF-2i - - 6.648E-3±4.899E-3 [171]
2*EGFR-EGFi
 EGFR-EGF-2i 1.432E-2±1.301E-2 4.332E0±7.81E0 - ‡
EGFR-EGF-2-p→ EGFR-EGF-2-pi - - 7.456E-2±8.563E-2 [171]
EGFR-EGF-2i
 EGFR-EGF-2-pi 2.347E0±3.074E0 1.54E-1±1.493E-1 - ‡
EGFR-EGF-2-p-Grb2→ EGFR-EGF-2-pi-Grb2 - - 7.874E-2±9.134E-2 [171]
EGFR-EGF-2-pi+Grb2
 EGFR-EGF-2-pi-Grb2 3.449E-3±2.48E-3 3.572E-1±3.045E-1 - ‡
EGFR-EGF-2-p-Grb2-Sos→ EGFR-EGF-2-pi-Grb2-Sos - - 1.541E-1±2.247E-1 [171]
EGFR-EGF-2-pi+Grb2-Sos
 EGFR-EGF-2-pi-Grb2-Sos 3.954E-3±3.183E-3 3.359E-1±2.71E-1 - ‡
EGFR-EGF-2-pi-Grb2+Sos
 EGFR-EGF-2-pi-Grb2-Sos 1.13E-2±1.034E-2 6.348E-1±6.501E-1 - ‡
EGFR-EGF-2-pi-Grb2-Sos+Ras-GDP 
 EGFR-EGF-2-pi-Grb2-
Sos-Ras-GDP
3.459E-3±3.064E-3 7.339E-2±8.78E-2 - ‡
EGFR-EGF-2-pi-Grb2-Sos-Ras-GDP → EGFR-EGF-2-pi-Grb2-
Sos+Ras-GTP
- - 1.199E0±9.562E-1 ‡
EGFR-EGF-2-pi-Grb2-Sos+ERK-pp
 EGFR-EGF-2-pi-Grb2-Sos-
ERK-pp
1.427E0±1.503E0 3.947E-4±2.363E-4 - ‡
EGFR-EGF-2-pi-Grb2-Sos-ERK-pp → EGFR-EGF-2-pi-
Grb2+Sos+ERK-pp
- - 1.617E0±1.465E0 ‡
EGFR-EGF-2-pi+Shc
 EGFR-EGF-2-pi-Shc 1 .367E-1±1.947E-1 6.82E0±6.97E0 - ‡
EGFR-EGF-2-p-Shc→ EGFR-EGF-2-pi-Shc - - 1.652E-1±3.045E-1 [171]
EGFR-EGF-2-pi-Shc→ EGFR-EGF-2-pi-Shc-p - - 9.176E0±1.724E1 ‡
EGFR-EGF-2-p-Shc-p→ EGFR-EGF-2-pi-Shc-p - - 9.441E-2±6.697E-2 [171]
EGFR-EGF-2-pi-Shc-p
 EGFR-EGF-2-pi+Shc-p 6.97E0±1.16E1 1.036E-3±7.374E-4 - ‡
EGFR-EGF-2-pi-Shc-p+Grb2
 EGFR-EGF-2-pi-Shc-p-Grb2 4.201E-3±7.391E-3 2.866E0±6.449E0 - ‡
EGFR-EGF-2-p-Shc-p-Grb2→ EGFR-EGF-2-pi-Shc-p-Grb2 - - 1.38E-1±1.346E-1 -
EGFR-EGF-2-pi-Shc-p-Grb2+Sos
 EGFR-EGF-2-pi-Shc-p-Grb2-
Sos
9.048E-3±4.866E-3 5.588E-1±7.609E-1 - ‡
EGFR-EGF-2-p-Shc-p-Grb2-Sos → EGFR-EGF-2-pi-Shc-p-Grb2-
Sos
- - 4.926E-1±1.139E0 -
EGFR-EGF-2-pi-Shc-p-Grb2-Sos
 EGFR-EGF-2-pi+Shc-p-Grb2-
Sos
3.537E0±3.537E0 3.606E-4±3.165E-4 - ‡
EGFR-EGF-2-pi-Shc-p-Grb2-Sos+Ras-GDP 
 EGFR-EGF-2-pi-
Shc-p-Grb2-Sos-Ras-GDP
5.62E-3±4.616E-3 7.134E-1±1.236E0 - ‡
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EGFR-EGF-2-pi-Shc-p-Grb2-Sos-Ras-GDP → EGFR-EGF-2-pi-
Shc-p-Grb2-Sos+Ras-GTP
- - 1.142E0±8.919E-1 ‡
EGFR-EGF-2-pi-Shc-p-Grb2-Sos+ERK-pp 
 EGFR-EGF-2-pi-
Shc-p-Grb2-Sos-ERK-pp
1.924E0±2.013E0 5.668E-4±4.798E-4 - ‡
EGFR-EGF-2-pi-Shc-p-Grb2-Sos-ERK-pp → EGFR-EGF-2-pi-Shc-
p-Grb2+Sos+ERK-pp
- - 4.336E0±4.556E0 ‡
AR+ERK-pp
 AR-ERK-pp 1.873E-3±1.23E-3 3.88E-1±8.593E-1 - [339]
AR-ERK-pp
 AR-p+ERK-pp 2.57E-2±1.979E-2 - - [339]
T+Rase5a
 T-Rase5a 2.171E-2±2.509E-2 3.308E-1±5.205E-1 - [387]
T-Rase5a→ DHT+Rase5a - - 1.374E0±1.034E0 [387]
AR+HSP
 AR-HSP 9.162E-3±6.375E-3 1.01E-3±8.283E-4 - [388]
AR+T
 AR-T 5.289E-3±4.359E-3 9.361E-4±1.289E-3 - [388]
AR-T
 AR-p-T 5.458E-2±1.612E-1 - - [388]
AR-p+AR-p-T
 AR-p-AR-p-T 5.32E-1±9.532E-1 6.128E-4±5.525E-4 - [388]
2*AR-p-T
 AR-p-T-2 5.835E-1±1.26E0 5.149E-4±2.812E-4 - [388]
2*AR-p
 AR-p-2 2.848E-1±4.904E-1 1.281E-1±2.018E-1 - [388]
AR+DHT
 AR-DHT 2.486E0±2.641E0 5.42E-5±6.636E-5 - [388]
AR-DHT
 AR-p-DHT 5.436E-1±4.693E-1 - - [388]
AR-p-DHT+AR-p-T
 AR-p-DHT-AR-p-T 6.895E-1±1.445E0 7.915E-4±5.504E-4 - [388]
AR-p-DHT+AR-p
 AR-p-DHT-AR-p 6.064E-1±1.283E0 3.362E-3±6.635E-3 - [388]
2*AR-p-DHT
 AR-p-DHT-2 1.026E0±1.066E0 1.013E-3±1.461E-3 - [388]
AR-p+Pase5
 AR-p-Pase5 5.409E-4±5.152E-4 4.6E-3±3.726E-3 - [388]
AR-p-Pase5→ AR+Pase5 - - 3.637E-3±2.758E-3 [388]
AR-p-T+Pase5
 AR-p-T-Pase5 1.671E-3±2.186E-3 7.194E-3±4.179E-3 - [388]
AR-p-T-Pase5→ AR-T+Pase5 - - 5.853E-3±5.596E-3 [388]
AR-p-DHT+Pase5
 AR-p-DHT-Pase5 7.907E-4±1.029E-3 7.667E-3±7.267E-3 - [388]
AR-p-DHT-Pase5→ AR-DHT+Pase5 - - 5.328E-2±1.285E-1 [388]
AR-p-2+g-cPAcP
 AR-p-2-g-cPAcP 1.618E-3±1.482E-3 9.872E-5±6.594E-5 - [341]
AR-p-DHT-2+g-cPAcP
 AR-p-DHT-2-g-cPAcP 8.423E-4±1.136E-3 1.366E-7±1.582E-7 - [341]
AR-p-DHT-AR-p+g-cPAcP
 AR-p-DHT-AR-p-g-cPAcP 4.544E-3±3.674E-3 1.314E-7±1.111E-7 - [341]
AR-p-T-2+g-cPAcP
 AR-p-T-2-g-cPAcP 6.374E-2±3.979E-2 2.954E-4±4.596E-4 - [341]
AR-p-AR-p-T+g-cPAcP
 AR-p-AR-p-T-g-cPAcP 6.191E-2±4.34E-2 1.099E-4±1.07E-4 - [341]
AR-p-DHT-AR-p-T+g-cPAcP
 AR-p-DHT-AR-p-T-g-cPAcP 1.543E-1±1.874E-1 2.343E-4±3.372E-4 - [341]
AR-p-2+g-sPAcP
 AR-p-2-g-sPAcP 9.585E-2±1.272E-1 2.558E-2±3.325E-2 - [341]
AR-p-DHT-2+g-sPAcP
 AR-p-DHT-2-g-sPAcP 9.074E-6±1.236E-5 1.017E-1±6.467E-2 - [341]
AR-p-DHT-AR-p+g-sPAcP
 AR-p-DHT-AR-p-g-sPAcP 5.658E-6±4.624E-6 1.447E-1±1.972E-1 - [341]
AR-p-T-2+g-sPAcP
 AR-p-T-2-g-sPAcP 4.345E-3±2.721E-3 7.3E-2±1.85E-1 - [341]
AR-p-AR-p-T+g-sPAcP
 AR-p-AR-p-T-g-sPAcP 1.811E-2±5.092E-2 6.045E-3±4.406E-3 - [341]
AR-p-DHT-AR-p-T+g-sPAcP
 AR-p-DHT-AR-p-T-g-sPAcP 1.125E-2±3.516E-2 2.44E-2±3.7E-2 - [341]
ERK-pp+ETS
 ERK-pp-ETS 2.109E-3±3.444E-3 4.624E-1±3.654E-1 - [298]
ERK-pp-ETS→ ERK-pp+ETS-p - - 2.534E-2±1.687E-2 [298]
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ETS-p+Pase5
 ETS-p-Pase5 3.753E0±3.797E0 2.548E-3±6.034E-3 - [298]
ETS-p-Pase5→ ETS+Pase5 - - 8.124E0±9.856E0 [298]
ERK-pp+AP1
 ERK-pp-AP1 1.403E-3±1.096E-3 5.971E-1±4.652E-1 - [298]
ERK-pp-AP1→ ERK-pp+AP1-p - - 2.556E-2±2.661E-2 [298]
AP1-p+Pase6
 AP1-p-Pase6 8.022E0±1.209E1 8.007E-4±7.727E-4 - [298]
AP1-p-Pase6→ AP1+Pase6 - - 1.54E1±2.376E1 [298]
Her2-2-p-Grb2-Sos+PI3K
 Her2-2-p-Grb2-Sos-PI3K 2.125E-1±2.91E-1 1.412E-2±3.191E-2 - [389, 171, 172]
Her2-2-p-Grb2-Sos-PI3K→ Her2-2-p-Grb2-Sos+Act-PI3K - - 1.941E-1±3.754E-1 [389, 171, 172]
Her2-2-p-Shc-p-Grb2-Sos+PI3K 
 Her2-2-p-Shc-p-Grb2-Sos-
PI3K
8.255E-2±8.716E-2 5.049E-3±7.031E-3 - [389, 171, 172]
Her2-2-p-Shc-p-Grb2-Sos-PI3K → Her2-2-p-Shc-p-Grb2-Sos+Act-
PI3K
- - 1.93E-1±1.462E-1 [389, 171, 172]
EGFR-EGF-2-p-Grb2-Sos+PI3K
 EGFR-EGF-2-p-Grb2-Sos-PI3K 4.34E-1±1.47E0 1.849E-2±4.73E-2 - [389, 171, 172]
EGFR-EGF-2-p-Grb2-Sos-PI3K → EGFR-EGF-2-p-Grb2-Sos+Act-
PI3K
- - 1.684E-1±2.04E-1 [389, 171, 172]
EGFR-EGF-2-p-Shc-p-Grb2-Sos+PI3K 
 EGFR-EGF-2-p-Shc-p-
Grb2-Sos-PI3K
1.722E-1±1.503E-1 8.976E-3±1.111E-2 - [389, 171, 172]
EGFR-EGF-2-p-Shc-p-Grb2-Sos-PI3K → EGFR-EGF-2-p-Shc-p-
Grb2-Sos+Act-PI3K
- - 1.01E-1±1.081E-1 [389, 171, 172]
PtdIns2+Act-PI3K
 PtdIns2-Act-PI3K 1.983E-1±1.959E-1 1.56E-2±9.585E-3 - [172, 390]
PtdIns2-Act-PI3K→ PtdIns3+Act-PI3K - - 9.81E-2±5.877E-2 [172, 390]
PtdIns3+PTEN
 PtdIns3-PTEN 3.036E-1±3.942E-1 2.262E-2±3.503E-2 - [172, 390]
PtdIns3-PTEN→ PtdIns2+PTEN - - 3.081E-1±2.74E-1 [172, 390]
PtdIns3+Akt
 PtdIns3-Akt 4.11E-1±7.091E-1 7.744E-3±1.008E-2 - [172, 390]
PtdIns3-Akt→ PtdIns3+Akt-m - - 2.839E-1±3.552E-1 [172, 390]
PtdIns3+Pdk1
 PtdIns3-Pdk1 2.436E-1±4.38E-1 4.369E-3±7.769E-3 - [172, 390]
PtdIns3-Pdk1→ PtdIns3+Pdk1-m - - 7.83E0±2.249E1 [172, 390]
Pdk1-m+Akt-m
 Pdk1-m-Akt-m 9.893E-2±6.529E-2 1.874E-2±4.907E-2 - [172, 390]
Pdk1-m-Akt-m→ Pdk1+Act-Akt - - 2.096E-1±3.052E-1 [172, 390]
Act-Akt+TOR
 Act-Akt-TOR 1.389E-1±1.405E-1 1.102E-1±7.477E-2 - [391]
Act-Akt-TOR→ Akt+Act-TOR - - 2.551E-1±1.76E-1 [391]
4E-BP1+eIF4E
 4E-BP1-eIF4E 1.779E-1±1.65E-1 1.58E-1±3.496E-1 - [392, 154, 177]
4E-BP1+Act-TOR
 4E-BP1-Act-TOR 1.347E-1±1.643E-1 1.947E-1±2.04E-1 - [392, 154, 177]
4E-BP1-Act-TOR→ 4E-BP1-P+Act-TOR - - 2.5E-1±2.358E-1 [392, 154, 177]
T-e
 T 1.449E0±1.377E0 1.555E0±1.212E0 - [388]
sPAcP→ sPAcP-e - - 1.86E0±2.631E0 -
g-CycD+RNAp
 g-CycD-RNAp 4.952E-5±5.451E-5 1.104E-1±9.207E-2 - 
g-CycD-RNAp→ g-CycD+RNAp+mRNA-CycD - - 1.099E-2±6.375E-3 
g-CycD+ETS-p
 g-CycD-ETS-p 1.38E-1±1.225E-1 1.26E0±1.424E0 - [298],
g-CycD-ETS-p+RNAp
 g-CycD-ETS-p-RNAp 2.931E-1±7.426E-1 9.037E-3±9.077E-3 - 
g-CycD-ETS-p-RNAp→ g-CycD-ETS-p+RNAp+mRNA-CycD - - 1.156E-2±1.103E-2 
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g-CycD+AP1-p
 g-CycD-AP1-p 3.726E-1±7.298E-1 2.171E0±3.083E0 - [298],
g-CycD-AP1-p+RNAp
 g-CycD-AP1-p-RNAp 4.288E-1±8.691E-1 2.945E-2±4.654E-2 - 
g-CycD-AP1-p-RNAp→ g-CycD-AP1-p+RNAp+mRNA-CycD - - 3.292E-2±5.52E-2 
g-PSA+RNAp
 g-PSA-RNAp 9.158E-9±5.822E-9 1.29E-4±9.22E-5 - 
g-PSA-RNAp→ g-PSA+RNAp+mRNA-PSA - - 2.873E-4±4.865E-4 
g-PSA+AR-p-2
 g-PSA-AR-p-2 1.372E-1±4.477E-1 4.913E-3±3.906E-3 - [354, 393],
g-PSA-AR-p-2+RNAp
 g-PSA-AR-p-2-RNAp 1.182E-4±9.273E-5 8.565E-5±6.869E-5 - 
g-PSA-AR-p-2-RNAp→ g-PSA-AR-p-2+RNAp+mRNA-PSA - - 8.167E-2±8.195E-2 
g-PSA+AR-p-DHT-2
 g-PSA-AR-p-DHT-2 8.626E-2±5.139E-2 2.007E-4±2.664E-4 - [354, 393],
g-PSA-AR-p-DHT-2+RNAp
 g-PSA-AR-p-DHT-2-RNAp 7.817E-2±7.669E-2 1.577E-4±3.931E-4 - 
g-PSA-AR-p-DHT-2-RNAp → g-PSA-AR-p-DHT-
2+RNAp+mRNA-PSA
- - 2.238E-2±1.652E-2 
g-PSA+AR-p-DHT-AR-p
 g-PSA-AR-p-DHT-AR-p 1.025E-2±1.364E-2 1.353E-4±2.42E-4 - [354, 393],
g-PSA-AR-p-DHT-AR-p+RNAp 
 g-PSA-AR-p-DHT-AR-p-
RNAp
1.091E-4±1.097E-4 1.029E-5±8.85E-6 - 
g-PSA-AR-p-DHT-AR-p-RNAp → g-PSA-AR-p-DHT-AR-
p+RNAp+mRNA-PSA
- - 3.064E-4±2.688E-4 
g-PSA+AR-p-T-2
 g-PSA-AR-p-T-2 9.22E-5±1.021E-4 8.384E-4±8.525E-4 - [354, 393],
g-PSA-AR-p-T-2+RNAp
 g-PSA-AR-p-T-2-RNAp 4.362E-4±9.551E-4 2.375E-4±3.218E-4 - 
g-PSA-AR-p-T-2-RNAp→ g-PSA-AR-p-T-2+RNAp+mRNA-PSA - - 8.891E-5±5.851E-5 
g-PSA+AR-p-AR-p-T
 g-PSA-AR-p-AR-p-T 4.169E-5±3.125E-5 5.429E-3±1.32E-2 - [354, 393],
g-PSA-AR-p-AR-p-T+RNAp
 g-PSA-AR-p-AR-p-T-RNAp 8.539E-5±1.306E-4 1.204E-4±1.07E-4 - 
g-PSA-AR-p-AR-p-T-RNAp → g-PSA-AR-p-AR-p-
T+RNAp+mRNA-PSA
- - 1.959E-4±2.315E-4 
g-PSA+AR-p-DHT-AR-p-T
 g-PSA-AR-p-DHT-AR-p-T 2.392E-4±1.671E-4 5.202E-4±3.549E-4 - [354, 393],
g-PSA-AR-p-DHT-AR-p-T+RNAp
 g-PSA-AR-p-DHT-AR-p-T-
RNAp
2.092E-4±2.523E-4 1.516E-4±1.413E-4 - 
g-PSA-AR-p-DHT-AR-p-T-RNAp → g-PSA-AR-p-DHT-AR-p-
T+RNAp+mRNA-PSA
- - 2.128E-4±2.825E-4 
g-cPAcP+RNAp
 g-cPAcP-RNAp 5.788E-2±8.352E-2 7.556E-2±7.697E-2 - 
g-cPAcP-RNAp→ g-cPAcP+RNAp+mRNA-cPAcP - - 1.311E-2±1.021E-2 
g-sPAcP+RNAp
 g-sPAcP-RNAp 4.894E-2±4.501E-2 1.238E-3±1.192E-3 - 
g-sPAcP-RNAp→ g-sPAcP+RNAp+mRNA-sPAcP - - 6.989E-1±8.214E-1 
mRNA-CycD+eIF4E
mRNA-CycD-eIF4E 2.137E-2±2.447E-2 8.14E-3±7.613E-3 - 
mRNA-CycD-eIF4E+40S
mRNA-CycD-eIF4E-40S 8.773E-2±8.511E-2 5.877E-3±2.975E-3 - 
mRNA-CycD-eIF4E-40S+60S
mRNA-CycD-eIF4E-40S-60S 7.418E-1±6.638E-1 1.306E-3±1.249E-3 - 
mRNA-CycD-eIF4E-40S-60S→ Rm-CycD+eIF4E - - 1.194E0±9.078E-1 
Rm-CycD→ Ar-CycD - - 9.399E-1±6.401E-1 
Ar-CycD→ CycD+40S+60S+mRNA-CycD - - 1.781E0±1.759E0 
mRNA-PSA+eIF4E
mRNA-PSA-eIF4E 1.278E-4±1.134E-4 5.894E-6±4.173E-6 - 
mRNA-PSA-eIF4E+40S
mRNA-PSA-eIF4E-40S 9.861E-4±8.116E-4 4.486E-6±2.712E-6 - 
mRNA-PSA-eIF4E-40S+60S
mRNA-PSA-eIF4E-40S-60S 7.736E-4±6.483E-4 6.108E-4±1.143E-3 - 
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mRNA-PSA-eIF4E-40S-60S→ Rm-PSA+eIF4E - - 3.98E-4±2.062E-4 
Rm-PSA→ Ar-PSA - - 7.268E-3±8.931E-3 
Ar-PSA→ PSA+40S+60S+mRNA-PSA - - 3.797E-2±1.084E-1 
mRNA-cPAcP+eIF4E
mRNA-cPAcP-eIF4E 1.351E-2±7.272E-3 9.892E-3±1.443E-2 - 
mRNA-cPAcP-eIF4E+40S
mRNA-cPAcP-eIF4E-40S 2.33E-1±3.139E-1 9.908E-3±9.67E-3 - 
mRNA-cPAcP-eIF4E-40S+60S
mRNA-cPAcP-eIF4E-40S-60S 9.053E-1±5.338E-1 1.499E-3±1.438E-3 - 
mRNA-cPAcP-eIF4E-40S-60S→ Rm-cPAcP+eIF4E - - 1.185E0±1E0 
Rm-cPAcP→ Ar-cPAcP - - 1.31E0±2.102E0 
Ar-cPAcP→ cPAcP+40S+60S+mRNA-cPAcP - - 1.612E0±1.219E0 
mRNA-sPAcP+eIF4E
mRNA-sPAcP-eIF4E 3.473E-4±2.456E-4 2.741E-2±7.506E-2 - 
mRNA-sPAcP-eIF4E+40S
mRNA-sPAcP-eIF4E-40S 3.844E-1±8.881E-1 7.084E-3±7.617E-3 - 
mRNA-sPAcP-eIF4E-40S+60S
mRNA-sPAcP-eIF4E-40S-60S 1.532E-2±2.378E-2 2.415E-3±2.381E-3 - 
mRNA-sPAcP-eIF4E-40S-60S→ Rm-sPAcP+eIF4E - - 1.089E0±8.417E-1 
Rm-sPAcP→ Ar-sPAcP - - 1.572E0±1.147E0 
Ar-sPAcP→ sPAcP+40S+60S+mRNA-sPAcP - - 1.474E0±1.459E0 
mRNA-CycD→ ∅ - - 8.094E-1±6.348E-1 -
mRNA-PSA→ ∅ - - 1.389E-1±1.328E-1 -
CycD→ ∅ - - 6.123E-3±5.87E-3 -
PSA→ ∅ - - 9.309E-6±7.499E-6 -
EGFi→ ∅ - - 1.057E0±1.053E0 -
cPAcP→ ∅ - - 1.208E-2±8.088E-3 -
mRNA-cPAcP→ ∅ - - 1.3E0±1.39E0 -
sPAcP→ ∅ - - 7.162E-4±7.064E-4 -
mRNA-sPAcP→ ∅ - - 1.12E-1±1.224E-1 -
2*cPAcP
 cPAcP-2 8.195E-2±1.868E-1 9.026E-2±6.808E-2 - [347]
2*cPAcP-2
 cPAcP-4 8.039E-2±1.344E-1 6.186E-2±3.229E-2 - [347]
2*Her2-2-p+cPAcP-2
 2Her2-2-p-cPAcP-2 1.292E2±3.518E2 2.069E-1±2.448E-1 - [347]
2Her2-2-p-cPAcP-2→ 2*Her2-2+cPAcP-2 - - 9.256E0±6.196E0 [347]
4*Her2-2-p+cPAcP-4
 4Her2-2-p-cPAcP-4 1.306E1±1.071E1 1.127E-2±1.019E-2 - [347]
4Her2-2-p-cPAcP-4→ 4*Her2-2+cPAcP-4 - - 7.811E0±5.607E0 [347]
Act-Akt+Pase7
 Act-Akt-Pase7 1.765E-3±1.65E-3 1.226E-3±2.158E-3 - -
Act-Akt-Pase7→ Akt+Pase7 - - 1.861E-3±3.179E-3 -
4E-BP1-eIF4E+Act-TOR
 4E-BP1-eIF4E-Act-TOR 1.603E-3±1.851E-3 7.501E-4±5.262E-4 - [392, 154, 177]
4E-BP1-eIF4E-Act-TOR→ 4E-BP1-P+eIF4E+Act-TOR - - 1.933E-3±4.962E-3 [392, 154, 177]
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Table C.2: Experimental training data used to estimate the ensemble of prostate
model parameters.
Experimental Setup Observation Simulation Setup citation
C-81 transfection cyclin D 0.7 model of C-33 †
with WT PAcP of C-81 WT
C-81 transfection cyclin D 0.3 model of C-81 †
with PAcP-IgG of C-81 with gcPAcP + =1
C-81 transfection +cyclin D 1.1 model of C-81 †
with PAcP-Prl of C-81 with gsPAcP +=1
Addition of 10nm PSA increase Allowed SS of C-81 [335]
DHT to C-81 added 10nM DHT
Addition of 10nM PSA & Her2 activation Allowed SS of C-33
DHT to C-33 increase and added 10nM DHT [335]
PAcP decrease
Overexpression of PSA mRNA 2.2 model of C-33 [339]
Her2 in C-33 of C-33 WT with 50% more Her2
Overexpression of PSA 2 fold model of C-33 [335]
Her2 in C-33 of C-33 WT with 50% more Her2
Transfection of constitutively PSA 3 fold model of C-33 [335]
active MEK in C-33 of C-33 WT with 50% more MEK
1µMMEK inhibitor PSA 0.6 model of C-81 with [335]
PD98059 in C-81 of C-81 WT 50% reduced MEK
MEK inhibitor PD98059 PSA 1.86 of C-33 model of C-33 with
in C-33 with Her2 WT (compared to 2 with 50% reduced MEK and [335]
overexpression Her2 overexpression alone) 50% more Her2
0.5µMHer2 inhibitor PSA 0.58 model of C-81 with [335]
AG879 in C-81 of C-81 WT 50% reduced Her2
10µMHer2 inhibitor PSA 0.17 model of C-81 with [335]
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Table C.2 (Continued)
Experimental Setup Observation Simulation Setup citation
AG879 in C-81 of C-81 WT 87.5% reduced Her2
EGFR inhibitor no PSA Removed EGFR from [335]
AG1478 in C-81 effect model of C-81
50ng/ml EGF to transient increase 8nM EGF to model [171]
HeLa cell culture in Erk activity of C-33 with no Her2
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Table C.3: Non-zero initial conditions estimated from the training data for the
C-33 LNCaP clone. The mean (µ) and standard deviation (σ) calculated over the
ensemble are shown.
species initial condition (µ ± σ)
Pase7 24.71 ± 23.66
AR 192.40 ± 260.66
HSP 486.15 ± 659.55
Rase5a 81.11 ± 66.98
Her2 131.57 ± 111.41
EGFR 115.41 ± 82.19
Shc 91.19 ± 71.89
Grb2 80.32 ± 67.10
Sos 35.79 ± 29.37
Ras-GDP 233.39 ± 456.75
Raf 76.83 ± 54.31
MEK 1572.31 ± 2260.09
ERK 587.24 ± 401.24
ETS 133.52 ± 150.03
AP1 107.34 ± 172.51
Pase1 181.67 ± 513.24
Pase2 20.88 ± 11.78
Pase3 22.76 ± 12.44
Pase5 65.13 ± 82.13
Pase6 168.28 ± 234.48
GAP 60.71 ± 100.62
PI3K 174.54 ± 240.45
PtdIns2 131.27 ± 122.14
PtdIns3 119.05 ± 94.11
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Table C.3 (Continued)
species initial condition (µ ± σ)
PTEN 123.84 ± 142.99
Akt 332.36 ± 585.30
Pdk1 190.88 ± 237.37
TOR 121.80 ± 120.53
4E-BP1 136.67 ± 107.57
eIF4E 3707.42 ± 3178.77
g-PSA 3.29 ± 1.87
g-CycD 2.90 ± 4.98
g-cPAcP 0.09 ± 0.06
g-sPAcP 0.11 ± 0.09
RNAp 371.62 ± 314.59
40S 8203.19 ± 16956.30
60S 4732.73 ± 4700.66
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Table C.4: Interactions determined to be significantly fragile for the C-33, C-51
and C-81 LNCaP clones. Overall State Sensitivity Coefficients (OSSCs) were cal-
culated over the parameter ensemble. The OSSC values were ranked ordered.
Reaction mean rank st. dev rank p-value
C-33
AR-p-DHT-2+g-sPAcP→AR-p-DHT-2-g-sPAcP 302.4059406 15.97843734 0.039916369
Ras-GTP-Raf→Ras-GTP+Raf-p 302.7821782 18.9159705 0.046713871
AP1-p-Pase6→AP1+Pase6 302.8118812 9.99773526 0.00082649
ETS-p+Pase5→ETS-p-Pase5 303.0693069 17.82547816 0.02648256
mRNA-sPAcP-eIF4E+40S→mRNA-sPAcP-eIF4E-40S 303.4851485 11.65648068 0.000567415
Pdk1-m+Akt-m→Pdk1-m-Akt-m 303.960396 8.723384746 1.11E-06
ETS-p-Pase5→ETS+Pase5 304.3465347 12.61418002 0.000133415
AP1-p+Pase6→AP1-p-Pase6 309.0891089 31.45076272 0.001584816
mRNA-sPAcP-eIF4E-40S-60S→Rm-sPAcP+eIF4E 309.8118812 21.69943781 3.90E-06
2*AR-p-DHT→AR-p-DHT-2 313.5643564 27.07211339 6.11E-07
mRNA-sPAcP→[] 315.7524752 63.3152424 0.006070198
2*Her2-2-p+cPAcP-2→2Her2-2-p-cPAcP-2 315.8613861 33.36003113 2.00E-06
ERK-pp-Pase3→ERK-p+Pase3 318.5148515 49.25034329 0.000106094
mRNA-CycD-eIF4E-40S+60S→mRNA-CycD-eIF4E-
40S-60S
318.8019802 31.76024659 1.25E-08
mRNA-CycD-eIF4E+40S→mRNA-CycD-eIF4E-40S 318.9306931 33.70966822 5.07E-08
AR-p-DHT+Pase5→AR-p-DHT-Pase5 319.3663366 26.60556138 1.80E-11
Her2-2-sPAcP→Her2-2-p+sPAcP 321.8217822 25.22037368 1.90E-14
Raf-p-Pase1→Raf+Pase1 323.7821782 22.38130583 8.18E-19
Act-Akt-Pase7→Akt+Pase7 325.4158416 60.54411162 2.25E-05
Her2-2-p-Shc-p-Grb2-Sos+ERK-pp→Her2-2-p-Shc-
p-Grb2-Sos-ERK-pp
326.8811881 33.90589397 8.76E-13
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Table C.4 (Continued)
Reaction mean rank st. dev rank p-value
g-PSA-AR-p-DHT-2-RNAp→g-PSA-AR-p-DHT-
2+RNAp+mRNA-PSA
327.990099 32.83064707 4.36E-14
g-PSA+AR-p-DHT-AR-p→g-PSA-AR-p-DHT-AR-p 328.1584158 15.42386775 2.07E-34
g-cPAcP-RNAp→g-cPAcP+RNAp 329.8217822 23.27042743 1.65E-23
AR-DHT→AR-p-DHT 330.039604 16.97809934 2.49E-33
ERK-pp-ETS→ERK-pp+ETS-p 330.4356436 22.63241163 7.61E-25
Her2-2-p-Shc-p-Grb2-Sos+Ras-GDP→Her2-2-p-Shc-
p-Grb2-Sos-Ras-GDP
330.7425743 29.10705861 1.40E-18
Shc-p→Shc 331.5346535 14.6216741 3.60E-40
Her2-2-p+cPAcP→Her2-2-p-cPAcP 331.5346535 28.40846491 9.25E-20
ERK-pp+Pase3→ERK-pp-Pase3 332.1980198 31.79669944 1.34E-17
mRNA-cPAcP-eIF4E-40S+60S→mRNA-cPAcP-
eIF4E-40S-60S
332.2871287 39.08921926 1.83E-13
AR+DHT→AR-DHT 335.4950495 28.38861289 8.88E-23
Ras-GTP-GAP→Ras-GTP+GAP 335.5049505 50.04604291 6.32E-11
ERK-pp-AP1→ERK-pp+AP1-p 336.960396 15.82823695 5.38E-43
mRNA-cPAcP-eIF4E+40S→mRNA-cPAcP-eIF4E-
40S
336.980198 41.72896522 9.27E-15
Her2-2-p-Shc-p-Grb2+Sos→Her2-2-p-Shc-p-Grb2-
Sos
338.0990099 35.12960585 3.83E-19
MEK-pp-Pase2→MEK-pp+Pase2 338.2871287 39.07173819 5.55E-17
ERK-pp-AP1→ERK-pp+AP1 338.7029703 18.00524926 5.81E-40
Her2-2+sPAcP→Her2-2-sPAcP 338.8415842 29.06930356 1.40E-24
ERK-pp-ETS→ERK-pp+ETS 339.5148515 23.01511078 3.15E-32
MEK-pp+Pase2→MEK-pp-Pase2 339.7227723 38.86613706 9.42E-18
mRNA-cPAcP+eIF4E→mRNA-cPAcP-eIF4E 339.8910891 35.54133028 5.79E-20
PtdIns3+PTEN→PtdIns3-PTEN 340.039604 27.87700028 1.17E-26
Grb2+Sos→Grb2-Sos 341.3564356 37.79192228 2.44E-19
Her2-2-p-Shc-p-Grb2→Her2-2-p-Shc-p+Grb2 341.3861386 30.78477517 9.83E-25
Her2-2-p-Grb2→Her2-2-p+Grb2 341.5742574 21.43160733 2.56E-36
ERK-MEK-pp→ERK-p+MEK-pp 342.2673267 31.13461386 5.26E-25
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Table C.4 (Continued)
Reaction mean rank st. dev rank p-value
MEK-p+Raf-p→MEK-p-Raf-p 343.5643564 37.26023438 5.78E-21
g-sPAcP+RNAp→g-sPAcP-RNAp 343.960396 21.50013622 3.89E-38
ERK-pp+AP1→ERK-pp-AP1 344.7227723 12.55571253 2.64E-59
AR-p-DHT+AR-p→AR-p-DHT-AR-p 345.8217822 17.42957316 2.33E-47
mRNA-sPAcP+eIF4E→mRNA-sPAcP-eIF4E 346.6435644 34.26818637 4.71E-25
ERK-p+Pase3→ERK-p-Pase3 346.9009901 24.64179214 1.26E-35
ERK-p+MEK-pp→ERK-p-MEK-pp 347.3465347 27.47147419 2.69E-32
sPAcP→sPAcP-e 348.2673267 27.44351213 5.87E-33
Her2-2-p-Shc-p+Grb2→Her2-2-p-Shc-p-Grb2 348.5346535 21.65689443 2.17E-41
g-PSA+AR-p-DHT-2→g-PSA-AR-p-DHT-2 348.7623762 17.48331511 1.32E-49
ERK-pp+ETS→ERK-pp-ETS 349.5346535 11.96328075 2.12E-65
g-cPAcP+RNAp→g-cPAcP-RNAp 349.8316832 6.127473123 7.84E-94
PtdIns3-PTEN→PtdIns2+PTEN 350.0990099 29.71098572 1.44E-31
g-sPAcP-RNAp→g-sPAcP+RNAp+mRNA-sPAcP 352.4851485 40.24617659 8.00E-24
Ras-GTP-GAP→Ras-GDP+GAP 353.2376238 19.0482184 1.17E-49
Her2-2-p-Grb2-Sos+ERK-pp→Her2-2-p-Grb2-Sos-
ERK-pp
354.019802 21.93102608 7.57E-45
Her2-2-p-Shc-p→Her2-2-p+Shc-p 355.3168317 18.11565195 4.27E-53
Her2-2-p-Grb2-Sos+Ras-GDP→Her2-2-p-Grb2-Sos-
Ras-GDP
355.4356436 18.33754782 1.06E-52
Her2-2-p+Grb2-Sos→Her2-2-p-Grb2-Sos 361.0792079 35.52873141 3.78E-32
Raf-p+Pase1→Raf-p-Pase1 361.6237624 16.52651724 4.71E-61
Her2-2-p+Shc→Her2-2-p-Shc 363.1485149 16.06569812 3.41E-63
Ras-GTP+Raf→Ras-GTP-Raf 366.8712871 9.359342626 3.28E-88
PtdIns2-Act-PI3K→PtdIns3+Act-PI3K 367.6732673 19.44024045 2.98E-58
Ras-GTP+GAP→Ras-GTP-GAP 368.3861386 6.688204923 1.46E-103
AR-HSP→AR+HSP 375.4950495 17.27851282 1.70E-67
ERK-p-Pase3→ERK+Pase3 377.1584158 15.50453953 6.74E-73
ERK+MEK-pp→ERK-MEK-pp 381.029703 4.115788113 7.95E-132
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Reaction mean rank st. dev rank p-value
C-51
AP1-p-Pase6→AP1+Pase6 302.1578947 8.575750131 0.001745756
Ras-GTP-Raf→Ras-GTP+Raf-p 303 19.88599084 0.045952102
ETS-p+Pase5→ETS-p-Pase5 303.3157895 16.59502979 0.014236152
Pdk1-m+Akt-m→Pdk1-m-Akt-m 303.7368421 9.106632084 9.61E-06
ETS-p-Pase5→ETS+Pase5 303.9473684 11.5297039 0.000161664
mRNA-sPAcP-eIF4E+40S→mRNA-sPAcP-eIF4E-40S 304.9684211 15.17439161 0.000369539
Her2-2-p-cPAcP→Her2-2+cPAcP 308.5578947 24.48144981 0.000269085
AP1-p+Pase6→AP1-p-Pase6 310.2421053 25.34383172 4.28E-05
mRNA-sPAcP-eIF4E-40S-60S→Rm-sPAcP+eIF4E 313.2947368 22.27666879 1.83E-08
mRNA-CycD-eIF4E-40S+60S→mRNA-CycD-eIF4E-
40S-60S
313.7052632 33.07913118 3.50E-05
g-PSA-AR-p-DHT-2-RNAp→g-PSA-AR-p-DHT-
2+RNAp+mRNA-PSA
313.8421053 38.17282467 0.000222221
2*AR-p-DHT→AR-p-DHT-2 314.1263158 24.0220259 2.85E-08
ERK-pp-Pase3→ERK-p+Pase3 316.9157895 48.00365406 0.000338143
mRNA-sPAcP→[] 317.5684211 63.22635237 0.003381905
2*Her2-2-p+cPAcP-2→2Her2-2-p-cPAcP-2 317.8421053 33.02608723 2.69E-07
AR-p-DHT+Pase5→AR-p-DHT-Pase5 318.0736842 24.49156336 3.60E-11
mRNA-CycD-eIF4E+40S→mRNA-CycD-eIF4E-40S 318.5894737 34.67548648 3.28E-07
Raf-p-Pase1→Raf+Pase1 321.3578947 22.06922878 6.66E-16
Act-Akt-Pase7→Akt+Pase7 325.3684211 60.78799269 4.01E-05
Her2-2-sPAcP→Her2-2-p+sPAcP 326.5789474 27.72708307 1.28E-15
ERK-pp+Pase3→ERK-pp-Pase3 326.6526316 33.45374447 3.03E-12
Her2-2-p-Shc-p-Grb2-Sos+ERK-pp→Her2-2-p-Shc-
p-Grb2-Sos-ERK-pp
327.9473684 37.42933508 3.32E-11
g-PSA+AR-p-DHT-AR-p→g-PSA-AR-p-DHT-AR-p 328.4842105 14.39799925 4.01E-35
AR-DHT→AR-p-DHT 329.1052632 16.30271123 8.22E-32
g-cPAcP-RNAp→g-cPAcP+RNAp 329.2736842 23.57449206 1.81E-21
Her2-2-p-Shc-p-Grb2-Sos+Ras-GDP→Her2-2-p-Shc-
p-Grb2-Sos-Ras-GDP
331.3368421 29.15859015 5.32E-18
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Reaction mean rank st. dev rank p-value
mRNA-cPAcP-eIF4E-40S+60S→mRNA-cPAcP-
eIF4E-40S-60S
331.4 39.66926425 4.29E-12
ERK-pp-ETS→ERK-pp+ETS-p 331.8 19.2636008 2.36E-29
Ras-GTP-GAP→Ras-GTP+GAP 333.0842105 51.16406287 3.58E-09
Shc-p→Shc 333.3684211 15.7600779 2.70E-37
ERK-pp-AP1→ERK-pp+AP1 336.7263158 20.51158446 8.55E-32
ERK-pp-AP1→ERK-pp+AP1-p 337.0736842 12.72150447 1.64E-48
MEK-pp-Pase2→MEK-pp+Pase2 337.2947368 37.76265872 3.96E-16
mRNA-cPAcP-eIF4E+40S→mRNA-cPAcP-eIF4E-
40S
337.3157895 42.40786004 7.00E-14
ERK-pp-ETS→ERK-pp+ETS 337.3473684 23.58267358 4.79E-28
AR+DHT→AR-DHT 338.2 24.96844324 5.00E-27
MEK-pp+Pase2→MEK-pp-Pase2 338.7157895 37.64590232 5.70E-17
Her2-2-p-Shc-p-Grb2+Sos→Her2-2-p-Shc-p-Grb2-
Sos
338.8105263 34.82597178 9.32E-19
Grb2+Sos→Grb2-Sos 338.9052632 39.71532216 6.11E-16
PtdIns3+PTEN→PtdIns3-PTEN 339.5684211 29.20838114 1.27E-23
Her2-2-p+cPAcP→Her2-2-p-cPAcP 340.0947368 29.00637813 3.67E-24
ERK-p+Pase3→ERK-p-Pase3 341.2842105 26.78949643 3.28E-27
Her2-2+sPAcP→Her2-2-sPAcP 342.4421053 30.45193479 2.28E-24
ERK-pp+AP1→ERK-pp-AP1 342.5894737 16.21597311 1.12E-44
Her2-2-p-Shc-p-Grb2→Her2-2-p-Shc-p+Grb2 342.7684211 25.81287016 2.40E-29
Her2-2-p-Grb2→Her2-2-p+Grb2 342.7789474 21.45407774 3.41E-35
g-sPAcP+RNAp→g-sPAcP-RNAp 342.9894737 21.4478534 2.31E-35
MEK-p+Raf-p→MEK-p-Raf-p 343.1578947 38.42622892 6.58E-19
ERK-MEK-pp→ERK-p+MEK-pp 343.7473684 27.89075245 1.05E-27
ERK-p+MEK-pp→ERK-p-MEK-pp 344.2315789 27.88791575 4.97E-28
mRNA-cPAcP+eIF4E→mRNA-cPAcP-eIF4E 345.6842105 36.12296635 8.80E-22
Her2-2-p-Shc-p+Grb2→Her2-2-p-Shc-p-Grb2 346.4315789 23.27666671 3.54E-35
AR-p-DHT+AR-p→AR-p-DHT-AR-p 346.8315789 16.13929669 2.98E-48
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Reaction mean rank st. dev rank p-value
g-PSA+AR-p-DHT-2→g-PSA-AR-p-DHT-2 347.2315789 16.73725918 3.13E-47
ERK-pp+ETS→ERK-pp-ETS 347.6736842 12.66611069 5.41E-58
mRNA-sPAcP+eIF4E→mRNA-sPAcP-eIF4E 347.7473684 35.32643812 1.66E-23
PtdIns3-PTEN→PtdIns2+PTEN 349.4105263 30.11608933 5.28E-29
g-cPAcP+RNAp→g-cPAcP-RNAp 349.7157895 6.308996347 4.17E-87
sPAcP→sPAcP-e 351.0105263 28.577317 1.40E-31
Ras-GTP-GAP→Ras-GDP+GAP 351.9473684 19.54340294 4.92E-45
g-sPAcP-RNAp→g-sPAcP+RNAp+mRNA-sPAcP 351.9578947 40.97365413 8.11E-22
Her2-2-p-Grb2-Sos+Ras-GDP→Her2-2-p-Grb2-Sos-
Ras-GDP
352.1789474 20.4743634 1.57E-43
Her2-2-p-Shc-p→Her2-2-p+Shc-p 354.9894737 16.77372302 1.03E-52
Her2-2-p-Grb2-Sos+ERK-pp→Her2-2-p-Grb2-Sos-
ERK-pp
355.8105263 19.06625276 1.64E-48
Her2-2-p+Grb2-Sos→Her2-2-p-Grb2-Sos 358.6631579 37.79657755 2.57E-27
Her2-2-p+Shc→Her2-2-p-Shc 361.2315789 19.83800321 1.95E-50
Raf-p+Pase1→Raf-p-Pase1 361.5157895 16.62646157 2.99E-57
Ras-GTP+Raf→Ras-GTP-Raf 366.5789474 9.591200954 6.39E-82
PtdIns2-Act-PI3K→PtdIns3+Act-PI3K 367.2210526 20.72790082 3.00E-52
Ras-GTP+GAP→Ras-GTP-GAP 367.8210526 7.643337584 8.85E-92
ERK-p-Pase3→ERK+Pase3 376.9894737 14.42986285 2.04E-71
AR-HSP→AR+HSP 377.8210526 5.201171826 6.56E-113
ERK+MEK-pp→ERK-MEK-pp 380.2315789 5.008314417 1.12E-115
C-81
ETS-p-Pase5→ETS+Pase5 301.1604938 11.5297039 0.044372614
Pdk1-m+Akt-m→Pdk1-m-Akt-m 304.308642 9.106632084 6.31E-05
Her2-2-p-Shc-p-Grb2-Sos-ERK-pp→Her2-2-p-Shc-
p-Grb2+Sos+ERK-pp
304.7160494 18.6392907 0.044183504
ETS-p+Pase5→ETS-p-Pase5 305.2222222 16.59502979 0.000259343
Rm-cPAcP→Ar-cPAcP 305.9259259 35.39776978 0.035058001
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Reaction mean rank st. dev rank p-value
ERK-pp+Pase3→ERK-pp-Pase3 306.8765432 33.45374447 0.006750525
mRNA-sPAcP-eIF4E+40S→mRNA-sPAcP-eIF4E-40S 306.8888889 15.17439161 0.000275699
AP1-p+Pase6→AP1-p-Pase6 309.037037 25.34383172 8.85E-10
Her2-2-p-Shc→Her2-2-p-Shc-p 309.5925926 28.82266729 0.001615564
AR-p-DHT+Pase5→AR-p-DHT-Pase5 310.0246914 24.49156336 9.34E-05
ERK-p+Pase3→ERK-p-Pase3 311.1234568 26.78949643 0.000360203
Her2-2-p-Grb2-Sos-ERK-pp→Her2-2-p-
Grb2+Sos+ERK-pp
313.0123457 25.30996979 0.000134248
mRNA-CycD-eIF4E+40S→mRNA-CycD-eIF4E-40S 314.0123457 34.67548648 3.02E-05
mRNA-sPAcP-eIF4E-40S-60S→Rm-sPAcP+eIF4E 314.1358025 22.27666879 2.25E-06
mRNA-sPAcP→[] 314.1604938 63.22635237 0.010774155
2*AR-p-DHT→AR-p-DHT-2 314.2469136 24.0220259 3.92E-07
mRNA-CycD-eIF4E-40S+60S→mRNA-CycD-eIF4E-
40S-60S
315 33.07913118 6.12E-06
Her2-2-sPAcP→Her2-2-p+sPAcP 315.3580247 27.72708307 3.46E-08
Her2-2-p-Grb2+Sos→Her2-2-p-Grb2-Sos 317.6296296 59.31322182 0.000564659
Raf-p-Pase1→Raf+Pase1 320.1481481 22.06922878 4.43E-16
MEK-p+Raf-p→MEK-p-Raf-p 320.8518519 38.42622892 8.15E-06
ERK-pp-AP1→ERK-pp+AP1 324.1975309 20.51158446 9.84E-12
Act-Akt-Pase7→Akt+Pase7 324.9382716 60.78799269 0.000162736
Ras-GTP-GAP→Ras-GTP+GAP 325.4691358 51.16406287 2.46E-06
Ar-cPAcP→cPAcP+40S+60S+mRNA-cPAcP 326.0246914 23.44263701 1.16E-07
ERK-p+MEK-pp→ERK-p-MEK-pp 327.0493827 27.88791575 1.06E-17
Grb2+Sos→Grb2-Sos 327.1604938 39.71532216 3.42E-08
Her2-2+sPAcP→Her2-2-sPAcP 327.3580247 30.45193479 1.27E-09
MEK-pp-Pase2→MEK-pp+Pase2 328.1604938 37.76265872 3.48E-10
ERK-pp-ETS→ERK-pp+ETS 328.1728395 23.58267358 8.85E-16
AR-DHT→AR-p-DHT 328.5061728 16.30271123 3.19E-20
MEK-pp+Pase2→MEK-pp-Pase2 329.691358 37.64590232 6.26E-11
g-PSA+AR-p-DHT-AR-p→g-PSA-AR-p-DHT-AR-p 330.1975309 14.39799925 6.17E-34
202
Table C.4 (Continued)
Reaction mean rank st. dev rank p-value
ERK-pp+AP1→ERK-pp-AP1 330.8518519 16.21597311 2.17E-17
ERK-MEK-pp→ERK-p+MEK-pp 332.1975309 27.89075245 1.29E-22
ERK-pp-ETS→ERK-pp+ETS-p 332.7654321 19.2636008 5.16E-28
mRNA-cPAcP-eIF4E-40S+60S→mRNA-cPAcP-
eIF4E-40S-60S
333.5802469 39.66926425 1.46E-11
g-cPAcP-RNAp→g-cPAcP+RNAp 334.0617284 23.57449206 2.04E-22
g-sPAcP+RNAp→g-sPAcP-RNAp 335.2345679 21.4478534 1.11E-25
ERK-pp-AP1→ERK-pp+AP1-p 336.5679012 12.72150447 1.21E-42
AR+DHT→AR-DHT 336.6419753 24.96844324 2.66E-19
Her2-2-p-Shc-p-Grb2-Sos+Ras-GDP→Her2-2-p-Shc-
p-Grb2-Sos-Ras-GDP
338.382716 29.15859015 1.19E-20
ERK-pp+ETS→ERK-pp-ETS 339.3580247 12.66611069 3.29E-31
g-PSA+AR-p-DHT-2→g-PSA-AR-p-DHT-2 339.4567901 16.73725918 1.08E-33
PtdIns3+PTEN→PtdIns3-PTEN 339.5432099 29.20838114 4.00E-19
Shc-p→Shc 340.962963 15.7600779 2.34E-36
mRNA-cPAcP-eIF4E+40S→mRNA-cPAcP-eIF4E-
40S
341.1234568 42.40786004 3.29E-14
Her2-2-p-Shc-p-Grb2-Sos+ERK-pp→Her2-2-p-Shc-
p-Grb2-Sos-ERK-pp
341.345679 37.42933508 6.94E-17
Her2-2-p-cPAcP→Her2-2+cPAcP 343.345679 24.48144981 1.80E-16
sPAcP→sPAcP-e 343.4691358 28.577317 1.82E-18
Her2-2-p+Grb2-Sos→Her2-2-p-Grb2-Sos 344.4074074 37.79657755 5.91E-14
Her2-2-p-Grb2-Sos+Ras-GDP→Her2-2-p-Grb2-Sos-
Ras-GDP
344.7654321 20.4743634 5.62E-29
mRNA-sPAcP+eIF4E→mRNA-sPAcP-eIF4E 345.8641975 35.32643812 2.14E-23
Her2-2-p-Shc-p-Grb2+Sos→Her2-2-p-Shc-p-Grb2-
Sos
346.345679 34.82597178 2.39E-23
g-sPAcP-RNAp→g-sPAcP+RNAp+mRNA-sPAcP 346.7530864 40.97365413 1.22E-18
PtdIns3-PTEN→PtdIns2+PTEN 348.4814815 30.11608933 6.77E-23
AR-p-DHT+AR-p→AR-p-DHT-AR-p 348.7530864 16.13929669 2.31E-37
Ras-GTP-GAP→Ras-GDP+GAP 349.2222222 19.54340294 1.37E-41
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Table C.4 (Continued)
Reaction mean rank st. dev rank p-value
Her2-2-p+cPAcP→Her2-2-p-cPAcP 351.1358025 29.00637813 1.58E-26
Her2-2-p-Grb2→Her2-2-p+Grb2 351.308642 21.45407774 8.46E-36
g-cPAcP+RNAp→g-cPAcP-RNAp 351.7037037 6.308996347 7.31E-52
mRNA-cPAcP+eIF4E→mRNA-cPAcP-eIF4E 353.0493827 36.12296635 8.29E-22
Her2-2-p-Shc-p-Grb2→Her2-2-p-Shc-p+Grb2 354.4567901 25.81287016 2.21E-40
Her2-2-p-Shc-p+Grb2→Her2-2-p-Shc-p-Grb2 355.7530864 23.27666671 3.34E-44
Raf-p+Pase1→Raf-p-Pase1 356.7037037 16.62646157 1.53E-46
Her2-2-p-Grb2-Sos+ERK-pp→Her2-2-p-Grb2-Sos-
ERK-pp
357.3333333 19.06625276 1.92E-52
ERK+MEK-pp→ERK-MEK-pp 363.691358 5.008314417 2.09E-35
ERK-p-Pase3→ERK+Pase3 364 14.42986285 3.04E-33
Ras-GTP+Raf→Ras-GTP-Raf 364.6296296 9.591200954 1.32E-59
Her2-2-p-Shc-p→Her2-2-p+Shc-p 364.9382716 16.77372302 1.25E-61
PtdIns2-Act-PI3K→PtdIns3+Act-PI3K 365.8395062 20.72790082 1.52E-39
Ras-GTP+GAP→Ras-GTP-GAP 366.2592593 7.643337584 4.45E-60
Her2-2-p+Shc→Her2-2-p-Shc 366.5555556 19.83800321 6.79E-53
AR-HSP→AR+HSP 373.962963 5.201171826 5.92E-56
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Table C.5: Statistically significant sensitivity differences between AI and AD
LNCaP clones. Negative changes in themean rank denote interactions that were
more sensitive in AI versus AD cells.
Reaction p-value ∆ mean rank
rank(C-33) - rank(C-81)
Her2-2→Her2-2-p 2.41E-14 -87.2565701
cPAcP→[] 2.97E-11 -60.05830583
Her2-2-p-cPAcP→Her2-2+cPAcP 1.11E-16 -46.32587703
Ar-PSA→PSA+40S+60S+mRNA-PSA 9.08E-14 -45.08495294
mRNA-cPAcP-eIF4E-40S-60S→mRNA-cPAcP-eIF4E-40S+60S 2.10E-05 -43.08984232
Ar-cPAcP→cPAcP+40S+60S+mRNA-cPAcP 8.00E-12 -40.0840973
MEK-pp-Pase2→MEK-p+Pase2 0.005304844 29.80992544
2*Her2-2-p+cPAcP-2→2Her2-2-p-cPAcP-2 2.34E-11 34.46632441
ERK-p+Pase3→ERK-p-Pase3 2.30E-14 35.77753331
cPAcP-4→2*cPAcP-2 1.74E-08 44.76995477
AR-p-DHT-2+g-sPAcP→AR-p-DHT-2-g-sPAcP 1.14E-14 44.86273072
2*cPAcP-2→cPAcP-4 9.22E-09 45.43002078
AR-p-DHT-AR-p+g-sPAcP→AR-p-DHT-AR-p-g-sPAcP 8.30E-10 46.80723628
g-PSA-AR-p-DHT-2-RNAp→g-PSA-AR-p-DHT-2+RNAp+mRNA-PSA 0 66.02713605
rank(C-33) - rank(C-51)
Her2-2-p-cPAcP→Her2-2+cPAcP 0.000173573 -11.53809276
2Her2-2-p-cPAcP-2→2*Her2-2+cPAcP-2 0.005962433 -10.58394997
Her2-2-p+cPAcP→Her2-2-p-cPAcP 0.039330397 -8.560083377
4Her2-2-p-cPAcP-4→4*Her2-2+cPAcP-4 0.030899498 -7.999478895
Ar-PSA→PSA+40S+60S+mRNA-PSA 0.0163948 -7.574361647
g-CycD-RNAp→g-CycD+RNAp+mRNA-CycD 0.008798024 6.428035435
Her2-2-p-Grb2-Sos→Her2-2-p-Grb2+Sos 0.03404035 10.82219906
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Table C.5 (Continued)
Reaction p-value ∆ mean rank
4*Her2-2-p+cPAcP-4→4Her2-2-p-cPAcP-4 7.57E-05 14.0875456
g-PSA-AR-p-DHT-2-RNAp→g-PSA-AR-p-DHT-2+RNAp+mRNA-PSA 0.006362828 14.14799375
rank(C-51) - rank(C-81)
Her2-2→Her2-2-p 2.28E-10 -73.21936322
cPAcP→[] 7.80E-07 -45.71812865
mRNA-cPAcP-eIF4E-40S-60S→mRNA-cPAcP-eIF4E-40S+60S 1.06E-05 -44.09317739
Ar-cPAcP→cPAcP+40S+60S+mRNA-cPAcP 1.22E-10 -37.77205978
Ar-PSA→PSA+40S+60S+mRNA-PSA 3.96E-10 -37.51059129
Her2-2-p-cPAcP→Her2-2+cPAcP 1.73E-10 -34.78778428
Her2-2-p-Shc-p-Grb2-Sos-ERK-pp→Her2-2-p-Shc-p-Grb2+Sos+ERK-pp 2.51E-09 -24.51604938
AR-p-DHT-AR-p-g-sPAcP→AR-p-DHT-AR-p+g-sPAcP 1.72E-05 25.18258609
4Her2-2-p-cPAcP-4→4*Her2-2+cPAcP-4 4.10E-05 29.57764782
ERK-p+Pase3→ERK-p-Pase3 1.68E-10 30.16075374
2*Her2-2-p+cPAcP-2→2Her2-2-p-cPAcP-2 3.71E-12 36.44704353
AR-p-DHT-2+g-sPAcP→AR-p-DHT-2-g-sPAcP 1.81E-13 42.27784276
cPAcP-4→2*cPAcP-2 4.06E-08 44.55932424
2*cPAcP-2→cPAcP-4 3.21E-08 44.70318389
AR-p-DHT-AR-p+g-sPAcP→AR-p-DHT-AR-p-g-sPAcP 2.05E-09 46.47654321
g-PSA-AR-p-DHT-2-RNAp→g-PSA-AR-p-DHT-2+RNAp+mRNA-PSA 5.55E-16 51.8791423
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